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Summary	
Anxiety	is	a	natural	response	to	a	real	or	perceived	threat	that	has	been	conserved	throughout	
evolution.	 From	 this	 perspective,	 sensation	 of	 anxiety	 is	 viewed	 as	 an	 adaptive	 behavioral	
state,	 which	 occurs	 in	 response	 to	 signals	 of	 danger.	 However,	 excessive	 or	 inappropriate	
anxiety	 can	 become	 pathological.	 Anxiety	 disorders	 represent	 one	 major	 burden	 of	 our	
modern	 society,	 and	 the	 available	 treatment	 options	 are	 limited	 by	 adverse	 side	 effects.	
During	the	last	decades,	research	centered	on	anxiety	disorders	has	focused	on	neuropeptides.	
Neuropeptide	S	(NPS)	and	oxytocin	(OXT)	represent	potential	neuropeptide	candidates	for	the	
treatment	 of	 various	 psychopathologies,	 including	 anxiety	 disorders	 due	 to	 their	 potent	
anxiolytic	 profile.	 Both	 signal	 through	 G	 protein-coupled	 receptors	 and	 thereby	 regulate	
complex	 neuronal	 signaling	 pathways.	 How	 these	 pathways	 contribute	 to	 behavioral	 and	
physiological	effects	of	NPS	and	OXT	remains	to	be	elucidated.	Therefore,	in	the	present	thesis	
I	 aimed	 to	 reveal,	 (i)	 whether	 NPS	 acts	 on	 the	 brain	 OXT	 system	 to	 exert	 its	 anxiolytic	
properties,	 (ii)	whether	 the	anxiolytic	profile	of	NPS	 is	mediated	 in	a	Gq	pathway-dependent	
manner,	 and	 (iii)	 to	 characterize	 the	 spatiotemporal	 characteristics	 of	 chemogenetically	
induced	OXT	neurons	activation.	
NPS	receptors	(NPSR)	are	found	within	the	hypothalamic	paraventricular	nucleus	(PVN),	where	
OXT	 is	 synthesized	 besides	 the	 supraoptic	 and	 accessory	 nuclei.	 Besides	 anxiolysis,	 NPS	 and	
OXT	share	other	effects,	such	as	the	reversal	of	social	fear,	the	attenuation	of	aggressive-like	
behavior	 as	 well	 as	 the	 inhibition	 of	 food-intake	 and	 anti-nociceptive	 properties	 as	
demonstrated	 in	 rodents.	 These	 behavioral	 similarities,	 together	 with	 the	 neuroanatomical	
overlapping	of	the	NPSR	and	OXT	expression	within	the	PVN,	led	me	to	hypothesize	that	NPS	
effects	are	mediated	by	acting	on	the	OXT	system	within	the	PVN.	Herein,	I	present	a	chain	of	
evidence	that	the	effects	of	NPS	within	the	PVN	are	mediated	via	actions	on	local	OXT	neurons	
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in	male	Wistar	rats.	Retrograde	tracing	revealed	that	NPS-immunoreactive	neurons	originating	
within	 the	 Locus	 coeruleus	 innervate	 the	 PVN.	Moreover,	 fluorescence-activated	 cell	 sorting	
identified	NPSR	expression	in	PVN-OXT	neurons.	NPS	reliably	induced	transient	Ca2+-influx	in	a	
subpopulation	 of	 OXT	 neurons	 -	 an	 effect	 mediated	 via	 the	 NPSR.	 Moreover,	
intracerebroventricular	 (icv)	 NPS	 evoked	 a	 significant	 release	 of	 OXT	 within	 the	 PVN	 as	
assessed	 by	 microdialysis	 in	 combination	 with	 a	 highly	 sensitive	 radioimmunoassay.	 Both,	
chemogenetic	 silencing	 of	 the	 endogenous	 OXT	 system	 using	 designer	 receptors	 exclusively	
activated	 by	 designer	 drugs	 (DREADD)	 as	 well	 as	 pharmacological	 blockade	 of	 brain	 OXT	
receptors	(OXTR)	abolished	the	anxiolytic	effect	of	NPS	infused	icv.	These	findings	provide	the	
first	evidence	for	an	intra-hypothalamic	mechanism	involving	NPSR-expressing	OXT	neurons	in	
the	 potent	 anxiolytic	 profile	 of	 NPS,	 and	 fill	 an	 important	 gap	 in	 our	 neurophysiological	
understanding	 of	 brain	 neuropeptide	 interactions	 in	 the	 context	 of	 regulation	 of	 emotional	
behaviour	within	the	hypothalamus.	
Next,	I	performed	studies	in	order	to	extend	our	knowledge	on	the	intraneuronal	mechanisms	
underlying	 the	anxiolytic	profile	of	NPS	by	 studying	 signaling	pathways	downstream	of	NPSR	
activation.	Here,	bilateral	microinfusion	of	NPS	into	the	medial	amygdala	(MeA)	of	male	adult	
Wistar	 rats	 reduced	 anxiety-related	behavior	 on	 the	 elevated	plus	maze	 and	 the	 open	 field.	
Moreover,	 icv	 infusion	 of	 NPS	 evoked	 expression	 as	 well	 as	 increased	 phosphorylation	 of	
Ca2+/calmodulin-dependent	kinase	II	in	the	amygdala,	and	subsequent	phosphorylation	of	the	
mitogen-activated	protein	kinase	ERK1/2.	Importantly,	NPS-induced	anxiolysis	in	the	MeA	was	
prevented	 by	 local	 inhibition	 of	 phospholipase	 C	 using	 the	 specific	 inhibitor	 U73122.	 In	
contrast,	 local	 pharmacological	 blockade	 of	 adenylyl	 cyclase	 signaling	 using	 the	 specific	
inhibitor	2’,5’-dideoxyadenosine	 failed	 to	 inhibit	 the	anxiolytic	effect	of	NPS	 infused	 into	 the	
MeA.	 Hence,	 NPS	 promotes	 acute	 anxiolysis	 within	 the	MeA	 dependent	 on	 NPSR-mediated	
phospholipase	C	signaling.		
Finally,	 in	order	 to	validate	an	 innovative	and	highly	 specific	 tool	 for	activating	OXT	neurons	
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within	the	PVN	in	a	behavioral	context,	I	performed	a	series	of	experiment	using	the	DREADD	
technique.		Acute	chemogenetic	activation	of	PVN-OXT	neurons	resulted	in	enhanced	release	
of	OXT	within	the	PVN	within	one	hour	as	assessed	using	intracerebral	microdialysis.	Further,	
DREADD	activation	reduced	anxiety-related	behavior	in	the	light/dark	box,	and	increased	self-
grooming	 behavior	 in	 the	 home	 cage.	 In	 addition,	 chemogenetic	 activation	 of	 PVN-OXT	
neurons	marginally	improved	ethanol-induced	locomotor	deficits.	
In	 summary,	my	experimental	data	advance	our	understanding	of	 the	mechanisms	by	which	
NPS	 promotes	 anxiolysis	 and	 the	 temporal	 release	 patterns	 of	 OXT	 following	 chemogenetic	
activation	and	its	behavioral	relevance.	
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Zusammenfassung	
Aus	evolutionsbiologischer	Sicht	ist	Angst	eine	konservierte,	natürliche	Reaktion	auf	eine	reale	
oder	gefühlte	Bedrohung.	Allerdings	können	exzessive	bzw.	unangepasste	Angstzustände	ein	
pathologisches	 Ausmaß	 annehmen.	 Angsterkrankungen	 repräsentieren	 daher	 eine	 der	
Hauptbelastungen	unserer	modernen	Gesellschaft.	Da	die	derzeitigen	Behandlungsmethoden	
limitiert	 und	 von	 Nebenwirkungen	 geprägt	 sind,	 rückten	 Neuropeptide	 in	 den	 letzten	
Jahrzehnten	 mehr	 und	 mehr	 in	 den	 Fokus	 der	 Wissenschaft.	 Aufgrund	 ihrer	 potenten,	
angstlösenden	Wirkung	repräsentieren	Neuropeptid	S	(NPS)	und	Oxytocin	(OXT)	zwei	mögliche	
Kandidaten	zur	Behandlung	von	Angsterkrankungen.	Beide	Neuropeptide	binden	an	G-Protein-
gekoppelte	 Rezeptoren	 und	 regulieren	 dadurch	 komplexe	 neuronale	 Signalwege.	 Daher	war	
das	Ziel	meiner	Doktorarbeit	zu	erforschen	(i)	welchen	Einfluss	OXT-Neurone	im	Hypothalamus	
auf	 die	 angstlösende	Wirkung	 von	NPS	 haben,	 (ii)	welche	 intrazellulären	 Signalkaskaden	der	
anxiolytischen	 Wirkung	 von	 NPS	 zugrunde	 liegen,	 und	 (iii)	 den	 zeitlichen	 Ablauf	 einer	
chemogenetischen	Aktivierung	der	OXT-Neurone	zu	charakterisieren.	
NPS-Rezeptoren	 (NPSR)	 werden	 im	 hypothalamischen	 Nucleus	 paraventricularis	 (PVN)	
exprimiert	 und	 zeigen	 eine	morphologische	 Überlappung	mit	 OXT-Neuronen,	 die	 sowohl	 im	
PVN	 also	 auch	 dem	 Nucleus	 supraopticus	 und	 den	 Nucleus	 accessorius	 lokalisiert	 wurden.	
Neben	 ihrer	 angstlösenden	Wirkung	 reduzieren	 sowohl	 NPS	 als	 auch	OXT	 soziale	 Angst	 und		
aggressives	Verhalten	in	Ratten	und	Mäusen.	Darüber	hinaus	mindern	beide	Neuropeptide	die	
Nahrungsaufnahme	 und	 hemmen	 die	 Schmerzwahrnehmung	 in	 Ratten.	 Aufgrund	 der	
ähnlichen	Verhaltenseffekte	beider	Neuropeptide	sowie	der	neuroanatomischen	Überlappung	
der	 neuronalen	 NPSR-	 und	 OXT-Expression	 untersuchte	 ich	 die	 Fragestellung,	 ob	 NPS-
induzierte	 Effekte	 über	 das	 Oxytocin-System	 im	 PVN	 vermittelt	 werden.	 Mittels	 einer	
retrograden	Markierung	konnte	ich	zeigen,	dass	NPS-immunoreaktive	Neurone	aus	dem	Locus	
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coeruleus	 zum	 PVN	 projizieren.	 Darüber	 hinaus	 bewies	 Fluoreszenz-aktivierte	 Zellsortierung,	
dass	 der	 NPSR	 in	OXT-Neuronen	 des	 PVN	 exprimiert	wird.	 In	 einer	 Subpopulation	 von	OXT-
Neuronen	 induzierte	 NPS	 durch	 die	 Bindung	 an	 seinen	 Rezeptor	 einen	 Anstieg	 des	
intrazellulären	 Calcium-Spiegels.	 Durch	 intrazerebrale	Mikrodialyse	 in	 Verbindung	mit	 einem	
hochsensitiven	 Radioimmunoassay	 für	 OXT	 konnte	 ich	 zeigen,	 dass	 NPS	 die	 somato-
dendritische	Freisetzung	von	OXT	im	PVN	erhöht.	Um	einen	kausalen	Zusammenhang	zwischen	
der	 NPS-induzierten	 Stimulation	 der	 OXT-Neurone	 und	 deren	 Effekt	 auf	 die	 angstlösende	
Wirkung	 von	 NPS	 zu	 untersuchen,	 habe	 ich	 eine	 chemogenetische	 Inhibierung	 der	 OXT-
Neurone	 sowie	 eine	 pharmakologische	 Blockade	 der	 OXT-Rezeptoren	 (OXTR)	 durchgeführt.	
Meine	Ergebnisse	demonstrieren,	dass	das	OXT-System	 im	PVN	eine	essentielle	Rolle	 für	die	
angstlösende	Wirkung	von	NPS	spielt.	
Um	das	Wissen	über	die	 intraneuronalen	Wirkmechanismen	von	NPS	 zu	erweitern,	habe	 ich	
die	NPSR-gekoppelten	Signalwege	untersucht.	Meine	Experimente	zeigten,	dass	eine	bilaterale	
Mikroinfusion	 von	 NPS	 in	 den	 Nucleus	 amygdalae	 medialis	 (MeA)	 das	 Angstverhalten	
männlicher	Wistar-Ratten	 sowohl	 auf	 der	 elevated	 plus	maze	 als	 auch	 in	 der	open	 field	 box	
reduziert.	 Zusätzlich	 demonstrierten	 die	 Untersuchungen,	 dass	 icv	 infundiertes	 NPS	 zur	
Expression	 und	 Phosphorylierung	 der	 Calcium/Calmodulin-abhängigen	 Kinase	 II	 und	 zur	
Phosphorylierung	der	Mitogen-aktivierten	Proteinkinase	ERK1/2	in	der	Amygdala	führt.	Durch	
die	Inhibierung	der	Phospholipase	C	mittels	des	spezifischen	Blockers	U73122	wurde	die	NPS-
induzierte	Anxiolyse	gehemmt.	Im	Gegensatz	dazu	verhinderte	die	pharmakologische	Blockade	
der	 Adenylatcyclase	 nicht	 die	 angstlösende	 Wirkung	 von	 NPS.	 Daher	 kann	 geschlussfolgert	
werden,	 dass	 die	 akute	 NPS-induzierte	 Anxiolyse	 von	 einem	 Phospholipase	 C-gekoppelten	
Signalweg	in	der	MeA	abhängig	ist.	
Im	 Hinblick	 auf	 die	 Validierung	 einer	 innovativen	 und	 hoch	 spezifischen	 Methode	 zur	
Aktivierung	 der	OXT-Neurone	 im	 PVN	 und	 den	 damit	 verbundenen	 Verhaltenskontext,	 habe	
ich	 die	 zeitliche	 Abfolge	 einer	 chemogenetischen	 Stimulation	 der	 OXT-Neurone	 untersucht.	
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Dadurch	konnte	ich	zeigen,	dass	die	chemogenetische	Aktivierung	innerhalb	einer	Stunde	zum	
Höhepunkt	der	OXT-Freisetzung	führt,	das	Angstverhalten	 in	der	Light/Dark	Box	mindert	und	
zu	einer	Zunahme	des	Putzverhaltens	 führt.	Darüber	hinaus	untersuchte	 ich	den	Einfluss	der	
chemogenetisch	aktivierten	OXT-Neurone	auf	die	Bewegungsaktivität	während	eines	Alkohol-
induzierten	Rauschzustandes.	Hierbei	hatte	die	endogene	OXT-Freisetzung	allerdings	nur	einen	
marginal	förderlichen	Effekt	auf	den	Bewegungsablauf.	
Zusammengefasst	erweitern	meine	experimentellen	Ergebnisse	unser	Verständnis	im	Hinblick	
auf	 den	 zugrundliegenden	 Mechanismus,	 der	 zur	 NPS-induzierten	 Anxiolyse	 führt,	 und	 den	
zeitlichen	 Verlauf	 der	 chemogenetisch	 induzierten	 Aktivierung	 von	 OXT-Neuronen	 im	 PVN	
sowie	deren	Einfluss	auf	definierte	Verhaltensweisen.	
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1	 Introduction	
1.1	 Definition	of	an	emotion	termed	anxiety	
Anxiety	 is	 a	 psychological	 and	 physiological	 state	 characterized	 by	 emotional,	 somatic,	 and	
behavioral	 imbalances	 (Seligman	 et	al.,	 2000).	 It	 is	 a	 state	 characterized	by	dreaded	 feelings	
about	something	that	appears	 intimidating	an	 individual.	 In	the	actual	or	 imaginary	presence	
of	 psychological	 stress,	 anxiety	 can	 create	 feelings	 of	 fear,	worry,	 and	uneasiness	 (Bouras	&	
Holt,	2007).	The	main	function	of	anxiety	is	to	act	as	a	signal	of	danger,	threat,	or	motivational	
conflict,	 and	 to	 trigger	 appropriate	 adaptive	 responses	 (Steimer,	 2002).	 Activation	 of	 the	
sympathetic	 nervous	 system	 resulting	 in	 increased	 heart	 rate,	 elevated	 blood	 pressure,	
enhanced	 vigilance,	 and	 increased	 autonomic	 and	 neuroendocrine	 activation	 may	 enable	
individuals	to	cope	with	a	precarious	situation	(Steimer,	2002).	These	physiological	adaptations	
are	 important	 and	 lead	 to	 fight-or-flight	 responses.	 Therefore,	 anxiety	 is	 considered	 to	 be	 a	
natural	 reaction	 to	 a	 stressor	 (Sokolowska	&	Hovatta,	 2013),	which	enhances	an	 individual’s	
lifespan	especially	 in	the	case	of	the	presence	of	predators	and	risky	situations	(Price,	2003).	
However,	 when	 anxiety	 becomes	 pathological	 and	 interfere	 with	 the	 ability	 to	 cope	
successfully	with	various	challenges	and	stressful	events,	it	may	fall	under	the	classification	of	
an	anxiety	disorder	(Lewis	et	al.,	2010).		
1.2	 Categories	and	comorbidity	of	anxiety	disorders	
The	 term	 anxiety	 disorder	 refers	 to	 panic	 disorders,	 post-traumatic	 stress	 disorders,	
agoraphobia,	 social	 anxiety	 disorders,	 obsessive-compulsive	 disorders,	 specific	 phobias	 and	
generalized	anxiety	disorders	 (GAD)	with	a	 lifetime	prevalence	of	 about	28	%	 (Kessler	 et	al.,	
2005).	 These	 anxiety	 disorders	 have	 specific	 symptoms,	 but	 all	 of	 them	 are	 dealing	 with	
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excessive,	 irrational	 fear	and	dread	 (Nutt	&	Ballenger,	2003).	Unlike	 the	 relatively	mild,	brief	
anxiety	caused	by	a	stressful	event	(such	as	speaking	in	public	or	a	first	date),	anxiety	disorders	
last	 at	 least	 six	 months	 (Kessler	 et	 al.,	 2005;	 Kessler	 &	 Wang,	 2008).	 Anxiety	 disorders	
commonly	occur	along	with	other	mental	or	physical	illnesses	making	the	diagnosis	of	anxiety	
disorders	 difficult	 (Nutt	 &	 Ballenger,	 2003).	 This	 is	 for	 instance	 exemplified	 by	 comorbid	
alcohol	 or	 substance	 abuse,	 which	 may	 mask	 anxiety	 symptoms	 or	 make	 them	 worse	
(Merikangas	et	al.,	1998;	Grant	et	al.,	2004;	Luthi	&	Luscher,	2014).	Furthermore	depressive-
like	 behavior,	 psychosomatic	 discomfort,	 eating	 disorders,	 as	 well	 as	 suicidal	 thoughts	
accompany	 anxiety	 disorders	 (Steimer,	 2002).	 A	 reinforcing	 factor	 is	 that	 impaired	 social	
interactions	 lead	 to	 isolating	 oneself	 from	 one	́s	 social	 environment,	 which	 results	 in	 social	
isolation	and	enhance	the	side	effects	mentioned	above	(Teo	et	al.,	2013).	Moreover,	anxiety	
disorders	require	increased	rates	of	chronic	medical	conditions	(Scott	et	al.,	2007).	
Steinhausen	and	colleagues	report	alarming	figures:	14	%	of	the	European	population	suffers	
from	 anxiety	 disorders,	 which	 constitute	 the	 second	 leading	 cause	 of	 mental	 illness	 after	
depression	 (Wittchen	 et	 al.,	 2011).	 In	 2010,	mental	 illnesses	 have	 caused	 costs	 around	 74.4	
billion	Euro	 in	the	health	system	of	the	European	Union	(Gustavsson	et	al.,	2011).	To	reduce	
these	costs,	and	to	improve	the	quality	of	life	of	those	suffering	from	anxiety	disorders,	several	
research	groups	are	working	to	develop	appropriate	therapeutic	approaches.		
1.3	 Drug	treatment	of	anxiety	disorders	
In	 December	 1951,	 Paul	 Charpentier	 synthetized	 the	 tricyclic	 antidepressant	 (TCA)	
chlorpromazine	 from	 synthetic	 histamines	 (Ban,	 2007).	 The	 psychiatric	 effects	 were	 first	
noticed	in	a	hospital	 in	Paris	 in	1952	and,	then,	widely	used	as	an	antipsychotic	drug	all	over	
the	 world.	 The	 TCAs	 with	 their	 3-ring	 molecular	 structure	 are	 primarily	 used	 in	 the	 clinical	
treatment	 of	 mood	 disorders	 such	 as	 major	 depression	 and	 anxiety	 disorders	 by	 inhibiting	
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both	 serotonin	 and	 norepinephrine	 reuptake	 from	 the	 synaptic	 cleft	 primarily	 by	 binding	 to	
and	modulating	serotonin	and	norepinephrine	transporters	(Feighner,	1999).	With	respect	to	
GAD,	 imipramine	 was	 found	 to	 exert	 anxiolytic-like	 effects	 (Rickels	 et	 al.,	 1993)	 and	 to	
decrease	 the	 risk	 of	 relapse	 (Mavissakalian	 &	 Perel,	 1999).	 The	major	 limiting	 factor	 to	 the	
more	widespread	use	of	TCAs	are	their	side	effects,	which	 includes	anti-cholinergic	and	anti-
adrenergic	 effects	 such	 as	 sedation,	 sexual	 dysfunction,	 dry	 mouth,	 constipation	 and	 their	
well-documented	toxicity	in	overdose	(Ravindran	&	Stein,	2009).	
Based	 on	 the	 knowledge	 that	 an	 imbalanced	 serotonin	 and	 norepinephrine	 system	 play	 a	
crucial	role	in	the	development	of	psychiatric	disorders,	monoamine	oxidase	inhibitors	(MAOI),	
selective	 serotonin	 reuptake	 inhibitors	 (SSRI),	 and	 serotonin/norepinephrine	 reuptake	
inhibitors	(SNRI)	were	developed	(Ravindran	&	Stein,	2009).	MAOIs	are	another	class	of	older	
antidepressants	 that	 has	 been	 investigated	 for	 anxiety	 disorders	 (Ravindran	 &	 Stein,	 2009).	
The	enzyme	monoamine	oxidase	is	irreversibly	inhibited	and	thereby	blocks	the	degradation	of	
monoamines	 such	 as	 serotonin	 and	 norepinephrine	 in	 the	 synaptic	 cleft.	 This	 results	 in	 an	
overall	 increased	 availability	 of	 these	 brain	 neurotransmitters.	 However,	 the	 efficacy	 and	
potency	of	MAOI	is	controversially	discussed	in	the	literature,	since	the	effectiveness	is	limited	
to	a	subpopulation	of	patients	suffering	from	anxiety	disorders	(Frank	et	al.,	1988;	Shestatzky	
et	al.,	1988;	Kosten	et	al.,	1991).	
More	 specifically,	 SSRIs	 and	 SNRIs	 inhibit	 the	 reuptake	 of	 the	 neurotransmitters	 via	 the	
presynaptic	serotonin/norepinephrine	transporter	pump,	resulting	in	increased	levels	of	brain	
serotonin	 and	 norepinephrine.	 Currently,	 six	 SSRIs	 are	 available	 for	 clinical	 use	 including	
fluoxetine	and,	most	recently,	escitalopram.	Due	to	their	tolerability,	efficacy	and	safety	they	
became	the	gold	standard	 for	 the	 treatment	of	GAD.	Moreover,	escitalopram	 is	effective	 for	
both	 acute	 and	 long-term	 treatment	 for	GAD	 (Davidson	 et	 al.,	 2004;	Goodman	 et	 al.,	 2005;	
Allgulander	 et	 al.,	 2006).	 The	 most	 prominent	 SNRI	 available	 for	 clinical	 use	 is	 venlafaxine,	
which	is	considered	as	alternative	first-line	agent	for	the	treatment	of	anxiety	disorders.	Tzanis	
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and	 colleagues	demonstrated	 that	 venlafaxine	was	effective	 to	prevent	 relapse	during	 a	 six-
month	 follow-up	 (Ferguson	 et	 al.,	 2007).	 However,	 it	 points	 out	 that	 drugs	 targeting	 the	
serotonin	 and/or	 norepinephrine	 system	 demonstrate	 a	 slow	 onset	 of	 actions	 and	 thereby	
require	a	constant	drug	intake	over	months.	
In	 1955,	 Leo	 Sternbach	 discovered	 an	 antipsychotic	 drug	 by	 chance	which	 core	 structure	 is	
based	on	a	benzene	ring	and	a	diazepine	ring.	A	few	years	later,	benzodiazepines	were	made	
available	 as	 diazepam	 (also	 called	Valium;	Hoffmann-LaRoche)(Wick,	 2013).	 Benzodiazepines	
enhance	signaling	of	the	neurotransmitter	gamma-aminobutyric	acid	(GABA)	by	binding	to	the	
GABAA	receptor	resulting	 in	 increased	total	conductance	of	chloride	 ions.	From	this	follows	a	
decreased	 excitability	 of	 neurons	 that	 brings	 about	 sedative,	muscle	 relaxant,	 anxiolytic	 and	
hypnotic	properties.	Based	on	their	 fast	onset	of	action	and	tolerability,	benzodiazepines	are	
commonly	used.	On	the	other	side,	benzodiazepine	treatment	 is	dangerous	 in	overdose	(due	
to	 oversedation,	 cognitive	 impairment,	 loss	 of	 locomotor	 coordination),	 comprises	 a	 risk	 of	
tolerance	 and	 dependence	 in	 long-term	 use.	 Moreover,	 individuals	 discontinuing	
benzodiazepine	 use	 may	 experience	 uncomfortable	 withdrawal	 symptoms.	 Thus,	
benzodiazepines	and	SSRIs	are	prescribed	simultaneously	to	treat	anxiety	disorders.	Once	the	
major	symptoms	are	attenuated	by	fast-acting	benzodiazepines,	SSRIs	stabilize	patient’s	mood	
for	a	longer	period	(Gross	&	Hen,	2004).	
So	 far,	 the	 development	 of	 therapeutics	 for	 anxiety	 disorders	 has	 generally	 focused	 on	 the	
improvement	 of	 acute	 symptoms	 and	 relapse	 prevention	 with	 little	 discussion	 of	 primary	
prevention	 (Mathew	 et	 al.,	 2008).	 Therefore,	 it	 is	 important	 to	 investigate	 neuropeptide	
systems	 and	 their	 involvement	 in	 anxiety	 disorders	 as	 this	 might	 help	 in	 the	 quest	 to	 i)	
understand	 the	 underlying	 mechanisms,	 which	 are	 responsible	 for	 the	 emergence	 of	 an	
anxiety	disorder	and	ii)	to	develop	new	pharmacological	tools	to	treat	anxiety	disorders.	
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1.4	 Neuropeptides	
Neurons	use	many	chemical	signals	to	convey	information,	including	more	than	100	different	
neuropeptides	 (Hokfelt	 et	 al.,	 2003).	 The	 human	 genome	 contains	 90	 genes	 that	 encode	
precursors	of	neuropeptides.	Neuropeptides	are	small	protein-like	molecules	composed	of	3-
100	amino	acids,	which	are	synthesized	at	ribosomes	in	the	perikaryon	(Hokfelt	et	al.,	2003).	
The	peptides	are	stored	in	vesicles	and	released	either	autocrine,	paracrine	or	neuroendocrine	
by	 various	 stimuli	 at	 axon	 collaterals	 and	 dendrites	 and	 then	 bind	 to	 G	 protein-coupled	
receptors	(GPCR)	presented	at	plasma	membrane	of	the	target	cell.	
Neuropeptides	 also	 function	 as	 neuromodulators:	 These	 neuronal	 signaling	molecules	 exert	
influence	on	the	activity	of	the	brain	in	specific	ways	and	are	thus	involved	in	particular	brain	
functions,	like	analgesia,	reward,	food	intake,	and	learning	and	memory	(Strand,	1999).		
Due	to	the	multifactorial	etiology	of	anxiety	disorders,	neuropeptides	have	been	recognized	to	
play	 a	 crucial	 role	 in	 the	development	of	 an	anxiety-like	phenotype,	 the	onset	of	 an	anxiety	
disorder	and	their	potential	as	a	pharmacological	tool.	Thus,	neuropeptides	are	a	“hot	spot”	in	
research	 for	which	 reason	a	 growing	number	of	 publications	over	 the	 last	 decades	 focus	on	
orexin,	 galanin,	 vasopressin,	 corticotropin	 releasing	 hormone,	 neuropeptide	 Y,	 substance	 P,	
prolactin,	oxytocin	(OXT)	and	neuropeptide	S	(NPS)	(Mathew	et	al.,	2008).	Understanding	the	
underlying	mechanisms	resulting	in	a	more	or	less	anxious	phenotype	may	lead	to	discover	the	
causes	of	anxiety	disorders	and	open	up	the	possibility	to	develop	new	therapies	and	drugs.		
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1.5	 The	brain	neuropeptide	S	system	
1.5.1	Discovery	of	Neuropeptide	S	receptor	and	its	endogenous	ligand	by	GPCR	
deorphanization	
GPCRs	are	a	main	component	 in	 the	 regulation	of	 cellular	homeostasis.	Activated	by	natural	
ligands,	 they	 induce	 the	 activation	 of	 various	 signaling	 cascades.	 At	 least	 800	 seven-
transmembrane	receptors	participate	in	diverse	physiological	and	pathological	functions	(Tang	
et	 al.,	 2012).	 Historically,	 ligands	were	 discovered	 first,	 but	 the	 advent	 of	molecular	 biology	
reversed	 this	 trend	 (Civelli,	 2012).	 Bioinformatics	 of	 DNA	 sequences	 gave	 rise	 to	 about	 140	
GPCRs	 whose	 natural	 ligands	 remain	 unknown.	 Thus,	 these	 GPCRs	 are	 called	 “orphan	
receptors”.	The	natural	 ligand	 is	discovered	by	so-called	“deorphanization”,	a	process	 that	 is	
based	on	reverse	pharmacology	(Pausch,	1997;	Chung	&	Civelli,	2006;	Civelli	et	al.,	2006;	Suga	
&	Haga,	2007).	
GPR154	 (also	known	as	GPRA,	PGR14,	ASRT2	and	VRR1)	and	 its	 ligand	were	 first	 reported	 in	
the	 patent	 literature	 (Sato	 et	 al.,	 2002).	 Searching	 public	 DNA	 databases,	 Reinscheid	 and	
colleagues	 identified	a	genomic	 sequence	encoding	 for	 the	GPR154	 ligand,	which	was	highly	
conserved	 among	 various	 species	 including	 humans,	 rats	 and	 mice	 (Xu	 et	 al.,	 2004).	 The	
precursor	protein	contains	a	hydrophobic	 signal	peptide	 that	 is	 immediately	 followed	by	 the	
initiator	 methionine.	 Moreover,	 a	 pair	 lysine/arginine	 motif	 might	 serve	 for	 proteolytic	
cleavage	 to	 process	 the	peptide	 (Reinscheid	&	Xu,	 2005b).	 The	mature	 ligand	 consists	 of	 20	
amino	acids	(N-SFRNGVGSGVKKTSFRRAKQ-C),	whereas	the	amino-terminal	residue	is	a	serine.	
According	to	the	nomenclature	that	has	been	used	earlier	(Shimomura	et	al.,	2002),	the	ligand	
was	named	NPS.		
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1.5.2	Expression	patterns	of	Neuropeptide	S	
NPS	 is	 expressed	 in	 all	 vertebrates	 with	 the	 exception	 of	 fish	 (Reinscheid,	 2007).	 In	 the	 rat	
brain,	NPS	mRNA	expression	was	examined	using	in	situ	hybridization.	NPS	mRNA	is	expressed	
discretely	in	a	few	brain	areas	with	strongest	expression	in	the	locus	coeruleus	(LC),	principle	
sensory	 5	 nucleus	 and	 the	 lateral	 parabrachial	 nucleus	 (Xu	 et	 al.,	 2004).	 Moderate	 NPS	
expression	 is	 present	 in	 the	dorsomedial	 hypothalamic	nucleus	 and	 the	 amygdala	 (Xu	 et	 al.,	
2004).	 Moreover,	 double	 in	 situ	 hybridization	 revealed	 that	 NPS	 mRNA	 colocalizes	
predominantly	with	vesicular	glutamate	transporter	(VGLUT)	mRNA,	indicating	that	these	cells	
are	 glutamatergic	 (Xu	 et	 al.,	 2007).	 A	 small	 number	 of	 NPS	 neurons	 coexpresses	 choline	
acetyltransferase	mRNA,	suggesting	presence	of	acetylcholine	(Xu	et	al.,	2007).	However,	NPS	
mRNA	expression	does	not	colocalize	with	tyrosine	hydroxylase	or	glutamate	decarboxylase	67	
(GAD67,	marker	for	GABAergic	neurons)	mRNA.	Moreover,	a	colocalization	of	NPS	mRNA	and	
corticotropin-releasing	 factor	 (CRF)	 mRNA	 is	 present	 in	 the	 lateral	 parabrachial	 nucleus.	
Densitometry	 analysis	 of	 rat	 NPS-immunoreactive	 fibers	 revealed	 that	 NPS-positive	 nerve	
endings	innervate	the	thalamus,	hypothalamus,	septal	nuclei	and	septal	border	zone	as	well	as	
amygdala	(Adori	et	al.,	2015).	
In	mice,	Pape	and	colleagues	showed	that	NPS	neurons	coexpress	the	CRF	receptor	1	(CRF-R1)	
and	are	in	close	proximity	to	CRF-containing	fibers	(Jungling	et	al.,	2012).	They	demonstrated	
that	CRF	depolarizes	NPS	neurons	through	activation	of	CRF-R1.	 In	vivo,	acute	immobilization	
stress	 leads	 to	 an	 activation	 of	 NPS	 neurons	 indicated	 by	 increased	 expression	 of	 the	
immediate	 early	 gene	 cFos	 (Jungling	 et	 al.,	 2012).	 Their	 data	 provide	 evidence	 for	 a	 direct	
interaction	between	the	CRF	and	NPS	system.	In	accordance,	forced	swim	stress	increases	the	
expression	 of	 cFos	 in	 NPS-immunoreactive	 neurons	 suggesting	 a	 role	 for	 NPS	 and	 its	
involvement	in	stress	system	(Liu	et	al.,	2011).	In	2011,	Singewald	and	colleagues	measured	in	
vivo	 release	of	NPS	following	stress	exposure.	Microdialysis	performed	within	the	basolateral	
amygdala	in	male	Sprague-Dawley	rats	revealed	increased	NPS-release	during	and	after	forced	
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swim	stress	suggesting	that	NPS	might	play	a	regulatory	role	in	stress	responsiveness	(Ebner	et	
al.,	2011).	
1.5.3	NPS	receptor	distribution	and	intracellular	signaling	
The	 NPS	 receptor	 (NPSR)	 is	 a	 typical	 GPCR	 composed	 of	 a	 7-transmembrane	 domain.	 The	
highest	 degree	 of	 similarity	 with	 respect	 to	 homology	 is	 found	 with	 vasopressin	 and	 OXT	
receptors	 (OXTR)	 (Reinscheid	 &	 Xu,	 2005b).	 Using	 in	 situ	 hybridization,	 Reinscheid	 and	
colleagues	 demonstrated	 NPSR	 mRNA	 expression	 widely	 throughout	 the	 central	 nervous	
system	with	moderate	to	high	levels	of	NPSR	expression	found	in	thalamus	and	several	nuclei	
of	the	hypothalamus,	including	the	paraventricular	hypothalamic	nucleus	as	well	as	cortex	and	
amygdala	(Xu	et	al.,	2004;	Reinscheid	&	Xu,	2005b).	Contrary,	within	the	brainstem	the	NPSR	
mRNA	 was	 detected	 at	 low	 levels.	 Similar	 expression	 patterns	 have	 been	 demonstrated	 at	
mRNA	levels	in	mouse	brain	(Clark	et	al.,	2011).	Thus,	the	expression	of	NPSR	mRNA	in	anxiety-
associated	neurocircuits	of	the	limbic	system	indicates	that	the	NPS	system	may	interact	with	
other	neurotransmitter	and	neuropeptide	systems.	
The	 pharmacological	 characteristics	 of	 NPSR	 activation	 were	 examined	 in	 both,	 Chinese	
hamster	ovary	(CHO)	cells	and	human	embryonic	kidney	293	T	(HEK293T)	cells	(Reinscheid	et	
al.,	2005;	Camarda	et	al.,	2009;	Liao	et	al.,	2016).	 In	vitro,	 cells	stably	 transfected	with	NPSR	
construct	 demonstrate	 reliable	 increases	 in	 intracellular	 Ca2+	 levels	 and	 cyclic	 adenosine	
monophosphate	 (cAMP)	 levels	 at	 low	 nanomolar	 concentrations	 of	 NPS	 (Reinscheid	 et	 al.,	
2005).	 This	 suggests	 that	 the	 NPSR	 is	 coupled	 to	 both	 Gq	 and	 Gs	 proteins	 (Xu	 et	 al.,	 2004;	
Reinscheid	 et	 al.,	 2005).	 In	 hippocampal	 NPSR-transfected	 neurons,	 researchers	 detected	 a	
biphasic	time	course	of	NPSR-mediated	Ca2+	influx	with	a	fast	and	slow	component	suggesting	
two	major	Ca2+	routes	via	intracellular	stores	and	extracellular	space	(Erdmann	et	al.,	2015).	In	
Ca2+-free	solution	the	slow	component	was	drastically	reduced	suggesting	Ca2+	influx	from	the	
extracellular	space.	However,	it	is	not	known	which	Ca2+	channel(s)	manage(s)	the	entry	of	the	
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divalent	ion	upon	NPS	administration.	Moreover,	NPS	induces	phosphorylation	and	thereby	an	
activation	of	the	mitogen-activated	protein	kinase	(MAPK)	pathway	(Reinscheid	et	al.,	2005).	
1.5.4	Single	nucleotide	polymorphism	in	NPSR	gene	
Two	 studies	 identified	 a	 possible	 panic	 disorder	 susceptibility	 locus	 on	 human	 chromosome	
7p15	 (Knowles	 et	 al.,	 1998;	 Logue	 et	 al.,	 2003).	 In	 2004,	 Kere	 and	 collogues	 described	 a	
number	 of	 single	 nucleotide	 polymorphisms	 (SNP)	 in	 the	 NPSR	 gene	 that	 is	 located	 on	
chromosome	7p14-15	(Laitinen	et	al.,	2004).	Analysis	of	genomic	DNA	from	blood	samples	of	a	
Japanese	cohort	revealed	that	the	functional	NPSR	A/T	polymorphism	(SNP	database	accession	
number	rs324981),	which	leads	to	an	amino	acid	exchange	of	asparagine	into	isoleucine	(Ile)	at	
position	 107,	 is	 associated	 with	 panic	 disorders	 in	 male	 patients	 (Okamura	 et	 al.,	 2007).	
Paradoxically,	 this	 SNP	 leads	 to	 a	 gain-of-function	 in	 NPSR	 functioning	 by	 increasing	 its	
sensitivity	 to	NPS	about	tenfold	 (Reinscheid	&	Xu,	2005a).	Moreover,	Therien	and	colleagues	
demonstrated	 an	 increased	 expression	 of	 Ile107	 allele	 that	 caused	 an	 increased	 cell	 surface	
expression	 in	vitro	(Bernier	et	al.,	2006).	This	effect	was	recently	confirmed	by	Neumann	and	
colleagues	 using	 a	 rat	 model	 selectively	 bred	 for	 high	 anxiety-related	 behavior;	 here	 a	
synonymous	 SNP	 was	 found	 (Slattery	 et	 al.,	 2015).	 It	 is	 speculated	 that	 the	 Ile107	 allele	
characterized	 by	 increased	 agonist	 sensitivity	 might	 lead	 to	 an	 overstimulation	 of	 neuronal	
circuits	 that	 are	 modulated	 by	 NPS	 (Okamura	 et	 al.,	 2007;	 Raczka	 et	 al.,	 2010).	 A	 second	
population-based	 study	 of	NPSR	 SNPs	 in	 a	 Swedish	 cohort	 confirmed	 a	 correlation	 between	
NPSR	 polymorphisms	 and	 anxiety	 disorders	 (Donner	 et	 al.,	 2010).	 Moreover,	 a	 multilevel	
approach	 was	 applied	 to	 further	 elucidate	 the	 role	 of	 NPS/NPSR	 system	 in	 the	 etiology	 of	
human	 anxiety	 (Domschke	 et	 al.,	 2011).	 Herein,	 the	 A/T	 polymorphism	 was	 found	 to	 be	
associated	 with	 panic	 disorders,	 too.	 Moreover,	 the	 T	 risk	 allele	 was	 related	 to	 increased	
anxiety	 sensitivity.	 As	 the	 amygdala	 has	 a	 pivotal	 role	 in	 transforming	 stressful	 events	 into	
anxiety	 (Roozendaal	 et	 al.,	 2009),	 Domschke	 and	 colleagues	 found	 the	 above-mentioned	
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functional	 SNP	 in	 the	 human	 NPSR	 gene	 to	 be	 associated	 with	 altered	 amygdala	
responsiveness	 to	 aversive	 stimuli	 in	 healthy	 European	 participants	 free	 from	 any	 life-time	
history	of	psychiatric	disorders	(Dannlowski	et	al.,	2011).	Hence,	this	might	contribute	to	the	
development	of	an	anxiety	disorders	(Dannlowski	et	al.,	2011).		
1.5.5	Neurobiological	actions	of	NPS	
Neurons	 from	 lateral	 parabrachial	 nucleus	 (which	 amongst	 others	 harbors	 a	 cluster	 of	 NPS-
immunoreactive	 cells)	 project	 to	 ventromedial	 and	 paraventricular	 hypothalamic	 nuclei,	
amygdala	 and	 periaqueductal	 gray	 (Gauriau	 &	 Bernard,	 2002).	 Since	 the	 NPSR	 is	 highly	
abundant	 in	 limbic	 brain	 regions	 such	 as	 amygdala,	 hypothalamus,	 bed	 nucleus	 of	 the	 stria	
terminalis,	 raphe	 nucleus	 and	 ventral	 tegmental	 area,	 NPS	 might	 influence	 emotional	
behaviors	and	body	homeostasis	(Reinscheid	&	Xu,	2005a).	
Reinscheid	 and	 colleagues	 demonstrated	 strong	 anxiolytic-like	 activity	 of	
intracerebroventricularly	 (icv)	 infused	 NPS	 in	 mice	 subjected	 to	 elevated	 plus	 maze	 (EPM),	
light/dark	box	(LDB)	and	open	field	(OF)	(Xu	et	al.,	2004).	Moreover,	the	anxiolytic	activity	was	
confirmed	by	a	marble-burying	test,	a	model	that	is	not	biased	by	locomotor	activity	(Xu	et	al.,	
2004;	 Paneda	 et	 al.,	 2009).	 Since	 2006,	 the	 anxiolytic	 action	 of	 NPS	 was	 confirmed	 using	
various	tests	in	mice	and	rats	following	icv	(Leonard	et	al.,	2008;	Rizzi	et	al.,	2008;	Vitale	et	al.,	
2008;	Wegener	et	al.,	2011;	Slattery	et	al.,	2015)	and	local	infusions	(Smith	et	al.,	2006)	as	well	
as	intranasal	applications	(Ionescu	et	al.,	2012;	Lukas	&	Neumann,	2012;	Dine	et	al.,	2015).	
Based	 on	 Pavlovian	 conditioning,	 an	 aversive	 stimulus	 such	 as	 an	 electric	 foot	 shock	 is	
associated	with	a	neutral	 stimulus	 (e.g.	 tone),	a	process	 termed	acquisition	phase.	This	cued	
fear	conditioning	paradigm	is	based	on	associative	fear	memory	that	is	tested	by	presentation	
of	 conditioned	 stimulus	 alone.	 The	 freezing	 behavior	 during	 extinction	 phase	 indicates	 fear	
response	of	an	animal.	However,	 repeated	presentation	of	 the	conditioned	stimulus	without	
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aversive	 stimulus	 leads	 to	 gradual	 extinction	 of	 fear	 response.	 NPS	 was	 found	 to	 reliably	
reverse	cued	fear	in	both	mice	and	rats	(Jungling	et	al.,	2008;	Slattery	et	al.,	2015;	Zoicas	et	al.,	
2016).	 This	 effect	 is	 mediated	 by	 NPS-evoked	 increase	 in	 glutamatergic	 transmission	 to	
intercalated	GABAergic	neurons	in	the	amygdala	(Jungling	et	al.,	2008;	Pape	et	al.,	2010).	More	
specifically,	 NPS	 blocked	 the	 expression	 of	 fear-potentiated	 startle	 (Fendt	 et	 al.,	 2010).	 In	
addition,	 NPS	 facilitates	 extinction	 of	 social	 fear	 and	 reduces	 avoidance	 behavior	 in	 a	 social	
defeat	 model	 in	 mice	 (Zoicas	 et	 al.,	 2016).	 Although	 NPS	 enhances	 object	 recognition	
(Okamura	 et	 al.,	 2011),	 it	 failed	 to	 prolong	 social	 memory	 in	 rats	 suggesting	 that	 NPS	 has	
memory-enhancing	effects	 in	a	non-social	context	 (Lukas	&	Neumann,	2012).	Reinscheid	and	
colleagues	 demonstrated	 an	 attenuation	 of	 NPS-induced	memory	 enhancement	 by	 blocking	
the	 adrenergic	 signaling,	 suggesting	 an	 interaction	 between	 NPS	 system	 and	 the	 brain	
noradrenergic	system	to	promote	arousal	(Okamura	et	al.,	2011).	
NPS	 effects	were	 also	 investigated	 in	 the	 context	 of	 aggressive-like	 behavior.	 Neumann	 and	
colleagues	demonstrated	anti-aggressive	effects	of	icv	infused	NPS	in	rats	selectively	bred	for	
low	anxiety-like	behavior	(Beiderbeck	et	al.,	2014).	This	effect	was	confirmed	in	mice	subjected	
to	the	resident/intruder	test	(Ruzza	et	al.,	2015).	Herein,	NPS	facilitated	anti-aggressive	effects	
that	were	abolished	in	the	presence	of	the	non-peptidergic	NPSR	antagonist	SHA-68.		
In	 2005,	 Sticker-Krongrad	 and	 colleagues	 described	 an	 anorexigenic	 effect	 of	 NPS.	 In	 Long-
Evans	rats,	icv	infused	NPS	strongly	inhibited	chow	intake	in	overnight	fasted	rats	(Beck	et	al.,	
2005).	Moreover,	they	demonstrate	that	this	effect	is	independent	of	neuropeptide	Y,	ghrelin	
and	leptin	pathways.	A	second	study	confirms	the	findings	as	both	 icv	and	intra-PVN	infusion	
of	 NPS	 reduced	 food	 intake,	 too	 (Smith	 et	 al.,	 2006).	 In	 2009,	 Ciccocioppo	 and	 colleagues	
identified	 the	hypothalamic	PVN	as	an	 important	 site	of	NPS’	anorexic	effect.	Moreover,	 the	
NPS	effects	on	 reduction	of	 food	 intake	were	completely	blocked	 in	 the	presence	of	a	NPSR	
antagonist	 (Fedeli	 et	 al.,	 2009).	 In	 addition,	 it	 was	 demonstrated	 that	 the	 NPS-induced	
decrease	of	 food	 intake	were	not	modified	by	CRF-R	antagonists	 indicating	 that	NPS’	effects	
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are	independent	of	the	hypothalamic	CRF	system	(Fedeli	et	al.,	2009;	Peng	et	al.,	2010).	
Patients	 suffering	 from	 chronic	 pain	 have	 an	 increased	 prevalence	 to	 develop	 an	 anxiety	
disorder	(Hasnie	et	al.,	2007;	Kroenke	et	al.,	2009;	Newcomer	et	al.,	2010;	Reme	et	al.,	2011).	
The	 periaqueductal	 gray	 is	 an	 important	 component	 of	 pain	 system	 (Fields	 et	 al.,	 1991).	
Moreover,	this	brain	region	has	been	demonstrated	to	express	high	levels	of	NPSR	mRNA	(Xu	
et	al.,	2007).	In	2009,	Wang	and	colleagues	demonstrated	an	anti-nociceptive	effect	of	NPS	in	a	
dose-dependent	manner	using	hot-plate	test	and	a	formalin	test,	an	effect	that	was	prevented	
in	 the	 presence	 of	 a	 NPSR	 antagonist	 (Li	 et	 al.,	 2009;	 Peng	 et	 al.,	 2010).	 In	 2014,	Mao	 and	
colleagues	demonstrated	that	sciatic	nerve	 injury	 increases	anxiety-like	behavior,	a	condition	
that	 was	 accompanied	 by	 a	 decreased	 NPS	 expression	 (Zhang	 et	 al.,	 2014).	 However,	
exogenously	applied	NPS	reversed	pain-induced	anxiety.	Herein,	they	argue	that	NPS	enhances	
GABAergic	transmission	in	the	amygdala	and	thus	reduces	anxiety-like	behavior.	
In	 summary,	 the	brain	NPS/NPSR	 system	promotes	 anxiolysis,	 reverses	 cued	 and	 social	 fear,	
enhances	 memory,	 facilitates	 anti-aggressive	 effects,	 reduces	 food	 intake	 and	 has	 anti-
nociceptive	 properties.	 Thus,	 the	 NPS/NPSR	 system	 is	 a	 strong	 regulator	 of	 both	 emotional	
behaviors	and	body	homeostasis.	
1.6	 The	brain	oxytocin	system	
1.6.1	Synthesis	and	release	of	oxytocin	
In	1906,	Sir	Henry	Dale	discovered	that	extracts	from	the	posterior	pituitary	stimulated	uterus	
contractions	of	a	cat.	It	was	also	Henry	Dale	who	coined	out	the	name	oxytocin	(OXT)	from	the	
Greek	 words	 “ὀξύς	 τόκος”,	 meaning	 swift	 birth.	 Accordant	 to	 the	 Greek	 name,	 the	 most	
prominent	 peripheral	 effect	 of	 OXT	 is	 the	 induction	 of	 uterine	 contractions	 facilitating	 birth	
(Fuchs	&	Poblete,	1970)	and,	moreover,	maintaining	well-known	neuroendocrine	effects	such	
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as	milk	ejection	and	orgasm	(Rhodes	et	al.,	1981;	Gimpl	&	Fahrenholz,	2001).		
The	 nonapeptide	 OXT	 is	 synthetized	 by	 neurons	 located	 in	 the	 hypothalamic	 PVN,	 the	
supraoptic	nucleus	 (SON),	and	accessory	nuclei	 (AN)	of	 the	hypothalamus	 (Fig.	1)	 (Rhodes	 et	
al.,	1981;	Swanson	&	Sawchenko,	1983).	Stored	in	large-dense	core	vesicles	(LDCV)	along	with	
their	 respective	 carrier	 proteins	 called	 neurophysins,	 OXT	 is	 released	 from	 magnocellular	
neurons	 with	 a	 diameter	 of	 20-30	 µm	 into	 the	 periphery	 via	 axons	 forming	 neurohemal	
contacts	 within	 the	 neurohypophysis	 (Gimpl	 &	 Fahrenholz,	 2001;	 Meyer-Lindenberg	 et	 al.,	
2011).		
	
Figure	1:	OXT	neurons	located	within	hypothalamic	PVN,	SON	and	AN.	Scale	bar	represents	500	µm.	Adapted	from	
Eliava	et	al.,	2016.	
	
Moreover,	magnocellular	PVN-OXT	neurons	innervate	forebrain	structures	such	as	the	nucleus	
accumbens	(Dolen	et	al.,	2013)	and	the	central	nucleus	of	the	amygdala	(CeA).	Within	the	CeA,	
Grinevich	and	colleagues	demonstrated	that	OXT	release	from	local	axonal	endings	specifically	
controls	region-associated	behaviors	such	as	decreased	freezing	responses	in	fear-conditioned	
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rats	(Knobloch	et	al.,	2012).		
Electron	microscopic	profiles	demonstrated	that	dendrites	of	magnocellular	OXT	neurons	have	
a	 strong	 peptide	 immunoreactivity	 (Armstrong,	 1995)	 revealing	 abundant	 LDCV	 in	
somatodendritic	structures	(Pow	&	Morris,	1989).	The	first	evidence	that	dendrites	could	be	a	
substantial	source	of	peptide	release	came	from	studies	of	the	magnocellular	neurons	of	the	
supraoptic	nucleus	demonstrating	that	central	and	peripheral	release	of	vasopressin	and	OXT	
differ	 in	 temporal	 dynamics	 and	 do	 not	 necessarily	 act	 in	 a	 linear	 fashion	 (Neumann	 et	 al.,	
1993a;	Ludwig,	1998;	Ludwig	&	Leng,	2006).		
In	 contrast	 to	magnocellular	 neurons,	 parvocellular	 OXT	 neurons	 terminate	mainly	 in	 spinal	
chord	 and	 brainstem	 (Swanson	 &	 Sawchenko,	 1983).	 It	 has	 been	 proposed	 that	 OXT	 from	
parvocellular	OXT	axonal	terminals	contributes	to	the	modulation	of	cardiovascular	functions,	
breathing,	 and	 feeding	 behavior	 (Mack	 et	 al.,	 2002;	 Petersson,	 2002;	 Atasoy	 et	 al.,	 2012).	
Recently,	 a	 subpopulation	 of	 parvocellular	 OXT	 neurons	 located	 within	 the	 PVN	 has	 been	
demonstrated	 to	 control	 the	 activity	 of	 magnocellular	 OXT	 neurons	 within	 the	 SON	 and	 to	
suppress	nociception	in	order	to	facilitate	analgesia	(Eliava	et	al.,	2016).	
The	 release	 of	 LDCVs	 is	 evoked	 by	 a	 rise	 in	 intracellular	 Ca2+	 levels	 (Hokfelt,	 1991).	
Magnocellular	neurons	synthesizing	OXT	are	densely	filled	with	LDCV,	representing	85%	of	the	
total	volume	of	the	neuron	and	thus	contain	very	large	amounts	of	OXT	(Stoop,	2012;	Stoop	et	
al.,	2015).	Under	physiological	conditions,	OXT-filled	LDCVs	are	bound	to	F-actin	(Ludwig	et	al.,	
2016).	 Once	 OXT	 neurons	 are	 activated	 (e.g.	 by	 transient	 Ca2+	 influx),	 F-actin	 is	 rapidly	 and	
reversibly	 depolymerized	 to	 G-actin,	 the	 OXT-filled	 vesicle	 is	 transported	 to	 the	membrane,	
and	 following	 binding	 of	 a	 SNARE	 complex,	 the	 vesicle	 fuses	 with	 the	 plasma	 membrane	
resulting	in	the	release	of	OXT	into	the	extracellular	space	(Ludwig	et	al.,	2016).	The	Ca2+	that	
triggers	release	of	OXT	can	originate	from	extracellular	and	intracellular	sources	such	as	N-type	
voltage-gated	 Ca2+	 channels	 which	 appeared	 to	 be	 particularly	 important	 for	 dendritic	 OXT-
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release	(Fisher	&	Bourque,	1996),	N-methyl-D-aspartate	receptors	that	influence	burst	firing	of	
OXT	 neurons	 (Hu	 &	 Bourque,	 1992),	 and	 intracellular	 Ca2+	 stores	 like	 the	 endoplasmic	
reticulum	 (Lambert	 et	 al.,	 1994).	 Similarly,	 dendritic	 release	 of	 OXT	 also	 depends	 on	 the	
increase	in	intracellular	Ca2+	(Neumann	et	al.,	1993b;	Lambert	et	al.,	1994;	Ludwig	et	al.,	2002;	
Landgraf	 &	 Neumann,	 2004;	 Ludwig	 &	 Leng,	 2006).	 Moreover,	 dendritic	 release	 is	
accompanied	 by	 “priming”,	 an	 effect	 facilitated	 by	 internal	 Ca2+	 mobilization	 which	 makes	
secretory	vesicles	available	for	release	in	response	to	electrical	stimuli	(Ludwig	&	Leng,	2006).	
Once	 released	within	 the	brain,	OXT	has	a	half-life	 time	of	20	min	 in	 the	 cerebrospinal	 fluid	
(Ludwig	&	Leng,	2006);	the	half-life	in	blood	was	assessed	to	be	about	1.5	min	(Higuchi	et	al.,	
1986).	Its	degradation	is	mainly	operated	by	aminopeptidases	(Stoop,	2012).	
Altogether,	these	studies	demonstrate	that	OXT	neurons	show	widespread	central	projections	
of	hypothalamic	OXT	neurons,	underlining	the	evolution	of	a	fine-tuned	network	composed	of	
various	projections	originating	from	hypothalamic	areas	(Viviani	et	al.,	2011;	Stoop,	2012).	
1.6.2	Brain	OXTR	distribution	and	intracellular	signaling	
The	 OXTR	 is	 a	 GPCR	 composed	 of	 a	 7-transmembrane	 domain.	 Most	 notably,	 the	 OXTR	
expression	 is	 located	 in	 cortical	 areas,	 the	 olfactory	 system,	 the	 basal	 ganglia,	 the	 limbic	
system	(e.g.	lateral	septum,	amygdala,	subiculum),	the	thalamus	and	hypothalamus,	the	brain	
stem	and	the	spinal	cord	(Gimpl	&	Fahrenholz,	2001).	The	OXTR	is	functionally	coupled	to	a	Gq	
protein	 that	 stimulates	 the	 activity	 of	 phospholipase	 C	 (PLC).	 Consequently,	 PLC	 cleaves	
inositol-4,5-bis-phosphate	 (PIP2)	 into	 1,2-diacylglycerol	 (DAG)	 and	 inositol-1,4,5-triphosphate	
(IP3),	 whereas	 DAG	 stimulates	 protein	 kinase	 C,	 and	 IP3	 increases	 intracellular	 Ca2+	 levels	
(Gimpl	&	Fahrenholz,	2001;	van	den	Burg	&	Neumann,	2011).	The	latter	is	of	great	importance	
in	 the	 regulation	 of	 firing	 patterns	 and	 excitability	 and,	 consequently,	 neurosecretion,	 gene	
transcription,	 and	 protein	 synthesis.	 In	 most	 cellular	 systems,	 the	 OXT-induced	 rise	 in	
intracellular	 Ca2+	 levels	 is	 more	 prominent	 in	 the	 presence	 of	 extracellular	 Ca2+	 (Clapham,	
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2007).	This	suggests	that	OXT	might	increase	intracellular	Ca2+	 levels	via	receptor-	or	voltage-
gated	 channels	 (Zhong	 et	 al.,	 2008).	 Recently,	 it	 has	 been	 shown	 that	 OXT	 stimulation	
promotes	 Ca2+	 influx	 via	 transient	 receptor	 potential	 vanilloid	 type	 2	 (TRPV2)	 channels	 in	 a	
phosphoinositide	 3-kinase	 (PI3K)-dependent	manner	 (van	 den	 Burg	 et	 al.,	 2015).	Moreover,	
Ca2+	 influx	 from	 extracellular	 space	 is	 necessary	 for	MAPK	 kinase	 (MEK1/2)	 phosphorylation	
and	 the	 anxiolytic	 effect	 of	 OXT	 within	 the	 PVN.	 In	 addition,	 Neumann	 and	 colleagues	
demonstrated	 that	 an	 OXT-induced	 phosphorylation	 of	 MEK1/2	 is	 necessary	 to	 promote	
anxiolysis	in	male	(Blume	et	al.,	2008)	as	well	as	in	female	virgin	and	lactating	rats	(Jurek	et	al.,	
2012).	
1.6.3	Central	effects	of	OXT	
Local	infusion	of	synthetic	OXT	into	the	hypothalamic	PVN	and	the	central	amygdala	promotes	
acute	anxiolytic	 activity	 in	both	males	and	 females	 (Neumann	 et	al.,	 2000;	Bale	 et	al.,	 2001;	
Blume	et	al.,	2008;	Neumann,	2008;	van	den	Burg	&	Neumann,	2011;	 Jurek	et	al.,	2012;	van	
den	Burg	et	al.,	2015).	Besides	induction	of	lordosis	behavior	in	females	and	erectile	effect	of	
OXT	 in	males	 in	response	to	the	expectation	of	copulation	(McCarthy	et	al.,	1994;	Argiolas	&	
Melis,	 2004),	 mating-induced	 release	 of	 endogenous	 OXT	 similarly	 reduces	 the	 state	 of	
anxiety-related	behavior	(Waldherr	&	Neumann,	2007).	
Furthermore,	OXT	has	been	demonstrated	to	reduce	pain	perception	(Juif	et	al.,	2013;	Juif	&	
Poisbeau,	 2013),	 which	 is	 maintained	 by	 a	 population	 of	 parvocellular	 OXT	 neurons	 that	
prevent	 inflammatory	pain	processing	by	 inhibition	of	 sensory	 spinal	 cord	neurons	 (Eliava	 et	
al.,	2016).	
In	1991,	Verbalis	and	colleagues	discovered	an	anorexic	effect	following	central	OXT	infusion.	
This	effect	was	confirmed	using	a	specific	OXTR	agonist,	whereas	an	OXTR	antagonist	(OXTR-A)	
blocked	the	anorexic	effect	in	food-deprived	rats	(Olson	et	al.,	1991a;	Olson	et	al.,	1991b).	
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Moreover,	 OXT	 was	 found	 to	 attenuate	 ethanol-induced	 motor	 impairments	 in	 rats	 by	
preventing	 ethanol	 actions	 at	 delta-subunit	 of	 the	 GABAA	 receptor	 (Bowen	 et	 al.,	 2015).	 In	
addition,	 central	 OXT	 infusion	 inhibits	 ethanol-induced	 dopamine	 release	 in	 the	 nucleus	
accumbens	and	reduces	ethanol	consumption	after	long-term	voluntary	ethanol	intake	(Peters	
et	al.,	2016).	
Besides	 OXT’s	 non-social	 effects,	 Kelsch	 and	 colleagues	 demonstrated	 that	 OXT	 enhances	
social	 recognition	 by	 modulating	 cortical	 control	 of	 early	 olfactory	 processing	 (Oettl	 et	 al.,	
2016).	Moreover,	social	fear	represents	a	main	symptom	of	social	anxiety	disorder	that	can	be	
mimicked	in	the	social	fear-conditioning	paradigm	(Toth	et	al.,	2012;	Toth	&	Neumann,	2013).	
Fittingly,	 synthetic	OXT	promotes	 extinction	of	 social	 fear	 (Zoicas	 et	 al.,	 2014).	 In	 extension,	
OXT	has	been	shown	to	facilitate	pro-social	behavior	and	it	prevents	social	avoidance	in	both	
rats	and	mice	(Lukas	et	al.,	2013).	In	addition,	OXT	increases	social	investigation	and	mediates	
rodent	 social	 memory	 in	 regions	 of	 the	 limbic	 system,	 namely	 lateral	 septum	 and	 medial	
amygdala	 (Lukas	 &	 Neumann,	 2013).	 Furthermore,	 OXT	 has	 been	 shown	 to	 be	 a	 crucial	
regulator	of	pair	bonding	(Insel	&	Shapiro,	1992;	Carter	et	al.,	1995;	Insel	&	Hulihan,	1995;	Cho	
et	al.,	1999)	and	maternal	behavior	(Pedersen	&	Prange,	1979;	Neumann	et	al.,	2000;	Bosch	et	
al.,	2004;	Bosch	et	al.,	2005;	Pedersen	et	al.,	2006).	Lastly,	OXT	has	been	demonstrated	to	play	
a	major	 role	 in	 the	 regulation	 of	 stress	 responsiveness	 and	 the	 regulation	 of	 hypothalamic-
pituitary-adrenal	 axis	 in	 response	 to	 a	 variety	 of	 emotional,	 but	 also	 physical	 and	
pharmacological	stressors	(Neumann,	2008;	Neumann	&	Slattery,	2016).	
Taking	 into	 account	 that	 OXT	 release	 is	 maintained	 by	 magnocellular	 and	 parvocellular	
neurons,	by	axonal	and/or	 somatodendritic	 release,	 the	 regulatory	 role	of	Ca2+	 influx	and	 its	
influence	 on	 OXT	 release	 and	 the	 numerous	 cell	 types	 expressing	 OXTRs	 might	 explain	 the	
distinct	impact	of	OXT	in	brain-region	specific	behaviors	(Lee	et	al.,	2009).	
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1.7	 Characterization	of	distinct	cellular	populations	by	
fluorescent	signals	
In	2008,	the	Nobel	Prize	in	Chemistry	was	awarded	to	Osamu	Shimomura,	Martin	Chalfie	and	
Roger	 Y.	 Tsien	 “for	 the	 discovery	 and	 development	 of	 the	 green	 fluorescent	 protein	 (GFP)”	
(Figure	 2).	 Originally	 derived	 from	 jellyfish	 Aequorea	 victoria,	 GFP	 is	 frequently	 used	 as	 a	
reporter	gene	and	redefined	fluorescent	microscopy	(Arun	et	al.,	2005;	Yuste,	2005).		
	
Figure	2:	Green	fluorescent	protein	(GFP).	Typical	beta-barrel	structure	of	the	green-light	emiting	protein	originally	
derived	from	Aequorea	victoria.	
	
Based	 on	 the	 properties	 of	 GFP,	 genetic	mutants	 have	 been	 examined	 for	 their	 fluorescent	
activity	 such	 as	 the	 yellow	 fluorescent	 protein	 (YFP).	 To	 date,	 improved	 versions	 of	 YFP	 are	
Citrine,	Ypet	and	Venus.	The	latter	contains	a	novel	amino	acid	substitution	transforming	the	
protein	 to	 the	 most	 powerful	 fluorescent	 protein	 to	 date	 (Miyawaki	 et	 al.,	 1997).	 Tagging	
proteins	of	 interest	with	Venus	allows	 identification	of	a	specific	cell	population	with	highest	
precision.	
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1.7.1	Fluorescence-activated	cell	sorting	
Recently,	 Grinevich	 and	 colleagues	 constructed	 an	 adeno-associated	 virus	 (AAV)	 expressing	
Venus	under	the	control	of	an	OXT	promoter	fragment	and	infused	it	 into	the	PVN,	SON	and	
AN	of	female	Wistar	rats.	More	than	97	%	colocalization	of	OXT	and	Venus	has	been	observed	
(Knobloch	et	al.,	2012)	underlying	the	high	specificity	of	this	construct.	Thus,	Venus-labeling	of	
OXT-immunoreactive	neurons	provides	the	basis	for	precise	cell	sorting.	
Fluorescence-activated	 cell	 sorting	 (FACS)	 is	 a	 specialized	 form	of	 flow	 cytometry.	Hereby,	 a	
heterogeneous	cell	population	 is	 sorted	cell-by-cell.	 First,	each	cell	enters	a	 single	droplet	as	
soon	 it	 leaves	 the	nozzle	 tip.	Since	each	 fluorophore	has	a	characteristic	peak	excitation	and	
emission	wavelength	 following	 excitation	 by	 laser,	 a	 detector	 characterizes	 each	 single	 cell.	
Depending	on	the	fluorescent	signal	of	the	cell,	the	drop	is	electronically	charged.	Next,	drops	
containing	 a	 single	 cell	 pass	 two	 deflection	 plates	 that	 either	 attract	 or	 repel	 the	 cells	
accordant	 to	 their	 charge	 into	 collection	 tubes.	 Following	 FACS,	 cells	 can	 be	 cultured	 or	
analyzed	 further	 for	 specific	 expression	 patterns,	 thereby	 allowing	 characterization	 of	 a	
distinct	cellular	population.	
1.7.2	Measuring	Ca2+	dynamics	in	living	cells	by	genetically	encodable	Ca2+	
indicators	
Ca2+	 is	 one	 of	 the	 most	 abundant	 mineral	 compounds	 of	 the	 vertebrate	 body.	 In	 form	 of	
hydroxyapatite,	Ca2+	is	stored	in	bones	and	teeth	and	thus	gives	stability	and	strength.	Outside	
of	 bones	 Ca2+	 acts	 as	 a	 versatile	 second	 messenger.	 It	 is	 involved	 in	 muscle	 contraction,	
exocytosis,	gene	expression,	proliferation,	differentiation,	blood	clotting	and	apoptosis	(Krebs,	
1998;	Clapham,	2007).		
The	Ca2+	 concentration	within	a	non-stimulated	cell	 is	 low.	A	 reason	 for	 this	phenomenon	 is	
that	 this	 divalent	 ion	 precipitates	 with	 phosphate.	 Thus,	 cells	 have	 to	 compartmentalize,	
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chelate,	or	extrude	it	(Clapham,	2007).	Concentrations	of	free	intracellular	Ca2+	are	regulated	
by	 a	 large	 variety	 of	 channels,	 exchangers	 and	 pumps	 on	 both	 the	 plasma	 membrane	 and	
intracellular	 storage	 organelles	 such	 as	 endoplasmic	 as	 well	 as	 sarcoplasmic	 reticula	 or	
mitochondria	 (Berridge	 et	 al.,	 2000).	 However,	 about	 0.1	 %	 of	 the	 Ca2+	 are	 located	 in	 the	
extracellular	space	and	available	as	free,	biologically	active	ions.	Ca2+	enters	the	cell	via	diverse	
set	of	Ca2+-permeable	channels	and	thus	regulates	intracellular	signaling	cascades	and	cellular	
activity.	Differences	 in	the	amplitude,	 frequency	and	 location	of	Ca2+	can	encode	a	variety	of	
messages	that	are	decoded	by	a	number	of	Ca2+	binding	proteins.		
In	order	 to	measure	cellular	activity,	enormous	effort	has	been	devoted	to	develop	tools	 for	
Ca2+	imaging	in	living	cells.	Such	indicators	allow	dissecting	spatial	and	temporal	Ca2+	signaling	
processes.	 Small	 molecule	 Ca2+	 indicators	 based	 on	 the	 chelating	 character	 of	 1,2-bis(o-
aminophenoxy)ethane-N,N,N’,N’-tetraacetic	 acid	 (BAPTA)	 are	 frequently	 used	 to	 measure	
changes	in	intracellular	Ca2+	 levels.	However,	 loading	cells	 in	vivo	with	these	Ca2+	 indicators	is	
invasive	 and	 does	 not	 allow	 chronic	 timescales.	 Thus,	 genetically	 encoded	 Ca2+	 indicators	
(GCaMP)	 have	 been	 developed	 based	 on	 the	most	 prominent	 representative	 of	 intracellular	
Ca2+-binding	 proteins	 named	 calmodulin	 (Cheung,	 1980).	 Calmodulin	 is	 a	 small,	 ubiquitous	
adaptor	 protein,	 which	 is	 evolutionary	 highly	 conserved	 and	 expressed	 in	 all	 eukaryotes	
(Clapham,	2007).	The	Ca2+-binding	EF-hand	has	a	 typical	helix-loop-helix	structure.	 Its	affinity	
for	 Ca2+	 is	 increased	 by	 interaction	with	 target	 proteins.	When	 Ca2+	 binds,	 the	 shape	 of	 the	
calmodulin	 domains	 changes,	 thus	 triggering	 the	 ability	 to	 remodel	 active	 sites	 (Hoeflich	 &	
Ikura,	2002).	Based	on	this	knowledge,	Ca2+	indicators	are	composed	of	calmodulin,	an	alpha-
helix	of	M13	protein	and	a	circularly	permutated	GFP	(fusion	of	N-	and	C-terminus).	Once	Ca2+	
is	 chelated	 by	 calmodulin,	 the	 latter	 undergoes	 a	 conformational	 change	 leading	 to	 a	
deprotonation	of	GFP.	Hence,	the	chromophore	changes	its	spectral	properties	and	thus	emits	
light	(Figure	3)	(Wang	et	al.,	2008;	Akerboom	et	al.,	2009).	
1	 Introduction	 	
	
33
	
Figure	3:	Principle	of	GCaMP.	 Following	Ca2+	binding,	 calmodulin	 (CaM)	undergoes	a	 conformational	 change	and	
thereby	deprotonates	green	 fluorescent	protein	 (GFP).	Hence,	 its	 spectral	properties	are	 changed	and	GFP	emits	
light.	
	
GCaMP	 expression	 is	 introduced	 into	 living	 cells	 using	 AAVs	 that	 allow	 genetically	 specified	
expression	 under	 the	 control	 of	 a	 promoter	 fragment.	 In	 2004,	 the	 first	 transgenic	 mouse	
expressing	GCaMP	was	reported	(Ji	et	al.,	2004).	However,	the	sensitivity,	thermostability	and	
response	 kinetics	were	 slow	 in	 comparison	 to	 BAPTA-based	 indicators	 (McCombs	&	 Palmer,	
2008).	Since	neural	activity	evokes	 fast	changes	 in	 intracellular	Ca2+	 levels	 (Tank	 et	al.,	1988;	
Kerr	 et	 al.,	 2000;	 Sabatini	 et	 al.,	 2002),	 efforts	have	been	made	 to	optimize	GCaMP	 system.	
Using	 structure-based	 mutagenesis	 and	 neuron-based	 screening,	 Kim	 and	 colleagues	
developed	 a	 family	 of	 ultrasensitive	 fluorescent	 Ca2+	 sensors	 (GCaMP6)	 that	 outperformed	
other	sensors	 in	cultured	neurons	and	 in	zebrafish,	 flies	and	mice	 in	vivo	 (Chen	et	al.,	2013).	
GCaMP6	 reliably	 detects	 single	 action	 potentials	 in	 neuronal	 somata	 and,	 hence,	 provides	 a	
new	window	 into	 the	organization	 and	dynamics	 of	 neural	 circuits	 over	multiple	 spatial	 and	
temporal	scales.		
In	conclusion,	rapid	intracellular	Ca2+	dynamics	can	be	monitored	using	genetically	engineered	
ultrasensitive	 fluorescent	proteins	and	 thus	allow	 imaging	of	neuronal	activity	 in	 and	ex	vivo	
over	a	large	timescale.	
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1.8	 Recent	technologies	to	selectively	regulate	cellular	activity	
In	1979,	Francis	Crick	predicted	that	in	order	to	elucidate	neuronal	codes	that	specify	behavior	
and	 perception	 ‘‘a	 method	 (is	 needed)	 by	 which	 all	 neurons	 of	 just	 one	 type	 could	 be	
inactivated,	 leaving	 the	 others	 more	 or	 less	 unaltered’’	 (Crick,	 1979).	 In	 the	 past	 decade,	
emerging	 synthetic	 biology	 technologies	 have	 been	 developed	 and	 thereby	 revolutionized	
selective	 targeting	 of	 specific	 neuronal	 populations	 similar	 like	 a	 remote	 control	 (Rogan	 &	
Roth,	 2011).	 The	 most	 prominent	 techniques	 are	 optogenetics,	 which	 is	 based	 on	 the	
activation	 of	 light-sensitive	 channels	 using	 an	 optrode,	 and	 chemogenetics,	 which	 uses	
engineered	 GPCRs	 that	 are	 activated	 by	 biologically	 inert	 drugs	 (Boyden	 et	 al.,	 2005;	
Armbruster	et	al.,	2007).	
The	term	chemogenetics	refers	to	a	designer	receptor	exclusively	activated	by	designer	drugs	
(DREADD).	 In	 2007,	 Roth	 and	 colleagues	 created	 a	mutated	 human	muscarinic	 acetylcholine	
receptor,	 which	 lost	 its	 affinity	 for	 its	 natural	 ligand	 (Armbruster	 et	 al.,	 2007),	 but	 has	 an	
increased	 affinity	 towards	 clozapine	 N-oxide	 (CNO),	 an	 otherwise	 chemically	 inert	 drug.	
Usually,	 DREADDs	 are	 introduced	 into	 cells	 using	 viral	 vectors	 such	 as	 AAV.	 The	 selective	
targeting	is	achieved	by	cell	type-specific	promoter	fragment	to	drive	DREADD	expression	(Fig.	
4).	 In	order	to	verify	successful	 transfection	and	expression	of	DREADD	 in	vivo,	 the	construct	
encodes	for	a	reporter	gene	(such	as	mCherry,	GFP,	tdTomato,	mCitrine	or	Venus).	Moreover,	
the	expression	can	further	be	controlled	using	recombinase-based	system	(CRE	recombinase-
dependent	manner),	which	allows	DREADD	expression	in	a	subpopulation	of	a	certain	cell	type	
(Boender	 et	 al.,	 2014).	 Once	 CNO	 is	 applied	 intraperitoneally	 via	 osmotic	minipumps,	 chow	
pellets,	 or	 drinking	 water,	 it	 crosses	 the	 blood-brain	 barrier	 and	 binds	 with	 low	 nanomolar	
affinity	to	its	receptor	(Armbruster	et	al.,	2007;	Dong	et	al.,	2010;	Urban	&	Roth,	2015;	Urban	
et	al.,	2016).		
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DREADDs,	much	like	endogenous	GPCRs,	are	either	coupled	to	inhibitory	(Gi)	or	excitatory	(Gq,	
Gs)	 signaling	 cascades	 (Whissell	 et	 al.,	 2016).	 CNO-evoked	 activation	of	 the	modified	human	
M4	class	muscarinic	DREADD	via	Gi-signaling	 (hM4Di	 receptor)	 induces	neuronal	 silencing	by	
transactivation	of	G	protein-coupled	 inwardly	rectifying	potassium	channels	(GIRK).	Thus,	the	
efflux	of	K+	induces	hyperpolarization	resulting	in	decreased	neuronal	firing.	Conversely,	CNO-
induced	 activation	 of	 the	 modified	 human	 M3	 class	 muscarinic	 DREADD	 via	 Gq-signaling	
(hM3Dq	 receptor)	 induces	 neuronal	 activation	 characterized	 by	 increased	 PLC	 activity,	
elevated	 IP3	 and	 DAG	 levels,	 and	 a	 rise	 in	 intracellular	 Ca2+	 concentration	 (Whissell	 et	 al.,	
2016).		
	
Figure	 4:	Theory	of	 designer	 receptors	 exclusively	 activated	by	designer	 drugs	 (DREADD).	 (A)	 Following	 cellular	
transfection,	 DREADDs	 are	 expressed	 within	 three	 weeks.	 (B)	 Cell	 type-specific	 promoter	 fragments	 achieve	
selective	 targeting	 and	 expression	 of	 hM3Dq	or	 hM4Di	 in	 combination	with	 a	 reporter	 gene	 (GFP,	mCherry).	 (C)	
Both	receptor	types	are	activated	by	clozapine	N-oxide	(CNO)	resulting	in	altered	intracellular	signaling	and	cellular	
activity	inducing	depolarization	in	a	Gq-	and	hyperpolarization	in	a	Gi-dependent	manner.	
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While	CNO	plasma	levels	following	ip	injection	peak	within	30	min	and	sharply	decline	within	
two	hours	(Guettier	et	al.,	2009),	the	amount	of	bioavailable	CNO	within	the	brain	is	currently	
not	known.	Various	reports	controversially	describe	the	duration	of	CNO-induced	activation	of	
DREADD-expressing	cell-types	ranging	from	30	min	up	to	six	hours	(Alexander	et	al.,	2009).		
Since	CNO-dependent	DREADDs	appeared	to	be	very	useful	for	manipulating	cell	activity,	there	
is	 a	 strong	 interest	 to	 develop	 new	 DREADD	 systems.	 Based	 on	 mutated	 kappa-opioid	
receptors	 (KOR)	 coupled	 to	 Gi-signaling	 cascade,	 so-called	 KOR	 DREADDs	 (KORD)	 have	 been	
developed	(Vardy	et	al.,	2015).	Based	on	the	principle	of	chemogenetics,	KORDs	are	exclusively	
activated	 by	 Salvinorin	 B	 (SALB).	 In	 a	 recent	 study,	 Roth	 and	 colleagues	 performed	 a	
bidirectional	 chemogenetic	 manipulation	 using	 two	 DREADDs,	 an	 excitatory	 hM3Dq	 and	 an	
inhibitory	 KORD	 within	 the	 same	 animal	 (Vardy	 et	 al.,	 2015).	 Thereby,	 they	 facilitated	 the	
multiplexed	 dissection	 of	 neural	 circuits	 and	 behavior	 in	mice.	Moreover,	 they	 demonstrate	
differences	in	pharmacokinetics	between	CNO	and	SALB.	SALB	was	shown	to	have	rapid	short-
lasting	effects,	whereas	CNO	mediates	delayed	long-lasting	effects	(Whissell	et	al.,	2016).		
In	conclusion,	DREADDs	represent	a	powerful	 technique	allowing	spatiotemporal	control	 in	a	
cell	 type-specific	 manner.	 Thus,	 this	 method	 allows	 activation	 or	 inhibition	 of	 specific	
neuropeptidergic	 neurons	 (Burnett	 &	 Krashes,	 2016),	 and	 was	 used	 in	 this	 thesis	 for	
modulating	 OXT	 neurons.	 Predominantly	 used	 in	 rodents,	 a	 first	 study	 has	 recently	 been	
published,	where	researchers	 introduced	the	DREADD	system	in	rhesus	monkeys	(Grayson	et	
al.,	 2016).	 Due	 to	 unlimited	 DREADD	 construct	 designs	 relating	 to	 promoter	 fragment,	 the	
potential	 combination	 in	 a	 CRE-dependent	 manner,	 and	 the	 acute,	 remote	 and	 reversible	
modulation	 of	 cellular	 activity	 open	 doors	 to	 new	 and	 enriching	 possibilities	 to	 study	
behavioral	 relevance	 of	 a	 defined	 cellular	 population.	 Thus,	 using	 this	 technique	 has	 the	
potential	 to	 map	 brain	 circuits	 and	 their	 possible	 interactions	 with	 other	 systems,	 and	 to	
bridge	the	gap	between	an	anatomical	structure	and	its	behavioral	relevance.	This	will	give	rise	
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to	 fundamental	knowledge	 in	neuroscience	to	develop	pharmacogenetic	 tools	 to	 treat	mood	
and	anxiety	disorders.		
1.9	 Aims	and	outline	of	the	present	study	
Psychopathologies	 associated	 with	 socio-emotional	 dysfunctions	 such	 as	 anxiety	 disorders	
have	 28%	 lifetime	 prevalence	 (Gross	 &	 Hen,	 2004;	 Kessler	 et	 al.,	 2005).	 Altogether,	 they	
decrease	 the	quality	of	 life,	may	 induce	social	 isolation	and	substance	abuse.	Both,	OXT	and	
the	 recently	 discovered	 NPS	 represent	 putative	 treatment	 options	 due	 to	 their	 potent	
anxiolytic	 activity	 described	 in	 pre-clinical	 studies.	 Although	 the	 knowledge	 about	 these	
neuropeptides	 increases	 continuously,	 many	 aspects	 of	 the	 underlying	 mechanisms	 at	
molecular,	 cellular	 and	 tissue-wide	 levels	 remain	 elusive.	 Therefore,	 three	 hypotheses	 have	
been	 postulated	 to	 gather	 more	 fundamental	 knowledge	 about	 the	 neuropeptidergic	
mechanisms	 that	 might	 influence	 the	 behavioral	 phenotype	 of	 an	 individual.	 Each	 of	 these	
questions	has	been	addressed	in	one	of	the	three	chapters	constituting	this	thesis.	
In	chapter	1,	I	tested	the	hypothesis	that	NPS	effects	are	mediated	via	OXT	neurons	within	the	
PVN	of	male	Wistar	 rats.	 Both,	NPS	and	OXT	have	been	described	 to	exert	 robust	 anxiolytic	
activity	(Neumann	et	al.,	2000;	Xu	et	al.,	2004;	Slattery	et	al.,	2015;	van	den	Burg	et	al.,	2015),	
to	 reverse	both	 social	 (Zoicas	 et	al.,	 2014;	Zoicas	 et	al.,	 2016)	and	cued	 fear	 (Jungling	 et	al.,	
2008;	Slattery	 et	al.,	 2015),	 to	decrease	aggressive-like	behavior	 (Beiderbeck	 et	al.,	 2014;	de	
Jong	et	al.,	2014;	Ruzza	et	al.,	2015),	and	to	exert	anorexic	effects	(Olson	et	al.,	1991a;	Smith	et	
al.,	 2006).	 Moreover,	 in	 situ	 hybridization	 data	 demonstrate	 a	 strong	 overlap	 of	 NPSR	 and	
OXTR	expression	in	limbic	brain	regions	(Yoshimura	et	al.,	1993;	Gimpl	&	Fahrenholz,	2001;	Xu	
et	 al.,	 2007).	More	 precisely,	 NPSR	 expression	 is	 highly	 abundant	within	 the	 PVN	 (Xu	 et	 al.,	
2007),	 a	 brain	 nucleus	 that	 harbors	 parvo-	 and	magnocellular	 OXT-immunoreactive	 neurons	
(Swanson	&	Sawchenko,	1980;	Gimpl	&	Fahrenholz,	2001).	Taken	together,	the	data	suggest	a	
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possible	 interaction	 between	 the	 NPSR-	 and	 OXT	 system.	 Specifically,	 I	 postulated	 that	 NPS	
evokes	activation	of	PVN-OXT	neurons.	As	 the	PVN	 is	abundantly	 innervated	by	NPS-positive	
fibers	in	mice	(Clark	et	al.,	2011),	I	analyzed	LC-NPS	afferents	within	the	PVN,	and	I	examined	
NPSR	 expression	 in	 PVN-OXT	 neurons.	 Using	 ultrasensitive	 fluorescent	 proteins	 and	
intracerebral	 microdialysis,	 I	 investigated	 potential	 effects	 of	 NPS	 on	 the	 endogenous	 OXT	
system.	 Moreover,	 I	 hypothesized	 that	 the	 anxiolytic	 effect	 of	 NPS	 is	 mediated	 via	 the	
paraventricular	OXT	system.	In	order	to	directly	reveal	the	involvement	of	endogenous	OXT	in	
the	anxiolytic	 effects	of	NPS	within	 the	PVN	 I	 employed	 two	experimental	 strategies:	 First,	 I	
blocked	 OXTR-mediated	 effects	 using	 a	 selective	 OXT	 receptor	 antagonist	 (OXTR-A),	 and	
second	I	inhibited	the	activity	of	OXT	neurons	within	the	PVN	by	chemogenetic	silencing	using	
a	Gi-coupled	DREADD,	prior	to	central	NPS	 infusion.	These	findings	provide	the	first	evidence	
for	 an	 intra-hypothalamic	mechanism	 involving	 NPSR-expressing	 OXT	 neurons	 in	 the	 potent	
anxiolytic	profile	of	NPS.	
In	 vitro	 studies	 in	 NPSR-transfected	 HEK293T	 and	 CHO	 cells	 revealed	 increased	 cAMP	
concentration	by	adenylyl	cyclase	 (AC)	activation	and	a	 rise	 in	 intracellular	Ca2+	 levels	due	to	
phospholipase	 C	 (PLC)	 stimulation	 suggesting	 that	 the	 NPSR	 is	 coupled	 to	 both	 Gs	 and	 Gq	
proteins	 (Reinscheid	 &	 Xu,	 2005a;	 Camarda	 et	 al.,	 2009;	 Erdmann	 et	 al.,	 2015;	 Liao	 et	 al.,	
2016),	 respectively.	 However,	 the	 underlying	mechanism(s)	mediating	 the	 anxiolytic	 activity	
following	 NPSR	 activation	 is	 still	 unknown.	 In	 chapter	 2,	 I	 hypothesized	 that	 the	 anxiolytic	
activity	 of	NPS	depends	on	Gq-dependent	 intracellular	 signaling.	 In	 situ	 hybridization	 studies	
revealed	that	NPSR	mRNA	expression	within	the	rat	amygdala	is	restricted	to	the	intercalated	
and	 the	medial	nucleus	 (MeA)	 (Xu	 et	al.,	2007).	As	 the	amygdala	 regulates	 fear	and	anxiety-
related	behavior	(Tovote	et	al.,	2015),	I	specifically	postulated	that	NPS	(i)	promotes	anxiolysis	
within	the	MeA,	(ii)	activates	Ca2+-dependent	signaling	pathways	in	the	amygdala	 in	vivo,	and	
(iii)	induces	anxiolysis	in	a	PLC-dependent	manner.	These	findings	increase	our	understanding	
with	 respect	 to	 the	 intracellular	 signaling	 mechanism	 that	 might	 be	 involved	 in	 the	
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pathophysiology	of	anxiety	disorders.		
Since	 2007,	 chemogenetics	 developed	 into	 a	 frequently	 used	 technical	 tool	 that	 allows	
spatiotemporal	 control	 over	 a	 distinct	 cellular	 population.	 However,	 the	 CNO-dependent	
potency	and	the	intracerebral	dynamics	are	controversially	discussed.	While	CNO	plasma	levels	
peak	within	30	min	and	sharply	decline	within	two	hours	(Guettier	et	al.,	2009),	the	amount	of	
bioavailable	 CNO	 within	 the	 brain	 is	 currently	 not	 known.	 Various	 reports	 controversially	
describe	the	duration	of	CNO-induced	activation	of	DREADD-expressing	cell-types	ranging	from	
30	min	up	to	six	hours	 (Alexander	et	al.,	2009).	Although	DREADDs	allow	selective	activation	
(or	inhibition)	of	specific	neuronal	populations	in	order	to	dissect	their	contribution	to	complex	
behaviors	and	brain	circuitries,	the	spatiotemporal	dynamics	of	DREADD	actions	with	respect	
to	 OXT	 neurons	 remain	 unknown.	 In	 chapter	 III,	 I	 analyzed	 the	 spatiotemporal	 dynamics	 of	
chemogenetic	 OXT	 neuron	 activation	within	 the	 rat	 PVN	 using	 DREADDs,	 and	 its	 behavioral	
relevance.	After	viral	vector-based	expression	of	an	excitatory	DREADD	(hM3Dq)	specifically	in	
OXT	 neurons,	 I	 monitored	 the	 dynamics	 of	 OXT	 release	 within	 PVN,	 lateral	 septum,	 and	
peripheral	 blood	 following	 chemogenetic	 stimulation	 initiated	 by	 CNO	 using	 microdialysis	
technique	 and	 via	 jugular	 vein	 catheter.	 Altogether,	 these	 results	 narrow	 down	 the	 time	
window,	 when	 chemogenetic	 stimulation	 of	 neuropeptidergic	 neurons	 can	 be	 efficiently	
applied	 for	 studying	 behavioral	 changes.	 Furthermore,	 my	 findings	 demonstrate	 that	
chemogenetic	 manipulation	 of	 OXT	 neurons	 is	 a	 powerful	 tool	 for	 dissection	 of	 novel	
functional	OXT	brain	circuits	and	hence	various	OXT-dependent	behaviors	under	normal	and	
psychopathological	conditions.	 	
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2	 Materials	and	methods	
2.1	 Animals	and	husbandry	
Male	Wistar	rats	(230-250	g;	Charles	River	Laboratories,	Bad	Sulzfeld,	Germany)	were	housed	
in	 groups	 of	 3-4	 under	 standard	 laboratory	 conditions	 with	 access	 to	 food	 and	 water	 ad	
libitum.	Rats	were	maintained	on	a	12:12	h	 light/dark	cycle	with	 lights	on	at	07.00	a.m.	 in	a	
temperature-	and	humidity-controlled	room	(21	–	23	°C,	55	%	humidity).	All	experiments	were	
performed	between	08:00	a.m.	–	01:00	p.m.	 in	 accordance	with	 the	Guide	 for	 the	Care	and	
Use	 of	 Laboratory	 Animals	 by	 the	 NIH,	 and	 were	 approved	 by	 the	 government	 of	 the	
Oberpfalz.	
2.2	 Surgical	procedures	
The	animals	were	allowed	at	least	one	week	of	habituation	before	they	were	used	for	surgical	
procedures.	Rats	received	a	subcutaneous	injection	of	the	antibiotic	Baytril	(Baxter,	10	mg/kg	
Enrofloxacin)	 and	 an	 intraperitoneal	 (ip)	 injection	 of	 the	 analgesic	 Buprenovet	 (Bayer,	 0.05	
mg/kg	Buprenorphine)	30	min	before	the	start	of	the	surgery.	All	stereotaxic	procedures	were	
performed	 under	 isofluran	 anesthesia	 and	 semi-sterile	 conditions.	 All	 coordinates	 used	 are	
based	on	the	rat	brain	atlas	(Paxinos	&	Watson,	1998)	and	summarized	below	(table	1).	
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Stereotaxic	coordinates	 AP	 ML	 DV	 angle	 Vol	
	
Intra-PVN	infusion	
	
AAV1/2	OXTpr-Venus,		
AAV1/2	OXTpr-GCaMP6s	
AAV1/2	OXTpr-hM3Dq:mCherry,	
AAV1/2	OXTpr-hM4Di:mCherry	
	
	
	
	
-1.8		
	
	
		
	
	
	
±0.3		
	
	
	
	
	
	
-8.0		
	
	
	
	
	
	
0°	
	
	
	
	
	
	
280	nl	
	
	
	
	
Intra-SON	infusion	
	
AAV1/2	OXTpr-Venus,	
AAV1/2	OXTpr-hM3Dq:mCherry	
	
	
	
	
-1.4		
	
	
	
±1.7		
	
	
	
-9.0		
	
	
	
0°	
	
	
	
280	nl	
	
Intra-AN	infusion	
	
AAV1/2	OXTpr-hM3Dq:mCherry	
	
	
	
	
-1.9		
	
	
	
±1.2		
	
	
	
-8.5		
	
	
	
0°	
	
	
	
280	nl	
	
Microdialysis	probe	implantation	
	
PVN	
	
Septum	
	
	
	
	
-1.4		
	
+0.5		
	
	
	
+1.8		
	
+0.7		
	
	
	
-8.3		
	
-6.2		
	
	
	
10°	
	
0°	
	
	
Guide	cannula	implantation	
	
icv	(12	mm,	21G)	
	
Above	PVN	(12	mm,	23	G)	
	
Above	MeA	(12	mm,	23	G)	
	
	
	
	
-1.0		
	
-1.4		
	
-2.3		
	
	
	
-1.6		
	
+1.8	/	-2.1		
	
±3.2		
	
	
	
-2.0		
	
-6.3		
	
-7.5		
	
	
	
0°	
	
10°	
	
0°	
	
	
Table	1:	 Stereotaxic	 coordinates	 (in	mm)	used	 for	 viral	 infusions	and	 implantation	of	microdialysis	probes	and	
guide	cannulas	accordant	to	bregma	(AP:	anteroposterior	axis;	ML:	mediolateral	axis;	DV:	dorsoventral	axis).	
2.2.1	Intracerebral	infusion	of	recombinant	adeno-associated	virus	
Either	 AAV1/2(OXTpr-Venus),	 AAV1/2(OXTpr-GCaMP6s),	 AAV1/2(OXTpr-hM3Dq:mCherry),	 or	
AAV1/2(OXTpr-hM4Di:mCherry)	 was	 bilaterally	 microinfused	 using	 a	 5-µl	 calibrated	
micropipette	(VWR,	inner	diameter:	0.3	mm),	which	was	pulled	to	create	a	long	narrow	shank.	
The	micropipette	shaft	was	marked	with	a	1-mm	scale	that	corresponds	to	a	volume	of	∼70	nl.	
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In	 total,	 280	 nl	 of	 cell-type	 specific	 recombinant	 adeno-associated	 viral	 vectors	 (rAAV)	were	
infused	slowly	by	pressure	infusion	into	each	PVN	or	PVN,	SON	and	AN,	respectively.	After	the	
infusion,	the	micropipette	was	kept	in	place	for	3	min	to	ensure	adequate	rAAV	diffusion.	The	
drill	hole	 in	 the	skull	was	closed	using	bone	wax	 (Ethicon,	Somerville,	New	Jersey,	USA),	and	
the	wound	was	 sutured	 using	 sterile	 nylon	material.	 After	 the	 surgery,	 animals	were	 single-
housed	for	48	h	to	recover	from	anesthesia	and	then	group-housed	for	16	days.	
2.2.2	Implantation	of	guide	cannulas	
For	icv	infusions,	a	12	mm	long	21-G	guide	cannula	was	stereotaxically	placed	2	mm	above	the	
lateral	 ventricle.	 For	 local	 infusions,	 12-mm	 long	 23-G	 guide	 cannulas	 were	 implanted	
bilaterally	 2	mm	 above	 the	 left	 and	 right	MeA	 or	 the	 PVN.	 The	 cannulas	were	 fixed	 to	 two	
stainless	steel	screws	using	dental	cement.	Rats	were	housed	singly	after	surgery,	allowed	to	
recover	for	at	least	5	days	and	handled	daily	to	habituate	them	to	the	infusion	procedures	and	
to	minimize	non-specific	 stress	 responses	at	 the	day	of	 experiment.	All	 guide	 cannulas	were	
closed	 using	 a	 stylet,	 which	 was	 cleaned	 daily	 during	 the	 handling	 procedure	 with	 70	 %	
ethanol.			
2.2.3	Implantation	of	a	microdialysis	probe	
A	U-shaped	microdialysis	 probe	 (self-made,	 for	 details	 see	 (Neumann	 et	 al.,	 1993b;	 Horn	&	
Engelmann,	2001))	with	a	molecular	cut-off	of	18	kDa	was	implanted	unilaterally	into	the	PVN.	
The	 implant	 was	 anchored	 to	 two	 stainless	 steel	 screws	 using	 dental	 cement.	 Following	
surgery,	animals	were	single-housed	and	allowed	to	recover	for	48	h	and	handled	trice	the	day	
after	surgery	to	habituate	to	the	microdialysis	procedure.	
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2.2.4	Implantation	of	jugular	vein	catheter	
Under	 urethane	 anesthesia	 and	 using	 sterile	 procedures,	 rats	 expressing	 hM3Dq-mCherry	
selectively	under	the	control	of	the	OXT	promoter	within	the	hypothalamic	PVN,	SON	and	AN	
were	 implanted	 with	 a	 jugular	 vein	 catheter	 19	 days	 following	 viral	 infusion	 as	 previously	
described	 (Neumann	 et	 al.,	 1998;	 Nyuyki	 et	 al.,	 2012).	 Briefly,	 the	 jugular	 vein	 catheter	
consisted	of	a	13-cm	piece	of	PE-20	tubing	(ID:	0.58	mm,	OD:	0.96	mm)	and	a	4.3-cm	piece	of	
silicone	tubing	(ID:	0.64	mm,	OD:	1.19	mm).	One	end	of	the	silicone	tubing	was	expanded	by	
dipping	 in	chloroform	for	15	s	 to	 facilitate	 insertion	of	 the	PE-20	tubing	with	an	overlap	of	1	
cm.	The	free	end	of	the	silicone	tubing	was	cut	to	an	angle	of	45°	to	allow	easy	insertion	into	
the	 jugular	 vein.	 The	 catheter	 was	 stored	 under	 aseptic	 conditions	 in	 70%	 ethanol.	 Before	
surgery,	 catheters	 were	 repeatedly	 flushed	 with	 sterile	 saline	 to	 remove	 remaining	 ethanol	
and	were	 filled	with	heparinized	 saline.	Next,	 a	 longitudinal	 skin	 incision	of	 about	 1	 cm	was	
made	above	the	right	clavicle	and	the	jugular	vein	was	exposed.	Then,	two	nylon	sutures	were	
placed	underneath	the	vein.	One	suture	was	tightly	knotted	cranially	to	occlude	the	vein	and	
interrupt	blood	 flow,	while	 the	 caudal	 suture	 remained	untied.	 Following	V-like	 incision	 into	
the	wall	of	the	vein	between	both	ligatures,	the	catheter	with	silicone	tubing	first	was	inserted	
3.3	cm	into	the	vessel	in	order	to	reach	the	right	atrium.	Subsequently,	the	catheter	was	filled	
with	sterile	saline	and	the	caudal	suture	was	repeatedly	knotted	on	top	of	the	silicone-PE-20	
tubing	 overlap	 and	 the	 free	 ends	 of	 the	 sutures	 were	 cut	 off.	 Then,	 the	 catheter	 was	
exteriorized	in	the	neck	and	the	wound	was	sutured	using	sterile	nylon	material.	
2.3	 Drug	infusion	in	conscious	rats	
For	 icv	or	 intra-PVN	infusions,	the	dummy	cannula	was	replaced	by	the	infusion	cannula	(icv:	
25	 G,	 14.7	 mm,	 intra-PVN:	 27	 G,	 14	 mm).	 All	 intracerebrally	 infused	 drugs	 were	 diluted	 in	
Ringer’s	 solution	 (B.	BRAUN	Melsungen	AG)	 from	highly	concentrated	stock	 solutions	on	 the	
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day	of	experiment.	 Sterile	Ringer’s	 solution	was	 infused	as	 control	 (vehicle,	Veh).	After	each	
infusion,	the	cannula	was	kept	in	place	for	10	s	to	allow	local	substance	diffusion.	None	of	the	
drug-infused	 rats	 showed	 any	 signs	 of	 tremor,	 convulsions,	 or	 wet-dog	 shakes	 in	 their	
homecage.	 	
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2.4		 Experimental	design	-	Chapter	I	
Retrograde	tracing	of	NPS-immunoreactive	neurons	
In	 order	 to	 test	 whether	 LC-NPS	 neurons	 project	 towards	 the	 hypothalamic	 PVN,	 0.5	 µl	 of	
Cholera	toxin	subunit	B	coupled	to	Alexa	Fluor	488	(CTB-488,	ThermoScientific,	5	µg/µl	PBS,	pH	
7.4)	were	infused	bilaterally	into	the	PVN	under	isofluran	anesthesia	via	30-G	infusion	cannula,	
which	 was	 connected	 via	 polyethylene	 tubing	 to	 a	 5-µl	 Hamilton	 microsyringe.	 Following	
infusion,	infusion	system	was	kept	in	place	for	3	min	to	ensure	adequate	tracer	diffusion	from	
the	infusion	tip.	Next,	animals	were	housed	singly	in	observation	cages.	Five	days	later,	animals	
were	 transcardially	 perfused	 and	 neurons	 immunoreactive	 for	 CTB-488,	 OXT,	 and	NPS	were	
analyzed	(for	details	see	2.9	Immunofluorescent	staining).	
Fluorescence-activated	cell	sorting	
In	 order	 to	 examine	 NPSR	 expression	 in	 OXT	 neurons,	 fluorescence-activated	 cell	 sorting	
(FACS)	was	performed	 in	combination	with	quantitative	RT-PCR.	Rats	were	 infused	with	cell-
type	 specific	 rAAV	 into	 the	SON	and	PVN	 to	express	Venus	 in	OXT	neurons	 (Knobloch	et	al.,	
2012).	 Three	 weeks	 later,	 the	 rats	 were	 killed	 by	 overdose	 of	 halothane,	 their	 brains	 were	
extracted,	 sectioned	 by	 large	 pieces,	 using	 rat	 brain	matrix	 (1-mm	 thick	 sections).	 SON	 and	
PVN	were	bilaterally	extracted	by	micro-punch	technique.		
FACS	 method	 of	 neuronal	 cells	 was	 modified	 from	 established	 protocol	 (Lobo	 et	 al.,	 2006;	
Guez-Barber	et	al.,	2012).	The	tissue	was	placed	 in	1	ml	of	dissection	buffer	 (in	mM:	sucrose	
(150),	 NaCl	 (125),	 KCl	 (3.5),	 NaH2PO4	 (1.2),	 CaCl2	 (2.4),	MgCl2	 (1.3),	 glucose	 (6.65	mM),	 and	
HEPES	 (2),	 pH	 6.9,	 osmolarity	 (326),	 all	 from	 Sigma)	 (Li	 et	 al.,	 2015)	 and	minced	with	 razor	
blades	on	an	 ice-cold	glass	plate.	Later,	dissection	buffer	was	replaced	with	1	ml	of	Accutase	
(Sigma-Aldrich,	 A6964)	 and	 tubes	were	 rotated	 for	 30	min	 at	 4°C.	 Then,	 tissue	 pieces	were	
rinsed	twice	 in	 ice-cold	Neurobasal-A	complete	medium:	50%	Neurobasal-A,	50%	Leibovitz	L-
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15	Medium	(31415,	Gibco),	2%	B27	supplement	(17504044,	Invitrogen),	DNase	I	0.001%,	0.5%	
penicillin-streptomycin	 (15140122,	 Invitrogen).	 To	 dissociate	 the	 cells,	 tissue	 pieces	 were	
triturated	 in	 1	 ml	 Neurobasal-A	 complete	 medium	 with	 a	 Pasteur	 pipette.	 Supernatant	
containing	cloudy	dissociated	cells	were	transferred	to	a	new	15	ml	Falcon	tube	on	 ice.	Cells	
were	filtered	with	70-μm	cell	strainer	and	centrifuged	for	3	min	at	430g	through	a	three-step	
density	gradient	of	Percoll	 (P1644,	Sigma).	Cells	at	 the	bottom	 layer	were	collected	 for	 later	
use.	For	FACS	of	OT-Venus+	cells,	propidium	iodide	(PI;	20	μg	ml−1)	was	used	to	label	dead	cells	
just	before	sorting.	Negative	controls	were	done	at	the	same	time.	Subsequently,	FACS-based	
purifications	 of	 Venus+PI-	 and	 Venus-PI-	 cells	 were	 sorted	 into	 RNase-free	 tubes	 with	 RNA	
extraction	lysis	buffer	by	BD	FACSAria	II	at	Flow	Cytometry	Core	Facility	at	DKFZ.	
Next,	total	RNAs	were	extracted	and	purified	from	FACS-sorted	cells	with	the	RNeasy	Mini	kit	
or	 RNeasy	 FFPE	 Kit	 (Qiagen).	 RNA	 was	 transcribed	 into	 cDNA	 using	 random	 primers	 (dN6,	
Roche)	and	M-MLV	reverse	transcriptase	(Promega).	cDNA	were	quantified	by	using	SYBR	gene	
expression	assays	(Qiagen)	or	Taqman	Probe	with	Absolute	Blue	qPCR	Rox	mix	(ThermoFisher	
Scientific),	on	the	CFX96	Real-time	System	(Biorad).	Primers	and	Probes	used	for	qRT-PCR	are	
listed	below	(table	2).		
NPSR	primer/probe	 5’	–	3`	Sequence	
NPSR	(forward)	 TCCAATGGTGAGGTACAGTGC	
NPSR	(reverse)	 ACACCAGAAAGGCAACGATG	
Beta	actin	(forward)	 TCCTGTGGCATCCATGAAAC 
Beta	actin	(reverse)	 ACAGCACTGTGTTGGCATAG	
	
Table	2:	List	of	NPSR	primers	used	for	mRNA	expression	studies	in	rats.	
Immunofluorescent	staining	of	NPSR	
Localization	patterns	of	NPSR	on	PVN-OXT	neurons	was	verified	in	perfused	brains	of	naïve	rats	
by	immunofluorescent	staining	of	NPSR	and	OXT	(for	detailed	immunofluorescent	staining	see	
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2.9).	
Characterization	of	NPSR	knockout	vs.	wild	type	mice	
NPSR	mRNA	expression	
	
In	order	to	characterize	the	molecular	background	of	transgenic	NPSR	C57Bl/6	mice,	RNA	was	
extracted	from	wildtype	(NPSR+/+)	and	knockout	(NPSR-/-)	mouse	tissue	micropunches	(1	mm	in	
diameter)	 containing	 the	 PVN	 using	 the	 isolation	 kit	 peqGOLD	 TriFast	 (Peqlab,	 Erlangen,	
Germany).	First,	tissue	micropunches	were	homogenized	in	200	µl	of	TriFast	reagent.	Next,	40	
μl	of	chloroform	were	added,	vortexed,	and	then	centrifuged	(20	min,	12.000	g,	4	°C).	During	
centrifugation	three	phases	develop	from	top	to	bottom:	A	colorless	phase	containing	RNA,	a	
middle	white	phase	containing	the	DNA	(with	low	amounts	of	proteins	such	as	histones),	and	
the	bottom	purple	phase	containing	proteins.	The	RNA-containing	phase	was	transferred	into	a	
new	cup	and	the	RNA	precipitated	with	an	equal	volume	of	isopropanol	overnight	at	-20	°C.		
On	the	next	day	the	samples	were	centrifuged	(30	min,	17.000	g,	4	°C).	The	supernatant	was	
discarded	and	the	pellet	was	washed	with	ice-cold	80	%	ethanol	and	centrifuged	again	(15	min,	
17.000	g,	4	°C)	to	extract	resting	isopropanol,	chloroform	and	phenol-containing	TriFast.	Next,	
15	 μl	 diethylpyrocarbonate-treated	 water	 (DEPC-H2O)	 (Ambion,	 Lifetechnologies,	 Carlsbad,	
California,	USA)	was	added	to	the	pellet	and	incubated	for	5	min	at	70	°C	and	1.000	rpm	in	a	
heating	block	 (Eppendorf,	Hamburg,	Germany).	 Subsequently	 the	 sample	was	 spinned	down	
and	 the	 RNA	 concentration	 was	 measured	 using	 Nanodrop	 (NanoDrop	 Technologies	 Inc.,	
Wilmington,	Delaware,	USA).	 For	evaluation,	 the	 software	ND-1000	 (NanoDrop	Technologies	
Inc.,	Wilmington,	Delaware,	USA)	was	used.	If	260/280-	and	260/230-quotients	were	1.5	<	x	<	
2,	the	sample	was	used	for	reverse	transcription	and	PCR	of	cDNA.		
Next,	 RNA	was	 reversely	 transcribed	 into	 cDNA.	 Here,	 1	 μg	 of	 RNA	was	mixed	with	 1	 μl	 of	
Random	Primers	(Invitrogen,	Lifetechnologies,	Carlsbad,	California,	USA)	and	1	μl	of	a	10-mM	
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dNTP	mix	(Invitrogen,	Lifetechnologies,	Carlsbad,	California,	USA).	The	sample	was	adjusted	to	
a	total	volume	of	15	μl	with	DEPC-H2O.	Then,	the	mixture	was	incubated	for	5	min	at	65	°C	to	
guarantee	 the	 annealing	 of	 the	 primers.	 Next,	 4	 μl	 of	 5x	 First	 Strand	 Buffer,	 2	 μl	 of	 0.1	M	
dithiothreitol,	 and	 40	 units	 of	 RNase	 OUT	 (all	 from	 Invitrogen,	 Lifetechnologies,	 Carlsbad,	
California,	 USA)	 were	 added	 and	 incubated	 for	 2	 min	 at	 room	 temperature.	 To	 test	
contamination	of	genomic	DNA,	5	μl	of	the	total	volume	were	separated	(-RT	sample).	To	the	
rest,	1	μl	of	SuperScript	 III	 (Invitrogen,	Lifetechnologies,	Carlsbad,	California,	USA)	was	added	
and	incubated	for	10	min	at	room	temperature.	This	step	is	followed	by	an	incubation	at	42	°C	
for	50	min,	which	guarantees	 the	 reverse	 transcription	and	elongation.	To	 inactivate	 reverse	
transcriptase,	the	sample	was	incubated	for	15	min	at	70	°C.	
Next,	1	µl	of	cDNA	(or	–RT	sample,	or	DEPC-H2O	as	negative	control)	was	mixed	with	12.5	μl	of	
DreamTAQ	(Fermentas,	Thermo	Scientific,	Waltham,	MA,	USA),	1	μl	of	2-μM	forward	and	1	μl	
of	2-μM	reverse	primer	(Metabion,	Planegg-Martinsried,	Germany),	and	9.5	μl	of	DEPC-H2O.	All	
primers	 were	 designed	 using	 PerlPrimer	 (an	 open	 source	 software)	 and	 ordered	 from	
Metabion	(Table	3).		
	 Forward	primer	(5’-3’)	 Reverse	primer	(5’-3’)	 Amplicon	(bp)	
NPSR	 CTCTTCACTGAGGTGGGCTC	 CCAGTGCTTCAGTGAACGTC	 196	
RPL13a	 CACTCTGGAGGAGAAACGGAAGG	 GCAGGCATGAGGCAAACAGTC	 182	
	
Table	3:	List	of	primers	used	for	mRNA	expression	studies	in	NPSR	wild	type	and	knockout	mice.	
PCR	was	 performed	using	 the	 ThermoCycler	 (BIORAD,	München,	Germany),	 starting	with	 an	
initial	denaturation	step	at	95	°C,	and	followed	by	40	cycles	consisting	of	denaturation	at	95	°C	
for	 30	 s,	 primer	 annealing	 at	 60	 °C	 for	 1	 min,	 and	 elongation	 at	 72	 °C	 for	 30	 s.	 A	 final	
prolongation	 step	 at	 72	 °C	 for	 10	 min	 was	 added	 to	 the	 end	 of	 the	 40th	 cycle	 to	 ensure	
complete	 prolongation	 of	 all	 cDNA	 amplicons.	 Amplification	 products	 were	 separated	 by	
agarose	gel	 electrophoresis	 at	140	V	 for	1	h,	 stained	with	RotiStain	 (Roth),	 and	 then	 images	
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were	captured	using	ChemiDoc	XRS	system	(Bio-Rad,	München,	Germany).		
Genotyping	of	NPSR1	knockout	mice	
	
Genomic	 DNA	 was	 prepared	 from	mouse	 brain	 tissue	 micropunches	 of	 NPSR+/+	 and	 NPSR-/-	
(kindly	 provided	 by	 Dr.	 Chiara	 Ruzza,	 University	 of	 Ferrara,	 Ferrara,	 Italy).	 Tissue	 was	
homogenized	and	incubated	overnight	in	200	µl	of	proteinase	K	lysis	buffer	containing	KCl	(50	
mM),	tris(hydroxymethyl)aminoethane-HCl	(10	mM,	pH	8.3),	MgCl2	(1	mM),	0.45	%	Nonidet	P-
40,	0.45	%	Tween	20,	gelatin	(0.1	mg/ml),	and	proteinase	K	(0.5	mg/ml)	at	55	°C	and	1.000	rpm	
with	horizontal	shaking	conditions.	Thereafter,	samples	were	incubated	for	10	min	at	95°C	and	
centrifuged	for	10	min	at	14.000	g,	4	°C.	Two	microliters	of	genomic	DNA	was	added	to	a	PCR	
mix	 containing	 DreamTaq	 PCR	 Master	 Mix	 (Thermo	 Scientific)	 and	 primers	 in	 a	 final	
concentration	of	0.2	µM.	The	following	three	oligonucleotide	primers	were	used:	the	forward	
primer	was	specific	 to	 the	endogenous	NPSR	 locus	 [5-CCTTATCCTCAAACCACGAAGTAT-3],	 the	
second	was	a	common	reverse	primer	[5	-GTGGGTACATGAGAAGGTTAGGAG-3],	and	the	third	
was	 a	 forward	 primer	 [5-AAATGCCTGCTCTTTACTGAAGG-3]	 specific	 to	 the	 targeting	 plasmid.	
The	 reaction	mix	was	 placed	 in	 a	 thermal	 cycler	 and	 incubated	 for	 5	min	 at	 95	 °C.	 The	 PCR	
proceeded	 for	 40	 cycles	 as	 follows:	 95	 °C	 for	 30	 s,	 55	 °C	 for	 30	 s,	 and	 72	 °C	 for	 1	 min.	
Additionally,	 samples	 were	 incubated	 at	 72	 °C	 for	 5	 min	 and	 was	 finally	 stored	 at	 12	 °C.	
Amplification	products	were	separated	by	agarose	gel	electrophoresis	at	140	V	for	1	h,	stained	
with	RotiStain	 (Roth),	 and	 then	 images	were	captured	using	ChemiDoc	XRS	 system	 (Bio-Rad,	
Munich,	Germany).		
Specificity	of	NPSR	antibodies	
	
In	 order	 to	 test	 the	 specificity	 of	 the	 NPSR	 antibody	 Ab2	 (Leonard	 &	 Ring,	 2011)	 and	 the	
commercially	available	NPSR1	antibody	(abcam,	ab	92425),	proteins	from	NPSR+/+	and	NPSR-/-	
hypothalamic	mouse	brain	tissue	micropunches	were	isolated.	Briefly,	tissue	was	homogenized	
in	 radioimmunoprecipitation	 assay	 buffer	 (composed	 of	 25	 mM	 tris(hydroxymethyl)-
2	 Materials	and	methods	 	
	
50
aminoethane	 pH	 7-8,	 150	mM	 sodium	 chloride,	 0.1	%	 sodium	dodecylsulfate,	 0.5	%	 sodium	
deoxycholate	and	1	%	Triton	X-100)	supplemented	with	0.1	M	phenylmethylsulfonyl	fluoride,	
0.1	M	sodium	orthovanadate,	and	protease	 inhibitor,	and	 incubated	on	 ice	 for	30	min.	After	
centrifugation	 (15	 min,	 14.000	 g,	 4°C),	 the	 supernatant	 was	 collected.	 The	 protein	
concentration	 in	all	samples	was	determined	using	the	Pierce	BCA	Protein	Assay	Kit	 (Thermo	
Scientific,	Rockford).	After	a	30-min	incubation	at	37	°C,	the	absorbance	was	measured	using	
the	microplate	reader	FLUOstar	OPTIMA	(BMG	Labtech,	Ortenberg,	Germany)	at	a	wavelength	
of	560	nm.	For	evaluation	the	software	OPTIMA	1.26	(BMG	Labtech,	Ortenberg,	Germany)	was	
used.	 Next,	 western	 blot	 analysis	 was	 carried	 out	 in	 order	 to	 test	 the	 specificity	 of	 the	
antibodies.	Thirty	microgram	of	each	protein	extract	was	separated	by	sodium	dodecyl	sulfate-
polyacrylamide	 gel	 electrophoresis.	 After	 transfer	 onto	 a	 nitrocellulose	 membrane,	 non-
specific	 binding	 was	 blocked	 using	 tris(hydroxymethyl)aminoethane-buffered	 saline/0.1	 %	
Tween-20	(TBS-T)	supplemented	with	2	%	non-fat	dry	milk	powder	for	1h	at	room	temperature	
and	 gently	 shaking	 conditions.	 NPSR	 protein	 was	 visualized	 by	 incubation	 with	 either	 Ab2	
antibody	(Leonard	&	Ring,	2011)	or	commercially	available	NPSR1	antibody	(abcam,	ab92425)	
over	 night	 at	 4°C.	 Next,	 membranes	 were	 washed	 3	 x	 5	 min	 each	 in	 TBS-T,	 incubated	 in	 a	
1:1.000	 dilution	 of	 horse-radish	 peroxidase-conjugated	 anti-rabbit	 antibody	 (New	 England	
Biolabs)	 in	 TBS-T	 for	 30	 min	 at	 room	 temperature,	 washed	 three	 times,	 and	 visualized	 by	
chemiluminescence	 (Western	 Lighting,	 PerkinElmer).	 Images	 were	 acquired	 using	 ChemiDoc	
XRS	system	(Bio-Rad,	Munich,	Germany).		
Ex-vivo	Ca2+	imaging	in	PVN-OXT	neurons	using	GCaMP6s	
To	examine	NPS-evoked	transient	Ca2+	increase	in	PVN-OXT	neurons,	Ca2+	imaging	in	PVN-OXT	
neurons	was	carried	out	using	ultrasensitive	fluorescent	proteins	(GCaMP6s).	300	nl	of	AAV1/2	
(OXTpr-GCaMP6s)	 was	 infused	 bilaterally	 into	 the	 PVN.	 Hence,	 expression	 of	 GCaMP6s	
indicator	was	confined	to	OXT	neurons.	
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Three	weeks	later,	animals	were	anaesthetized	using	a	ketamine/xylazine	(Imalgene	90	mg/kg,	
Rompun,	10	mg/kg)	mixture	administered	ip.	Transcardial	perfusion	was	then	performed	using	
one	 of	 the	 following	 artificial	 cerebrospinal	 fluids	 (ACSFs)	 dissection	 solutions.	 For	 rats	
between	20	and	22	weeks	old,	an	 ice-cold	NMDG-based	ACSF	was	used	containing	 (in	mM):	
NMDG	 (93),	 KCl	 (2.5),	 NaH2PO4	 (1.25),	 NaHCO3	 (30),	MgSO4	 (10),	 CaCl2	 (0.5),	 HEPES	 (20),	 D-
Glucose	 (25),	 L	 ascorbic	 acid	 (5),	 Thiourea	 (2),	 Sodium	pyruvate	 (3),	N-acetyl-L-cysteine	 (10),	
Kynurenic	acid	(2).	The	pH	was	adjusted	to	7.4	using	HCl,	after	bubbling	in	95%	O2-5%	CO2	gas;	
bubbling	 was	 maintained	 throughout	 the	 duration	 of	 use	 of	 the	 various	 ACSFs.	 Following	
decapitation,	the	brain	was	swiftly	transferred	into	the	same	ice-cold	ACSFs	dissection	solution	
as	 for	 transcardial	 perfusion,	 and	 300	 μm-thick	 coronal	 slices	 containing	 the	 PVN	 were	
obtained	using	a	Leica	VT1000s	vibratome.	After	slicing,	brain	slices	were	placed	in	35°C	NMDG	
ACSF	for	10	min.	Next,	brain	slices	were	placed	in	a	room-temperature	holding	chamber	with	
normal	 ACSF,	 for	 a	minimum	 of	 1	 hour	 before	 the	 conduction	 of	 any	 experiments.	 Normal	
ACSF,	also	used	during	experiments,	was	composed	of	(in	mM):	NaCl	(124),	KCl	(2.5),	NaH2PO4	
(1.25),	NaHCO3	 (26),	MgSO4	 (2),	CaCl2	 (2),	D-Glucose	 (15),	adjusted	 for	pH	values	of	7.4	with	
HCl	and	continuously	bubbled	 in	95%	O2-5%	CO2	gas.	All	ACSFs	were	 checked	 for	osmolarity	
and	 kept	 for	 values	 between	 300-310	 mOsm/l.	 In	 Ca2+	 imaging	 experiments,	 slices	 were	
transferred	from	the	holding	chamber	to	an	immersion	recording	chamber	and	superfused	at	a	
rate	of	2	ml/min	with	normal	ACSF	unless	indicated	otherwise.	
Spinning	disk	confocal	microscope	used	to	perform	OXT	neuron	Ca2+	imaging	was	composed	of	
a	Zeiss	Axio	examiner	microscope	with	a	20x	water	immersion	objective	(numerical	aperture	of	
1.0),	mounted	with	a	X-Light	Confocal	unit	–	CRESTOPT	spinning	disk.	Images	were	acquired	at	
5Hz	with	 an	 optiMOS	 sCMOS	 camera	 (Qimaging,	 BC,	 Canada).	 Cells	 within	 a	 confocal	 plane	
were	illuminated	for	100	to	150	ms	for	each	wavelength	(GCaMP6s:	475	nm)	using	a	Spectra	7	
LUMENCOR.	 The	 different	 hardware	 elements	 were	 synchronized	 through	 the	 MetaFluor	
software,	which	was	also	used	for	online	and	offline	quantitative	fluorescence	analysis.		
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OXT	neuron	calcium	levels	were	measured	in	hand	drawn	regions	of	interest	(ROIs)	comprising	
the	 cell	 body.	 [Ca2+]i	 variation	 were	 estimated	 as	 changes	 in	 fluorescence	 signals	 over	 the	
baseline	(ΔF/F)	after	drug	applications.	NPS	(2	µM,	Bachem)	and	SHA-68	(NPSR	antagonist,	100	
µM,	Tocris)	were	bath	applied	during	20	s	and	>	15	min,	respectively.	Baseline	was	established	
for	 each	 ROI	 as	 the	 average	 fluorescence	 over	 all	 pictures.	 Bleaching	was	 corrected	 using	 a	
linear	 regression	 on	 the	 overall	 ΔF/F	 trace	 for	 each	 OXT	 neurons,	 which	 values	 were	 then	
subtracted	to	the	ΔF/F.	Upon	extraction	of	data,	calculations	and	corrections	of	ΔF/F	for	each	
neuron,	the	area	under	the	curve	(AUC)	was	calculated	over	a	time	period	of	5	min	before	and	
after	drug	application.	An	OXT	neuron	was	considered	as	being	responsive	if	the	relative	ratio	
of	AUCs	after	drug/light	application	over	baseline	was	20%	greater	than	in	baseline	conditions.	
The	 relative	AUCs	 ratios	 values	were	 used	 for	 quantitative	 analysis	 and	 called	 “relative	AUC	
ratio”.	Maximal	peak	reached	after	drug	application	was	also	measured	in	responsive	cells	and	
used	 in	quantitative	analysis.	Data	were	averaged	across	OXT	neurons	per	slices,	which	were	
used	as	the	statistical	unit	over	a	minimum	of	3	animals	per	condition.	 Image	J	software	was	
also	used	on	GCaMP6s	pictures	 to	produce	 illustrative	pictures	 such	as	 the	one	 in	 Fig.	 2.	All	
calcium	imaging	experiments	were	conducted	at	conditioned	room	temperature	of	22°C.	
Monitoring	of	intra-PVN	release	of	OXT	
To	analyze	NPS-induced	OXT	release,	a	microdialysis	probe	(U-shaped,	molecular	cut-off	of	18	
kDa,	for	details	see	(Neumann	et	al.,	1993b;	Bosch	et	al.,	2005))	was	implanted	into	the	right	
PVN	and	a	guide	cannula	(21	G,	12	mm)	was	stereotaxically	placed	2	mm	above	the	left	lateral	
ventricle.	Following	surgery,	animals	were	allowed	to	recover	for	48	h	and	handled	trice	a	day	
to	 habituate	 to	 the	 microdialysis	 and	 the	 infusion	 procedure.	 Microdialysis	 probes	 were	
connected	 to	 a	 syringe	 mounted	 onto	 a	 microinfusion	 pump	 via	 polyethylene	 tubing	 and	
perfused	with	sterile	Ringer’s	solution	(3.3	µl/min)	starting	at	8:00	a.m.	for	2	h	before	the	start	
of	 the	 experiment	 to	 establish	 equilibrium	 between	 inside	 and	 outside	 of	 the	microdialysis	
membrane.	 Then,	 five	 consecutive	 30-min	 dialysates	 were	 collected:	 samples	 1	 and	 2	 were	
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taken	under	basal	conditions	and	sample	3,	4	and	5	after	icv	infusion	of	either	NPS	(1	or	5	nmol	
/	5µl)	or	Veh	(5	µl).	The	outflow	of	the	microdialysis	probe	was	equipped	with	a	tube	holder	
that	allowed	direct	sample	collection	 into	a	1.5-ml	Eppendorf	tube	containing	10	µl	of	0.1	M	
HCl.	Following	this,	samples	were	immediately	frozen	on	dry	ice,	and	subsequently	stored	at	-
20	 °C	 until	 quantification	 of	 OXT.	 OXT	 content	was	measured	 in	 evaporated	 dialysates	 by	 a	
highly	 sensitive	 and	 selective	 radioimmunoassay	 (detection	 limit	 0.1	 pg	 per	 sample,	 cross-
reactivity	of	the	antisera	with	other	related	peptides	was	<7%,	for	details	see	(Landgraf	et	al.,	
1995;	de	Jong	et	al.,	2015)).		
Pharmacological	inhibition	of	the	OXTR	system	
In	 order	 to	 analyze	 the	 behavioral	 importance	 of	 the	 OXT	 receptor	 (OXTR)	 system	 on	 NPS-
evoked	 anxiolysis,	 guide	 cannulas	 were	 implanted	 2	 mm	 above	 the	 lateral	 ventricle	 for	 icv	
infusion	or	the	PVN	for	 intra-PVN	infusions,	respectively.	For	evaluation	of	the	 local	effect	of	
the	OXT	receptor	antagonist	(OXTR-A)	des-Gly-NH2,d(CH2)5[Tyr(Me)2,Thr4]OVT	(Manning	et	al.,	
2012)	on	NPS-induced	anxiolysis,	 four	groups	of	conscious	 rats	were	studied,	which	received	
either	Veh/Veh,	Veh/NPS,	OXTR-A/Veh	or	OXTR-A/NPS	with	a	5-min	interval.	The	infused	dose	
of	 the	OXTR-A	 (icv:	 0.75	µg	 /	 5	μl;	 intra-PVN:	 0.15	µg	 /	 0.5	µl)	was	 selected	on	 the	basis	 of	
earlier	experiments	(Lukas	et	al.,	2013).	NPS	was	infused	icv	(1	nmol	/	5	µl)	or	 intra-PVN	(0.2	
nmol	/	0.5	µl);	controls	were	 infused	with	an	equal	volume	of	sterile	Ringer’s	solution	(Veh).	
Next,	anxiety-related	behavior	was	tested	using	the	LDB	and	the	OF	(for	details	see	2.7)	15	min	
after	last	intracerebral	infusion.	
Chemogenetic	silencing	of	PVN-OXT	neurons	
To	verify	 the	behavioral	 relevance	of	NPS-evoked	activation	of	OXT	neurons,	0.3	µl	of	AAV1/2	
OXTpr-hM4Di:mCherry	was	bilaterally	microinfused	into	the	PVN,	and	an	icv	guide	cannula	was	
implanted	as	described	above.	Three	weeks	later,	the	designer	receptor	hM4Di	was	activated	
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by	ip	injection	of	CNO	(2	mg/kg);	controls	received	1	ml/kg	of	sterile	phosphate-buffered	saline	
(PBS,	pH	7.4).	NPS	(1	nmol)	or	Veh	(5	µl)	were	infused	icv	40	min	later.	Testing	on	the	EPM	(for	
details	 see	 2.7.3)	 was	 carried	 out	 15	 min	 after	 intracerebral	 infusion.	 Expression	 of	 OXTpr-
hM4Di:mCherry	was	verified	in	perfused	brains	by	immunofluorescent	staining	of	mCherry	and	
OXT	(for	details	see	2.9).	
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2.5		 Experimental	design	-	Chapter	II	
Bilateral	infusion	of	NPS	into	the	MeA	on	anxiety-related	behavior	
To	examine	the	effect	of	a	subsequent	intra-MeA	infusion	of	NPS	on	anxiety-related	behavior,	
adult	male	Wistar	rats	were	infused	with	NPS	(Bachem,	H-6164)	at	0.2	nmol	/	0.5	µl	or	0.5	µl	of	
sterile	 Ringer’s	 solution	 as	 control	 (Veh)	 per	 hemisphere	 using	 a	 14-mm	 long	 27-G	 infusion	
cannula.	 Behavioral	 assessment	 was	 performed	 15	 min	 after	 the	 last	 intracerebral	 infusion	
using	the	EPM	and	the	OF	(for	details	see	2.7).	
Effects	of	icv	NPS	on	Ca2+/calmodulin-dependent	kinases	and	ERK1/2	in	the	
amygdala		
In	order	to	assess	NPS-induced	activation	of	intracellular	signaling	pathways,	rats	were	infused	
icv	with	either	NPS	 (1	nmol	/	5	µl)	or	Veh	 (5	µl)	using	a	14.7-mm	long	25-G	 infusion	system.	
Animals	were	sacrificed	by	rapid	decapitation	15	min	after	drug	infusion,	brains	were	removed	
and	amygdala	tissue	was	harvested	using	a	2	mm-wide	micropuncher	accordant	to	the	brain	
atlas.	 The	 cytoplasmic	 and	 nuclear	 proteins	 from	 amygdala	 tissue	 micropunches	 were	
extracted	consecutively	using	a	protein	extraction	kit	(Cat	No.	40010,	Active	Motif,	Rixensart,	
Belgium).	 In	detail,	 tissue	micropunches	were	homogenized	 in	1x	hypotonic	buffer	consisting	
of	 PBS,	 hypotonic	 buffer,	 phosphatase	 and	 protease	 inhibitors	 for	 15	min	 on	 ice.	 Following	
centrifugation	 for	 10	 min	 at	 3.200	 rpm	 and	 4	 °C,	 the	 supernatant	 containing	 cytoplasmic	
proteins	was	collected	and	transferred	into	a	pre-chilled	cup.	The	remaining	pellet	was	washed	
once	with	 ice-cold	 PBS	 to	wash	 away	 any	 remaining	 cytoplasmic	 proteins.	 Subsequently	 the	
pellet	 was	 re-suspended	 in	 complete	 lysis	 buffer,	 supplemented	 with	 dithiothreitol,	 and	
phosphatase	and	protease	inhibitors.	The	samples	were	incubated	on	ice	for	30	min,	vortexed,	
and	centrifuged	for	10	min	at	13.000	rpm	and	4	°C.	Then,	the	supernatant	containing	nuclear	
proteins	 was	 collected.	 The	 protein	 concentration	 was	 determined	 using	 the	 Pierce	 BCA	
Protein	 Assay	 Kit	 (Thermo	 Scientific,	 Cat	 No.	 23225).	 Thirty	 micrograms	 of	 each	 cytosolic	
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protein	extract	were	separated	by	sodium	dodecyl	sulfate-polyacrylamide	gel	electrophoresis.	
After	 transfer	onto	a	nitrocellulose	membrane,	non-specific	binding	was	blocked	using	TBS-T	
supplemented	with	non-fat	milk	powder	(2%	for	(p)CaMKII)	or	bovine	serum	albumin	(5%	for	
(p)ERK1/2)	 for	 1h	 at	 room	 temperature	 and	 gently	 shaking	 conditions.	 (p)CaMKII	 and	
(p)ERK1/2	 levels	 were	 visualized	 by	 incubation	 with	 respective	 antibodies	 against	 either	
pCaMKII	 (1:500,	 Thr286,	 Santa	 Cruz	 Biotechnology,	 sc-12886-R)	 or	 pERK1/2	 (1:1.000,	 Cell	
Signaling	 Technology,	 #8544S)	 over	 night	 at	 4°C.	 Thereafter,	 the	 membranes	 were	 washed	
three	times	for	5	min	each	in	TBS-T,	incubated	in	a	1:1.000	dilution	of	horseradish	peroxidase-
conjugated	anti-rabbit	antibody	(Cell	Signaling	Technology,	#7074)	in	TBS-T	for	30	min	at	room	
temperature,	washed	 three	 times,	and	visualized	by	chemiluminescence	using	ECL	Detection	
Reagent	 (Amersham	 Biosciences).	 Images	 were	 acquired	 using	 ChemiDoc	 XRS+	 system	
(BIORAD,	 Germany)	 and	 evaluated	 using	 ImageLab	 software	 (BIORAD).	 After	 imaging,	
immunocomplexes	were	removed	from	the	blot	with	Re-Blot	Plus	Solution	(Millipore),	probed	
with	 anti-total	 CaMKII	 (1:500,	 Santa	 Cruz	 Biotechnology,	 sc-13082)	 or	 ERK1/2	 (1:1.000,	 Cell	
Signaling	 Technology,	 #4695S),	 and	 imaged	 as	 described	 above.	 beta-tubulin	 was	 used	 as	 a	
loading	control	(1:1.000,	Cell	Signaling	Technology,	#2146).	
Effect	of	simultaneous	blockade	of	both	phospholipase	C	and	adenylyl	cyclase	
on	NPS-induced	anxiolysis	
In	 order	 to	 reveal	 the	 relevance	 of	 the	 NPSR-mediated	 phospholipase	 C	 (PLC)	 and	 adenylyl	
cyclase	(AC)	activation	on	NPS-induced	anxiolysis,	PLC	and	AC	were	blocked	simultaneously	by	
infusion	 of	 an	 inhibitor-cocktail	 (Inh)	 composed	 of	 the	 AC	 inhibitor	 2’,5’-dideoxydenosine	
(DDA,	 EnzoLifeScience,	 BML-CN110)	 and	 the	 PLC	 inhibitor	 U73122	 (EnzoLifeScience,	 BML-
ST391).	The	infused	dose	of	DDA	(12.5	nmol)	and	U73122	(0.5	nmol)	was	selected	on	the	basis	
of	previous	 in	vitro	studies	and	their	half-maximal	 inhibitory	dose	(for	details	see	(Holgate	et	
al.,	1980;	Smallridge	et	al.,	1992;	Ogawa	et	al.,	1995;	Feisst	et	al.,	2005)).	As	DDA	and	U73122	
stocks	were	diluted	in	dimethyl	sulfoxide	(DMSO,	Merck),	Veh1	was	composed	of	20	%	DMSO	
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and	80	%	Ringer’s	solution;	Veh2	was	composed	of	Ringer’s	solution.	Consequently,	4	groups	of	
conscious	 rats	 received	 the	 following	 two	 subsequent	 intra-MeA	 infusions	 of	 Veh1/Veh2,	
Veh1/NPS,	Inh/Veh2	or	Inh/NPS	with	a	20-min	interval	between	infusions.	Next,	anxiety-related	
behavior	was	assessed	15	min	after	the	 last	 intracerebral	 infusion	using	the	EPM	and	the	OF	
(for	details	see	2.7).	
Specific	effects	of	blockade	of	either	PLC	or	the	AC	signaling	on	NPSR-mediated	
anxiolysis	in	the	MeA	
To	assess	whether	the	anxiolytic	activity	of	NPS	is	mediated	via	the	NPSR-evoked	activation	of	
PLC	or	AC	or	via	both	signaling	pathways	within	the	MeA,	U73122	(0.5	nmol),	DDA	(12.5	nmol),	
or	Veh1	were	separately	infused	bilaterally	20	min	prior	to	NPS	or	Veh2	infusion	into	the	MeA.	
Then,	anxiety-related	behavior	was	assessed	using	the	EPM	and	the	OF	(for	details	see	2.7)	15	
min	after	the	last	drug	infusion.	
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2.6		 Experimental	design	-	Chapter	III	
Monitoring	of	chemogenetically	induced	intracerebral	OXT-release	
In	order	to	analyze	OXT	release	as	a	consequence	of	chemogenetic	activation	of	OXT	neurons,	
rats	 were	 implanted	 with	 a	 U-shaped	 microdialysis	 probe	 into	 PVN	 or	 lateral	 septum,	
respectively,	 19	 days	 following	 infusion	 of	 AAV1/2OXTpr-hM3Dq:mCherry	 into	 either	 PVN	 or	
PVN,	SON	and	AN.		
To	 monitor	 OXT	 release	 within	 the	 PVN	 of	 conscious	 rats,	 the	 microdialysis	 probes	 were	
connected	 to	 a	 syringe	 mounted	 onto	 a	 microinfusion	 pump	 via	 polyethylene	 tubing	 and	
perfused	with	 sterile	Ringer’s	 solution	 (3.3	µl	 ⁄	min)	 starting	 at	 8:00	 a.m.	 for	 2	h	before	 the	
start	 of	 the	 experiment	 to	 establish	 equilibrium	 between	 inside	 and	 outside	 of	 the	
microdialysis	 membrane	 two	 days	 after	 surgery.	 Five	 consecutive	 30-min	 dialysates	 were	
collected	on	both	experimental	day	1	and	day	2.	On	day	1,	samples	1	and	2	were	taken	before,	
and	sample	3,	4	and	5	after	ip	injection	of	CNO	(2	mg/kg)	or	sterile	PBS	as	control.	On	day	2,	
sample	 1	 was	 taken	 before,	 and	 samples	 2	 and	 3	 after	 ip	 injection	 of	 CNO	 or	 control.	
Thereafter,	rats	were	exposed	to	5-min	forced	swim	stress	(water	temperature	22-24°C),	and	
samples	4	and	5	were	collected.	The	outflow	of	the	microdialysis	probe	was	equipped	with	a	
tube	holder	that	allowed	direct	sample	collection	into	a	1.5-ml	Eppendorf	tube	containing	10	
µl	of	0.1	M	HCl.		
To	monitor	OXT	release	within	the	lateral	septum	of	urethane-anesthetized	rats	expressing	an	
excitatory	DREADD	 selectively	 under	 the	 control	 of	 an	OXT	promoter	 fragment	 in	 PVN,	 SON	
and	AN,	the	microdialysis	procedure	was	performed	as	described	above.	Here,	five	consecutive	
30-min	dialysates	were	collected:	samples	1	and	2	were	taken	before,	and	sample	3,	4	and	5	
after	ip	injection	of	CNO	(2	mg/kg)	or	sterile	PBS	as	control.	
All	 dialysates	 were	 immediately	 frozen	 on	 dry	 ice	 and	 subsequently	 stored	 at	 -80	 °C	 until	
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quantification	 of	 OXT	 by	 radioimmunoassay.	 Expression	 of	 OXTpr-hM3Dq:mCherry	 was	
verified	in	perfused	brains	by	immunofluorescent	staining	of	mCherry	and	OXT	(for	details	see	
2.9).	
Monitoring	of	chemogenetically	induced	peripheral	OXT-release		
To	monitor	peripheral	OXT	 release,	blood	 samples	were	 taken	via	 jugular	 vein	 catheter.	 The	
catheters	 were	 connected	 to	 a	 1-ml	 plastic	 syringe	 filled	 with	 sterile	 heparinized	 saline	 (30	
IU/ml,	 Heparin-Natrium,	 Ratiopharm,	 Ulm,	 Germany),	 and	 the	 rats	 were	 then	 placed	 on	 a	
heating	 plate	 to	 maintain	 homeostasis	 of	 body	 temperature.	 45	 min	 before	 and	 after	 ip	
injection	of	CNO	or	PBS,	500	µl	of	blood	was	taken.	The	same	volume	of	blood	was	replaced	
with	 sterile	 saline	before	 the	PE-20	 tubing	was	 filled	with	heparinized	saline	again.	All	blood	
samples	 were	 collected	 on	 ice	 in	 EDTA-coated	 tubes	 (Bayer	 AG,	 Leverkusen,	 Germany)	 and	
centrifuged	(13.000	rpm,	10	min,	4	°C).	200	µl	of	plasma	samples	were	separated	and	stored	at	
-80	°C	until	quantification	of	OXT.		
Behavioral	consequences	induced	by	chemogenetic	activation	of	the	
endogenous	OXT	system	
In	 a	 separate	 cohort,	 the	 consequence	 of	 increased	 intracerebral	 OXT-release	 on	 anxiety-
related	 behavior	 was	 tested	 in	 the	 LDB	 55	 min	 after	 CNO	 injection	 (for	 details	 see	 2.7.1).	
During	ongoing	microdialysis	on	day	1,	an	experimenter	blind	to	treatment	analyzed	food	and	
water	intake,	sleep,	exploration	and	self-grooming	every	fifth	minute.	
Effects	of	chemogenetic	activation	of	the	PVN-OXT	system	on	ethanol	intoxication	
Icv	infusion	of	1	µg	of	OXT	attenuates	locomotor	impairments	induced	by	ethanol	intoxication	
(Bowen	 et	 al.,	 2015).	 Herein,	 I	 tested	 whether	 chemogenetic	 activation	 of	 the	 endogenous	
PVN-OXT	 system	 inhibits	 ethanol-induced	 ataxia.	 Briefly,	 to	 evoke	 endogenous	 OXT-release,	
hM3Dq,	an	activating	designer	receptor,	was	expressed	selectively	under	the	control	of	an	OXT	
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promoter	fragment	in	PVN-OXT	neurons.	Conscious	rats	were	injected	ip	with	CNO	(2	mg/kg)	
or	PBS	as	control	(Veh)	21	days	following	intra-PVN	infusion	of	AAV1/2OXTpr-hM3Dq:mCherry.	
Thirty	minutes	later,	animals	were	injected	either	with	ethanol	(1.5	g/kg,	15%	wt/vol)	or	PBS.	
Five	minutes	 after	 the	 last	 drug	 infusion,	 animals	 underwent	 the	wire-hanging	 test	 and	 the	
rightning-reflex	test	as	described	in	detail	below.	Both	tests	were	repeated	30	min	later.		
Wire-hanging	test	
The	wire-hanging	test	is	sensitive	to	ethanol-induced	locomotor	impairments,	such	as	reduced	
muscle	strength	(Shukitt-Hale	et	al.,	1998;	Crabbe	et	al.,	2003;	Boyce-Rustay	&	Holmes,	2006).	
First,	animals	were	placed	on	a	standard	cage	grid.	An	experimenter	softly	shakes	the	platform	
horizontally	 for	 4	 times	 and	 then	 the	platform	 is	 inverted	at	 a	height	of	 80	 cm	above	a	box	
filled	with	bedding	to	avoid	injuries	to	the	rat	from	the	fall.	The	duration	the	rat	spent	hanging	
at	 the	 cage	 grid	 is	 indicative	 for	 the	 degree	 of	 locomotor	 impairments	 due	 to	 ethanol	
intoxication.	Each	trial	was	recorded,	evaluated	using	Final	Cut	Pro	(Apple,	California,	USA)	and	
an	average	time	of	the	three	consecutive	trials	were	used	for	statistical	analysis.		
Righting-reflex	test		
The	 righting-reflex	 test	 is	 used	 to	 investigate	 motor	 coordination	 and	 sedation	 in	 ethanol-	
intoxicated	animals	(Little	et	al.,	1996).	Briefly,	rats	were	placed	on	a	table	and	turned	on	their	
back	by	an	experimenter.	The	latency	to	right	all	four	paws	on	the	ground	after	release	by	the	
experimenter	 was	 recorded.	 The	 rightning-reflex	 test	 was	 performed	 immediately	 after	 the	
wire-hanging	 test	 on	 each	 of	 the	 three	 consecutive	 trials	 and	 evaluated	 using	 Final	 Cut	 Pro	
(Apple,	California,	USA).	The	average	of	three	trials	at	each	time	point	was	used	for	statistical	
analysis.		
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2.7	 Anxiety-related	behavior	
Following	the	respective	treatment,	the	anxiety-related	behavior	was	assessed	using	the	LDB,	
OF,	 and	 the	 EPM.	 Basically,	 these	 tests	 generate	 a	 natural	 conflict	 between	 the	 explorative	
drive	and	the	 innate	 fear	of	open,	 lit	and	exposed	areas.	The	more	anxious	an	animal	 is,	 the	
less	time	it	spends	in	bright,	potentially	unsecure	areas	and	vice	versa.	
2.7.1	Light-dark	box	
In	detail,	the	LDB	setup	consisted	of	two	compartments	(one	lit	compartment	(40	x	50	cm,	100	
lux;	 light	 box)	 and	 one	 dark	 compartment	 (40	 x	 30	 cm,	 0	 lux)).	 Each	 compartment	 was	
connected	via	a	small	opening	(7.5	x	7.5	cm)	enabling	transition	between	the	two	floors.	Rats	
were	placed	in	the	light	compartment	after	the	last	drug	infusion	for	5	min,	and	the	time	spent	
in	 the	 light	 box	 and	 numbers	 of	 entries	 into	 the	 light	 box	were	 taken	 as	measurements	 for	
anxiety-related	behavior.	LDB	testing	was	analyzed	using	an	automated	video	tracking	system	
(Noldus,	EthoVision	X7,	Netherlands).		
2.7.2	Open	field	
For	 the	OF,	 rats	were	 placed	 in	 the	 center	 of	 the	 box	 (80	 x	 80	 x	 40	 cm,	 140	 lux)	 and	were	
allowed	 to	 freely	 explore	 the	 arena	 during	 a	 5-min	 test.	 The	 time	 the	 animals	 spent	 in	 the	
center	zone	(40	x	40	cm),	the	number	of	center	zone	entries	and	the	travelled	distance	as	an	
indicator	of	locomotor	activity	were	assessed	on	video	recordings	using	EthoVision	X7.	
2.7.3	Elevated	plus	maze	
Five-minute	 testing	on	 the	EPM	was	performed	on	a	plus-shaped	maze,	which	was	elevated	
(70	cm)	 from	the	 floor	and	consisted	of	 two	closed	arms	 (50	x	10	cm,	10	 lux)	and	 two	open	
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arms	(50	x	10	cm,	40-50	lux)	separated	by	a	central	neutral	zone	(10	x	10	cm).	A	camera	above	
the	maze	enabled	video	recordings	and	subsequent	assessment	of	behavior.	The	test	started	
by	placing	the	animal	 in	the	neutral	zone	facing	a	closed	arm.	The	percentage	time	spent	on	
the	open	versus	all	 arms,	 as	 an	 indicator	of	 anxiety-related	behavior,	was	determined	by	an	
observer	 blind	 to	 treatment.	 The	 number	 of	 closed	 arm	entries	was	 used	 as	 an	 indicator	 of	
locomotor	activity.		
2.8	 Verification	of	cannula	and	microdialysis	probe	placement	
After	 the	 behavioral	 experiments,	 animals	 were	 sacrificed	 by	 CO2	 and	 rapidly	 decapitated,	
brains	 were	 snap-frozen	 in	 pre-chilled	 N-methylbutane	 on	 dry	 ice,	 and	 the	 placement	 of	
microdialysis	 probes	 and	 cannulas	 was	 verified	 on	 40-μm	 thick	 Nissl-stained	 coronal	
cryosections	 according	 to	 brain	 atlas.	 Only	 animals	 with	 correctly	 positioned	 probes	 and	
cannulas	were	included	for	statistical	analyses.	
2.9		 Immunofluorescent	staining	
In	order	to	analyze	retrogradely	labeled	neurons,	to	localize	NPSR	protein	expression	in	PVN-
OXT	 neurons	 and	 to	 verify	 successful	 DREADD	 expression	 (hM3Dq	 or	 hM4Di,	 respectively)	
within	 the	 PVN,	 rats	 were	 deeply	 anesthetized	 with	 Xylazin	 (2%,	 0.5	 ml/kg,	 Bernburg)	 and	
Ketamine	(10%,	1	ml/kg,	WDT),	and	perfused	transcardially	with	100	ml	of	0.01	M	PBS	(pH	7.4)	
and	300	ml	of	PBS	supplemented	with	4	%	paraformaldehyde.	Next,	brains	were	removed	and	
post-fixed	 overnight	 at	 4	 °C	 in	 paraformaldehyde	 solution	 (4	 %),	 cryo-protected	 in	 30	 %	
sucrose	for	3	days	at	4	°C,	and	snap-frozen	in	N-methylbutane	cooled	by	dry	ice.		
Coronal	brain	slices	(40	µm)	containing	the	PVN	or	the	LC	were	collected,	washed	3	x	5	min	in	
PBS	supplemented	with	0.3	%	Triton-X	(PBS-T),	and	were	blocked	in	PBS-T	supplemented	with	
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1	%	bovine	serum	albumine	for	1h	at	room	temperature	(RT).	Brain	slices	were	incubated	with	
primary	antibodies	(summarized	in	table	4)	overnight	at	4	°C,	then	rinsed	3	x	10	min	with	PBS-T	
and	 incubated	with	 the	 corresponding	AlexaFluor	 488-	 or	AlexaFluor	 594-coupled	 secondary	
antibody	 (1:1.000,	 2h,	 RT,	 Lifetechnologies),	 washed	 again	 in	 PBS-T,	 and	 mounted	 with	
Vectashield	Hard	Set	Mounting	Medium	(Vector	Labs)	onto	SuperFrost	object	slides.	
Antibody	 Host	 Dilution	 Origin	
mCherry	 Rabbit	polyclonal	 1:1.000	 Abcam,	ab167453	
OXT	 Mouse	monoclonal	 1:500	 (Ben-Barak	et	al.,	1985)	
NPS	 Rabbit	polyclonal	 1:500	 Abcam,	ab18252	
NPSR	 Rabbit	polyclonal	 1:1.000	 (Leonard	&	Ring,	2011)	
	
Table	4:	List	of	antibodies	used	for	immunofluorescent	protein	labeling.	
Images	were	acquired	using	 Leica	DM5000B	and	Leica	TCS	SP8	microscope.	Digitized	 images	
were	analyzed	using	FIJI	(NIMH,	Bethesda,	MD,	USA).		
Pre-incubation	of	the	OXT	antibody	with	the	sister-nonapeptide	vasopressin	had	no	effect	on	
immunoreactivity,	further	demonstrating	the	specificity	of	the	antibody	(see	also	(Ben-Barak	et	
al.,	1985)).		
2.10	 Statistical	analysis	
Two-tailed	t-test	or	non-parametric	Mann-Whitney	U-test	was	used	in	order	to	evaluate	FACS	
analysis,	 to	 analyze	 differences	 of	 a	 single	 drug	 treatment	 on	 a	 specific	 selected	 behavior	
according	to	the	experimental	protocol,	and	to	evaluate	Western	blot	data.	
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In	 experiments	 designed	 out	 of	 four	 groups,	 anxiety-related	 behavior	 was	 analyzed	 using	 a	
two-way	 analysis	 of	 variance	 (ANOVA,	 factors	 treatment	 1	 x	 treatment	 2).	 OXT	 content	 in	
microdialysates	 and	 plasma,	 and	 behavioral	 evaluation	 during	 ongoing	 microdialysis	 was	
analyzed	using	two-way	ANOVA	with	repeated	measures	(factor	time	x	treatment).	Any	overall	
statistical	differences,	which	were	set	at	p	<	0.05,	were	further	analyzed	using	Tukey	́s	post-hoc	
test.		
Data	are	expressed	as	group	mean	+	SEM.	Statistical	analyses	were	performed	using	SigmaPlot	
13	(Systat).	
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Chapter	I	–	NPS	evokes	anxiolysis	by	acting	on	paraventricular	
OXT	neurons	
The	results	of	Chapter	1	have	been	submitted	to	the	Journal	of	Physiology	on	6th	of	
June	2017.	
	
Grund,	T.,	Goyon,	S.,	Charlet,	A.,	Grinevich,	V.,	Neumann,	I.D.	(submitted)	At	the	core	
of	neuropeptidergic	modulation	of	anxiety:	Activation	of	oxytocin	neurons	by	
neuropeptide	S.		
Journal	of	Physiology	
	
1.	LC-NPS	afferents	towards	the	hypothalamic	PVN		
To	examine	whether	NPS	neurons	 located	in	the	LC	 innervate	the	PVN,	the	retrograde	tracer	
cholera	 toxin	 subunit	 B	 conjugated	 to	Alexa	 Fluor-488	 (CTB-488)	was	 infused	bilaterally	 into	
the	 PVN	 of	 male	 rats.	 Five	 days	 later,	 this	 tracing	 resulted	 in	 dense	 labeling	 of	 NPS-
immunoreactive	neurons	throughout	the	LC,	indicating	prominent	LC-PVN	afferents	to	the	PVN	
(Fig.	5).	
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Figure	5:	Retrograde	tracing	of	NPS	neurons	innervating	the	hypothalamic	PVN.	A)	OXT-immunoreactive	neurons	
demonstrate	correct	intra-PVN	infusion	site	of	cholera	toxin	subunit	B	conjugated	to	Alexa	Fluor-488	(CTB-488).	B)	
Five	 days	 following	 intra-PVN	 infusion	 of	 the	 tracer,	 retrogradely	 transported	 CTB-488	 labeled	 neurons	
immunoreactive	for	NPS	in	the	LC.	Scale	bar:	A3=100	µm,	B3=30	µm.	Right	site:	Schematic	drawing	of	the	bilateral	
intra-PVN	infusion	sites	of	CTB-488	and	pericoerulear	region	harboring	NPS-immunoreactive	neurons.	
	
2.	PVN-OXT	neurons	express	NPSR	
Declaration:	 FACS	 analysis	 was	 performed	 in	 collaboration	 with	 Valery	 Grinevich,	 Marina	
Eliava,	Haikun	Liu,	and	Yuting	Li	 (DKFZ,	University	of	Heidelberg,	Germany).	Chiara	Ruzza	and	
Girolamo	 Calo	 (University	 of	 Ferrara,	 Italy)	 kindly	 provided	 frozen	 brains	 from	wild	 type	 and	
NPSR	knockout	mice.	
NPSR	 expression	 has	 been	 described	 in	 the	 rat	 PVN	 (Xu	 et	 al.,	 2007).	 Thus,	 I	 specifically	
investigated	NPSR	expression	in	PVN-OXT	neurons.	In	the	absence	of	a	specific	NPSR	antibody	
(Slattery	 et	 al.,	 2015),	 I	 performed	 FACS	 analysis	 in	 extracted	 PVN	 samples	 3	 weeks	 after	
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bilateral	intra-PVN	infusion	of	a	cell-type	specific	rAAV	expressing	Venus	selectively	under	the	
control	 of	 an	 OXT	 promoter	 fragment	 (AAV1/2(OXTpr-Venus)).	 Hence,	 Venus	 expression	 was	
confined	 to	 PVN-OXT	 neurons	 (Knobloch	 et	 al.,	 2012).	 FACS	 analysis	 of	 viable	 cells	 in	
combination	 with	 quantitative	 RT-PCR	 revealed	 that	 NPSR	 mRNA	 was	 predominantly	
expressed	 in	Venus+	neurons,	whereas	NPSR	expression	 in	Venus-	 cells	was	almost	negligible	
(Fig.	6).	
	
Figure	 6:	 OXT	 neurons	 within	 the	 hypothalamic	 PVN	 express	 NPSR	mRNA.	 FACS	 plots	 indicate	 that	 cells	 were	
sorted	by	A)	size	via	side-	(SSC)	and	forward-scattered	light	(FSC)	and	B)	fluorescence	intensity	in	living	cells	negative	
for	propidium	iodide	(PI).	C)	qRT-PCR	of	reversely	transcribed	RNA	isolated	from	sorted	viable	cells	demonstrated	
prominent	NPSR	mRNA	expression	in	Venus+	neurons,	whereas	NPSR	mRNA	expression	in	Venus-	cells	was	almost	
negligible.	Data	represent	mean	+	SEM.	*p<0.05.	
To	 investigate	 the	 localization	 of	 the	 NPSR	within	 the	 PVN	 at	 protein	 level,	 I	 performed	 an	
immunofluorescent	 staining	 of	 both	 NPSR	 and	 OXT.	 NPSR	 immunoreactivity	 using	 Ab2	
(Leonard	 &	 Ring,	 2011)	 was	 mostly	 somatic	 and	 punctuate,	 suggesting	 vesicular	 and	
membrane	microdomain	localization	in	OXT-immunopositive	neurons	(Fig.	7).	Further,	cellular	
resolution	revealed	few	cells	 immunoreactive	for	NPSR,	but	not	OXT,	suggesting	that	NPSR	is	
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not	exclusively	localized	on	PVN-OXT	neurons.	
	
Figure	7:	Immunofluorescent	staining	demonstrates	NPSR	localization	on	PVN-OXT	neurons.	Scale	bar:	50	µm	
Specificity	of	NPSR	antibody	Ab2	and	 commercially	 available	NPSR1	antibody	 (ab92425)	was	
examined	using	NPSR	knockout	and	wild	type	hypothalamic	mouse	tissue	micropunches.	First,	
knockout	 tissue	 was	 analyzed	 to	 confirm	 molecular	 background	 of	 transgenic	 mice.	 NPSR	
mRNA	 expression	was	 not	 detectable	 in	 knockout	mouse	 tissue	micropunches	 compared	 to	
wild	 type	 (Fig.	 8).	 Second,	 genotyping	 of	 DNA	 indicated	 a	 PCR	 product	 of	 418	 bp	 from	 the	
homozygous	 wild-type	 mice	 (NPSR+/+)	 and	 a	 599-bp	 DNA	 fragment	 was	 amplified	 from	
homozygous	knockout	mice	(NPSR-/-)	accordant	to	the	literature	(Camarda	et	al.,	2009).	More	
importantly,	I	performed	western	blot	analysis	in	both	knockout	and	wild-type	tissue.	Herein,	a	
band	was	present	at	predicted	size	in	both	NPSR+/+	and	NPSR-/-	tissue	micropunches	suggesting	
that	neither	NPSR1	antibody	(ab92425,	Fig.	8C)	nor	Ab2	(Fig.	8D)	are	specific.	This	 important	
finding,	which	has	been	 included	 in	a	 recent	manuscript	 (Slattery	 et	al.,	 2015),	 excluded	 the	
further	use	of	the	only	available	NPSR1	antibody	for	my	future	studies.	
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Figure	8:	Unspecific	binding	of	NPSR	antibodies.	A)	RT-PCR	demonstrates	NPSR	expression	at	mRNA	(196	bp)	level	
in	NPSR+/+	 (WT),	but	not	NPSR-/-	 (KO)	hypothalamic	 tissue	micropunches.	RPL13a	 (182	bp)	was	used	as	 reference	
gene.	B)	PCR	analysis	of	DNA	from	NPSR	WT	and	KO	mice	revealed	a	PCR	product	of	418	bp	from	the	homozygous	
NPSR	WT	mice;	a	599-bp	DNA	fragment	was	amplified	 from	homozygous	KO	mice.	Western	blot	analysis	 in	NPSR	
WT	and	KO	mouse	hypothalamic	tissue	micropunches	revealed	bands	at	predicted	size	of	NPSR	protein	for	both	C)	
NPSR1	antibody	(abcam,	ab92425)	and	D)	Ab2	antibody.	
3.	NPS	evokes	transient	Ca2+	influx	in	PVN-OXT	neurons	
Declaration:	 Ca2+	 imaging	 in	 GCaMP6s-positive	 PVN-OXT	 neurons	 was	 performed	 in	
collaboration	with	Alexandre	Charlet	and	Stephanie	Goyon	(University	of	Strasbourg,	France),	
Valery	Grinevich	Grinevich	and	Marina	Eliava	(DKFZ,	University	of	Heidelberg,	Germany).	
Next,	 I	examined	 the	hypothesis,	whether	NPS	 is	 capable	of	activating	PVN-OXT	neurons.	To	
test	 this,	 I	used	ultrasensitive	 fluorescent	proteins	 for	 imaging	neuronal	activity	 (Chen	 et	al.,	
2013).	 Three	 weeks	 following	 bilateral	 infusion	 of	 AAV1/2(OXTpr-GCaMP6s)	 into	 the	 PVN,	
GCaMP6s	was	selectively	expressed	under	the	control	of	the	OXT	promoter	fragment	(Fig.	9).	
3		 Results	 	
	
71
Following	 hypothalamic	 slice	 preparation,	 the	 majority	 of	 OXT	 neurons	 were	 identified	 as	
constitutively	 silent	 (235/337	 neurons,	 69.7	 %),	 whereas	 a	 smaller	 number	 of	 neurons	
(approximately	 30	%)	 displayed	high	 variability	with	 respect	 to	 intracellular	 Ca2+	 fluctuations	
and,	 thereby,	 were	 characterized	 as	 constitutively	 active.	 A	 subpopulation	 of	 silent	 OXT	
neurons	 (32/237=13.5	 %)	 responded	 to	 NPS	 (2	 µM	 for	 20	 s)	 by	 increased	 fluorescence	
indicative	 for	 transient	 rise	 in	 intracellular	 Ca2+	 levels.	 In	 the	 presence	 of	 a	 selective	 NPSR	
antagonist	(SHA-68,	100	µM,	30	min),	NPS	failed	to	induce	any	cellular	response	compared	to	
baseline	 indicating	 that	 the	 NPS-induced	 increase	 in	 intracellular	 Ca2+	 in	 OXT	 neurons	 is	
specifically	mediated	via	the	NPSR.	
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Figure	9.	NPS	effects	on	PVN-OXT	neurons	 in	hypothalamic	slice	preparation	(A-D).	A)	Schematic	drawing	of	the	
PVN	OXTpr-GCaMP6s	virus	infusion	and	subsequent	[Ca2+]i	imaging	of	OXT	neurons.	B)	Basal	activity	of	two	distinct	
subpopulations	of	OXT	neurons	 (silent,	purple;	active,	pink)	 illustrated	by	typical	ΔF/F	traces.	Pie	charts	show	the	
proportion	of	silent	(left)	and	active	(right)	OXT	neurons	(n	slices	(ns)	=	11,	n	OXT	neurons	(nn)	=	237).	C)	Pie	charts	
of	the	proportion	of	responsive	OXT	neurons	to	NPS	application	alone	(2	µM,	20s;	ns	=	11,	nn	=	32/237;	light	blue)	or	
in	presence	of	NPSR	antagonist	 (SHA-68	100	µM,	>	15	min;	ns	=	5,	nn	=	3/100;	dark	blue)	and	typical	ΔF/F	traces.	
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Pseudo-color	video	extract	of	identified	OXT	neurons	through	GCaMP6s	imaging	[Ca2+]i	either	in	control	conditions	
(gray),	in	presence	of	NPS	(light	blue),	or	NPS	+	SHA-68	(dark	blue)	(stacks	of	50	images/10s	of	recording).	Scale	bar:	
20	µm.	D)	Ratio	of	ΔF/F	AUCs,	maximal	peak	values	and	response	duration	of	OXT	neurons	in	presence	of	NPS	(ns	=	
11,	 nn	 =	 32;	 light	 blue),	 or	 NPS	 +	 SHA-68	 (ns	 =	 5,	 nn	 =	 3;	 dark	 blue).	 Only	 OXT	 neurons	 that	 responded	 are	
represented	here.	White	circles	represent	individual	neuron	values.	
4.	NPS	evokes	release	of	OXT	within	the	PVN	
Declaration:	 Radioimmunoassay-based	 quantification	 of	 OXT	 content	 in	 microdialysates	 was	
performed	by	Rainer	Landgraf	(RIAgnosis,	Sinzing,	Germany).	
Another	 indicator	 for	 a	 stimulated	 activity	 of	 OXT	 neurons	 is	 increased	 OXT	 release,	 for	
example	within	the	PVN	in	a	somato-dendritic	fashion	(Neumann	&	Landgraf,	2012),	and	Ca2+	
availability,	 specifically	 an	 increase	 in	 intracellular	 Ca2+,	 is	 a	 prerequisite	 for	 such	 release	
(Neumann	et	al.,	1993b;	Fisher	&	Bourque,	1996;	Ludwig	et	al.,	2002).	Thus,	I	monitored	OXT	
release	 within	 the	 PVN	 of	 conscious	 rats	 in	 response	 to	 NPS	 (1	 nmol	 or	 5	 nmol,	 icv)	 using	
intracerebral	 microdialysis	 (Landgraf	 &	 Neumann,	 2004).	 NPS	 dose-dependently	 evoked	 a	
significant	rise	in	local	OXT	release	(factors	time	x	treatment;	F8,79=5.931;	p<0.001)	during	the	
first	(5	nmol,	p<0.001	vs.	vehicle	(Veh))	and	during	the	2nd	and	3rd	(1	nmol,	p<0.05	vs.	Veh)	30-
min	dialysis	period,	respectively,	following	NPS	(Fig.	10).		
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Figure	 10.	NPS	 effects	 on	 intracerebral	OXT	 release	 in	 the	 PVN	of	 conscious	male	 rats.	 OXT	 content	 in	 30-min	
microdialysates	sampled	within	the	PVN	under	basal	conditions	(b1	and	b2),	and	after	icv	infusion	of	either	Veh,	or	
NPS	(1	nmol,	5	nmol),	as	well	as	a	representative	microphotograph	of	a	Nissl-stained	coronal	section	demonstrating	
the	placement	of	the	microdialysis	probe	within	the	PVN.	Data	are	expressed	as	percentage	of	baseline	(mean	of	
basal	1	and	2;	=100%;	dotted	line)	±	SEM,	n=5-6.	**p<0.01	vs.	all;	*p<0.05	vs.	respective	Veh.		
5.	Selective	inhibition	of	OXTR	and	chemogenetic	silencing	of	OXT	neurons	
within	the	PVN	prevent	NPS-induced	anxiolysis	
To	examine	the	behavioral	relevance	of	NPS-evoked	activation	of	OXT	neurons,	two	strategies	
were	employed:	First,	OXTRs	were	pharmacologically	blocked	by	icv	or	intra-PVN	infusion	of	a	
specific	OXTR	antagonist	(OXTR-A,	des-Gly-NH2,d(CH2)5[Tyr(Me)2,Thr4]OVT)	prior	to	icv	or	local	
infusion	of	NPS	and	behavioral	testing	on	the	light/dark	box	(LDB)	and	in	the	open	field	(OF),	
respectively,	 to	 assess	 anxiety-related	 behavior.	 Secondly,	 PVN-OXT	 neurons	 were	
chemogenetically	silenced	prior	to	 icv	 infusion	of	NPS	and	behavioral	testing	on	the	elevated	
plus	maze	(EPM).	
OXTR	antagonism	prevents	NPS-induced	anxiolysis	
Pharmacological	blockade	of	OXTR	signaling	by	pre-infusion	of	a	selective	OXTR-A	(icv:	0.75	µg,	
intra-PVN:	0.15	µg)	5	min	prior	 to	NPS	 infusion	 (icv:	1	nmol,	 intra-PVN:	0.2	nmol)	prevented	
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NPS-induced	 anxiolysis	 in	 two	 relevant	 behavioral	 tests	 (Fig.	 11).	 Specifically,	 comparison	 of	
the	 following	 4	 groups	 (Veh/Veh,	 Veh/NPS,	 OXTR-A/Veh,	OXTR-A/NPS)	 revealed	 that	 in	 Veh	
pre-infused	 rats,	 icv	 NPS	 increased	 the	 percentage	 of	 time	 the	 rats	 spent	 in	 the	 lit	
compartment	 of	 the	 LDB	 (F1,31=	 4.25,	 p=0.049;	 Veh/NPS	 vs.	 Veh/Veh:	 p=0.006),	whereas	 icv	
OXTR	antagonism	blocked	this	effect	 (Veh/NPS	vs.	OXTR-A/NPS:	p=0.036).	The	OXTR-A	alone	
did	 not	 affect	 anxiety-related	 behavior	 (OXTR-A/Veh	 vs.	 Veh/Veh:	 p=0.48).	 Neither	 NPS	 nor	
OXTR-A,	 alone	 or	 in	 combination,	 influenced	 the	 locomotor	 activity	 indicated	 by	 traveled	
distance	(F1,31=0.50,	p=0.49).	Similarly,	in	the	OF	icv	NPS	produced	a	robust	anxiolytic	effect	as	
animals	 spent	 more	 time	 in	 the	 center	 zone	 (F1,31=4.46,	 p=0.043;	 Veh/NPS	 vs.	 Veh/Veh:	
p=0.002).	In	contrast,	in	OXTR-A	pre-infused	rats,	NPS	failed	to	induce	anxiolysis	(OXTR-A/NPS	
vs.	 Veh/NPS:	 p=0.003).	 None	 of	 the	 treatments	 changed	 locomotor	 activity	 in	 the	 OF	 as	
reflected	by	the	traveled	distance	(F1,31=0.57,	p=0.46).	
In	order	to	localize	the	effects	of	OXTR-A	pretreatment	and	NPS	within	the	PVN,	local	infusions	
were	 performed.	 In	 Veh-pretreated	 rats,	 local	 NPS	 exerted	 a	 robust	 anxiolytic	 effect,	 which	
was	comparable	to	that	seen	after	icv	infusion.	Pre-infusion	of	the	OXTR-A	bilaterally	into	the	
PVN	prevented	the	anxiolytic	effect	of	NPS	infused	5	min	later	(Fig.	11).	Specifically,	in	the	LDB,	
NPS	increased	the	time	the	rats	spent	in	the	lit	compartment	(F1,41=6.65,	p=0.014;	Veh/NPS	vs.	
Veh/Veh:	 p=0.003),	 whereas	 pre-infusion	 of	 OXTR-A	 prevented	 this	 effect	 (OXTR-A/Veh	 vs.	
OXTR-A/NPS:	 p=0.49).	 Neither	 local	 OXTR-A	 nor	 NPS,	 alone	 or	 in	 combination,	 changed	 the	
locomotor	activity	 indicated	by	 the	distance	 traveled	 in	 the	 LDB	 (p=0.60).	 The	 result	of	 local	
blockade	of	OXTR	preventing	the	anxiolytic	NPS	effects	within	the	PVN	was	recapitulated	in	the	
OF:	 in	Veh-pretreated	 rats	NPS	 increased	 the	 time	 spent	 in	 the	 center	 of	 the	OF	 (F1,35=4.17,	
p=0.049;	 Veh/NPS	 vs.	 Veh/Veh:	 p=0.033),	 whereas	 pre-infusion	 of	 OXTR-A	 prevented	 this	
anxiolytic	effect	(OXTR-A/Veh	vs.	OXTR-A/NPS:	p=0.49).	In	the	OF,	NPS	increased	the	traveled	
distance	indicative	of	increased	locomotor	activity	(F1,35=6.82,	p=0.014;	Veh/NPS	vs.	Veh/Veh:	
p=0.049).	
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Figure	11:	Icv	and	intra-PVN	pre-infusion	with	an	OXTR	antagonist	blocked	NPS-induced	anxiolysis.	Male	rats	were	
infused	with	 a	 selective	OXTR	 antagonist	 (OXTR-A,	 icv:	 0.75	 µg,	 intra-PVN:	 0.15	 µg)	 prior	 to	 NPS	 infusion	 (icv:	 1	
nmol,	intra-PVN:	0.2	nmol)	or	control	(Veh).	The	percentage	of	time	spent	in	the	lit	compartment	of	the	LDB	and	the	
time	 spent	 in	 the	 center	 zone	of	 the	OF	 indicate	anxiety-related	behavior.	 Traveled	distance	 indicates	 locomotor	
activity	 in	 each	 compartment.	 Data	 represent	mean	 +	 SEM,	 group	 sizes:	 n=8-13.	 *p<0.05,	 **p<0.01	 vs.	 all	 or	 as	
indicated.	
Chemogenetic	silencing	of	PVN-OXT	neurons	blocks	NPS-evoked	anxiolysis	
Following	intra-PVN	infusion	of	AAV1/2	OXTpr-hM4Di:mCherry,	a	Gi-coupled	designer	receptor	
(hM4Di)	was	expressed	under	the	control	of	the	OXT	promoter	fragment.	The	infusion	of	this	
rAAV	 into	 the	 rat	 PVN	 resulted	 in	 selective	 expression	 of	 hM4Di:mCherry	 in	 OXT	 neurons.	
Quantitative	analysis	in	the	PVN	showed	that	92.98	±	1.35	%	of	mCherry-immunopositive	cells	
(n=278)	 expressed	OXT	 (94.16	 ±	 1.22	%	 of	 OXT-immunoreactive	 neurons	 (n=274)	 expressed	
hM4Di:mCherry),	revealing	an	efficient	and	highly	specific	virus	expression.	In	the	presence	of	
CNO	 (2	 mg/kg,	 ip,	 Fig.	 5),	 a	 chemically	 inert	 compound	 that	 specifically	 activates	 hM4Di,	
chemogenetic	silencing	of	PVN-OXT	neurons	has	been	observed	(Eliava	et	al.,	2016).	Herein,	in	
CNO-pretreated	 rats	 icv	 NPS	 (1	 nmol)	 failed	 to	 induce	 anxiolysis	 suggesting	 that	 PVN-OXT	
neurons	mediate	NPS-induced	anxiolysis.	On	the	EPM,	two-way	ANOVA	revealed	a	main	effect	
of	the	first	(F1,31=6.63,	p=0.016,	CNO	vs.	PBS)	and	second	infusion	(F1,31=7.65,	p=0.010,	NPS	vs.	
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Veh).	 In	detail,	NPS	 increased	the	percentage	of	 time	spent	on	the	open	arms	of	 the	EPM	in	
PBS-pretreated	rats	(PBS/NPS	vs.	PBS/Veh:	p=0.008)	indicative	of	an	anxiolytic	effect,	whereas	
CNO-pretreatment	prevented	the	effect	of	NPS		(CNO/NPS	vs.	PBS/NPS:	p=0.014;	CNO/Veh	vs.	
CNO/NPS:	p=0.25).	Moreover,	NPS	increased	the	percentage	of	open	arm	entries	(main	effect	
of	 the	 1st	 infusion:	 F1,35=11.60,	 p=0.002;	 2nd	 infusion:	 F1,31=10.42,	 p=0.003;	 PBS/NPS	 vs.	
PBS/Veh:	p=0.048),	 an	effect	 that	was	 also	blocked	by	 chemogenetic	 silencing	 (CNO/NPS	vs.	
PBS/NPS:	p=0.042;	CNO/Veh	vs.	CNO/NPS:	p=0.019).	CNO	alone	resulted	in	a	partial	increase	in	
anxiety-related	behaviour	as	seen	by	a	reduction	 in	the	percentage	of	open	arm	entries	only	
(p<0.05	 vs.	 all),	 and	 this	 may	 indicate	 that	 endogenous	 OXT	 originating	 from	 PVN	 neurons	
contributes	to	the	general	anxiety	level	of	an	individual.	However,	icv	NPS	partly	reversed	the	
effect	of	neuronal	OXT	silencing	possibly	by	acting	on	other	limbic	regions.	None	of	the	drugs	
altered	locomotor	activity	expressed	by	the	number	of	closed	arm	entries	(F1,31=1.69,	p=0.21).			
	
Figure	 12:	 Chemogenetic	 silencing	 of	 PVN-OXT	 neurons	 prevented	 the	 anxiolytic	 effect	 of	 a	 subsequent	 NPS	
infusion.	 A)	 Schematic	 drawing	 of	 rAAV	 used	 to	 transfect	 PVN	 neurons.	 B)	 Expression	 of	 Gi-coupled	 DREADD	
(hM4Di:mCherry)	in	OXT	neurons	on	tissue-wide	and	cellular	level	(scale	bar:	100	µm).	Rats	were	pretreated	either	
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with	PBS	or	CNO	(2	mg/kg;	 ip),	 followed	by	 icv	 infusion	of	either	Ringer’s	solution	(Veh,	5	µl)	or	NPS	(1	nmol).	C)	
Percentage	of	time	spent	on	the	open	arms	of	the	EPM	and	D)	percentage	of	open	arm	entries	 indicates	anxiety-
related	behavior.	 E)	Number	of	 closed	 arm	entries	 reflects	 locomotor	 activity	 during	 the	5-min	 test	 period.	Data	
represent	mean	+	SEM,	group	sizes:	n=8-9,	except	CNO/Veh:	n=6.	*p<0.05	and	**p<0.01	vs.	all	or	as	 indicated;	#	
p<0.05	vs.	all.	 	
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Chapter	II	–	NPSR	activation	is	anxiolytic	in	a	Gq	pathway-
dependent	manner	
The	results	of	Chapter	2	have	been	submitted	to	Neuropsychopharmacology	on	10th	of	
March	2017:		
	
Grund,	T.,	Neumann,	I.D.	(in	revision)	Neuropeptide	S	induces	acute	anxiolysis	by	
phospholipase	C-dependent	signaling	within	the	medial	amygdala.	
Neuropsychopharmacology	
	
1.	Effect	of	bilateral	infusion	of	NPS	into	the	MeA	on	anxiety-related	behavior	
Bilateral	infusion	of	NPS	(0.2	nmol)	into	the	MeA	significantly	reduced	anxiety-related	behavior	
of	male	rats	both	on	the	EPM	and	in	the	OF	compared	with	Veh-infusion	(Fig.	14).	NPS-treated	
rats	spent	a	higher	percentage	of	time	on	the	open	arms	(t15=	-2.46,	p=0.027)	without	effects	
on	 the	 percentage	 of	 entries	 into	 the	 open	 arms	 (t15=	 -0.37,	 p=0.72)	 and	 on	 the	 number	 of	
closed	arm	entries	 (t15=	 -0.32,	p=0.75).	Notably,	 the	anxiolytic	effect	of	NPS	 in	 the	MeA	was	
confirmed	 in	 the	OF	 test	 two	days	 later,	as	NPS	 increased	 the	 time	 the	animals	 spent	 in	 the	
center	zone	(U=11.00,	p=0.034)	and	almost	doubled	the	number	of	center	zone	entries	(t14=	-
2.58,	p=0.022),	when	compared	with	Veh-treated	rats.	Moreover,	NPS	increased	the	distance	
rats	travelled	in	the	OF	(t14=	-3.44,	p=0.004)	indicative	of	hyperlocomotion	effect.	
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Figure	14:	Anxiolytic	effect	of	NPS	infusion	bilaterally	into	the	MeA	of	male	rats	as	assessed	on	the	EPM	(A-C)	and	
the	OF	(D-F).	During	the	5-min	testing	on	the	EPM	A)	the	percentage	of	time	spent	on,	B)	the	percentage	of	entries	
into	the	open	arms,	and	C)	number	of	closed	arm	entries	were	monitored.	During	the	5-min	testing	in	the	OF	D)	the	
time	spent	in,	E)	the	entries	into	the	center	zone,	and	F)	travelled	distance	were	analyzed.	Data	represent	mean	+	
SEM,	*p<0.05,	**p<0.01	vs.	Veh	(Ringer’s	solution);	group	sizes:	n=7-9,	outsider:	n=2.	G)	Schematic	drawing	of	the	
MeA	in	grey	(opt:	optic	tract,	3V:	third	ventricle)	and	H)	representative	microphotographs	of	bilateral	MeA	infusion	
sites	in	a	coronal	brain	slice	(H1	and	H2).	H3	represents	an	infusion	site	considered	as	outsider.	
2.	Effects	of	icv	NPS	on	Ca2+/calmodulin-dependent	kinase	IIɑ	and	ERK1/2	in	the	
amygdala		
Western	blot	 analysis	of	 amygdala	 tissue	micropunches	 revealed	 increased	amounts	of	both	
phospho-Ca2+/calmodulin-dependent	 kinase	 (CaMK)	 IIɑ	 (t20=	 -2.480,	 p=0.022,	 Fig.	 15B)	 and	
total	CaMKIIɑ	(t20=	-2.097,	p=0.049,	Fig.	15C)	relative	to	beta-tubulin	following	icv	 infusion	of	
NPS	 (1	 nmol).	 phospho-CaMKIIɑ	 levels	 compared	 to	 total	 CaMKIIɑ	 were	 not	 altered	 (U=57,	
p=0.84,	Fig.	15A).	
Moreover,	 NPS	 increased	 cytoplasmic	 pERK1/2	 levels.	 This	 applied	 to	 both	 the	 pERK1/2	 /	
ERK1/2	(pERK1/ERK1:	U=23,	p=0.027;	pERK2/ERK2:	U=21,	p=0.018,	Fig.	15D)	and	the	pERK1/2	/	
beta-tubulin	 ratios	 (pERK1/beta-tubulin:	 t18=	 -2.12,	 p=0.048;	 pERK2/beta-tubulin:	 t18=	 -2.18,	
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p=0.043,	 Fig.	 15E).	 Total	 ERK1/2	 levels	were	 not	 altered	 by	 icv	 NPS	 (ERK1/beta-tubulin:	 t19=	
0.93,	p=0.37;	ERK2/beta-tubulin:	t18=	-0.11,	p=0.92,	Fig.	15F).	
	
Figure	15:	Effects	of	icv	NPS	(1	nmol/5	µl)	on	relative	amount	of	phosphorylated	CaMKIIɑ	(pCaMKIIɑ)	compared	to	
A)	total	CaMKIIɑ	and	B)	beta-tubulin	 in	the	cytosolic	 fraction	of	amygdala	tissue	micropunches	of	male	rats.	 	NPS	
evoked	synthesis	of	C)	CaMKIIɑ	 in	 relation	 to	beta-tubulin.	Relative	amount	of	phosphorylated	ERK1/2	 (pERK1/2)	
compared	 to	D)	 total	 ERK1/2	and	E)	beta-tubulin	without	 affecting	 F)	 total	 ERK1/2	 levels	 relative	 to	beta-tubulin	
following	NPS	 infusion.	Data	 represent	mean	+	 SEM,	*p<0.05	versus	Veh;	 group	 sizes:	n=9-12.	G)	Representative	
Western	blots	of	(p)CaMKIIɑ,	(p)ERK1/2,	and	beta-tubulin.	
3.	Effects	of	simultaneous	blockade	of	both	PLC	and	AC	on	NPS-induced	
anxiolysis		
Pre-infusion	 of	 an	 inhibitor-cocktail	 consisting	 of	 both,	 the	 phospholipase	 C	 (PLC)	 blocker	
U73122	 and	 the	 adenylyl	 cyclase	 (AC)	 inhibitor	 DDA	 bilaterally	 into	 the	MeA	 prevented	 the	
anxiolytic	effect	of	subsequent	locally	infused	NPS	demonstrating	that	PLC	and/or	AC	mediate	
the	 anxiolytic	 effect	 (Fig.	 16).	 On	 the	 EPM,	 we	 found	 an	 interaction	 between	 the	 first	 and	
second	 infusion	 on	 the	 percentage	 of	 time	 the	 rats	 spent	 on	 the	 open	 arms	 (F(1,46)=4.23,	
p=0.046),	whereas	the	percentage	of	entries	 into	the	open	arms	was	not	altered	(F(1,46)=1.13,	
p=0.29).	 Post	 hoc	 analysis	 revealed	 that	NPS	 increased	 the	 percentage	 of	 time	 on	 the	 open	
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arms	in	Veh1-pre-treated	(p=0.003),	but	not	in	rats	pre-treated	with	U73122/DDA	(p=0.004).	In	
Veh2-infused	rats,	U73122/DDA-pre-infusion	did	not	 influence	anxiety	on	the	EPM.	Local	NPS	
did	 not	 affect	 locomotor	 activity,	 as	 measured	 by	 the	 number	 of	 closed	 arm	 entries	
(F(1,46)=2.856,	p=0.098)	in	both	Veh1-	as	well	as	U73122/DDA-pre-treated	rats.		
In	 the	OF,	 the	 anxiolytic	 effect	 of	 intra-MeA	NPS	was	 likewise	 prevented	 by	 pre-infusion	 of	
U73122/DDA,	as	assessed	by	the	time	the	rats	spent	in	the	center	zone	(F(1,50)=3.37,	p=0.073,	
1st	infusion:	F(1,50)=13.72,	p<0.001,	2nd	infusion:	F(1,50)=4.12,	p=0.048)	and	the	number	of	center	
zone	 entries	 (interaction:	 F(1,50)=7.99,	 p=0.007).	 Moreover,	 statistical	 analysis	 revealed	
increased	locomotion	(interaction:	F(1,50)=8.28,	p=0.006),	an	effect	caused	by	NPS	in	Veh1-pre-
infused	 rats	 (p<0.001).	 In	 the	 OF,	 pre-infusion	 of	 the	 inhibitor-cocktail	 also	 blocked	 NPS-
induced	hyperlocomotion	(p<0.001).	
	
Figure	16:	Effects	of	pre-infusion	of	an	 inhibitor-cocktail	 (Inh-cock)	consisting	of	U73122	 (PLC	 inhibitor,	0.5	nmol)	
and	DDA	(AC	inhibitor,	12.5	nmol)	on	the	anxiolytic	effect	of	NPS	bilaterally	infused	into	the	MeA	(0.2	nmol/0.5	µl)	
on	the	EPM	(A-C)	and	OF	(D-F).	A)	Percentage	of	time	spent	on,	B)	percentage	of	entries	performed	into	the	open	
arms,	 C)	 closed	 arm	 entries,	 and	 D)	 time	 spent	 in,	 E)	 entries	 performed	 into	 the	 center	 zone,	 and	 F)	 distance	
travelled.	As	Veh1,	 0.5	µl	 of	 Ringer’s	 solution	 supplemented	with	DMSO,	 and	 as	Veh2,	 0.5	µl	 of	 Ringer’s	 solution	
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were	 used.	 Data	 represent	mean	 +	 SEM,	 **p<0.01,	 ***p<0.001	 versus	 all	 other	 groups	 (A,	 E,	 F)	 or	 as	 indicated;	
group	sizes:	n=13-15,	except	Inh-cock/Veh2:	n=6-8.	
4.	Effects	of	specific	blockade	of	either	PLC	or	AC	on	NPSR-mediated	anxiolysis	in	
the	MeA		
To	 assess	 whether	 the	 anxiolytic	 activity	 of	 NPS	 is	 mediated	 via	 NPSR-evoked	 activation	 of	
either	 PLC	 or	 AC,	 or	 via	 both	 pathways	 within	 the	MeA,	 we	 next	 pre-infused	 U73122	 (PLC	
inhibitor),	 DDA	 (AC	 inhibitor)	 or	 Veh1	 bilaterally	 into	 the	 MeA	 prior	 to	 local	 NPS	 or	 Veh2	
infusion.	 Selective	 inhibition	 of	 PLC	 signaling	 by	 pre-infusion	 of	 U73122	 prevented	 NPS-
induced	anxiolysis,	whereas	 specific	blockade	of	 the	AC	by	DDA	pre-infusion	 failed	 to	 inhibit	
the	anxiolytic	properties	of	NPS	(Fig.	17).		
In	detail,	specific	 inhibition	of	the	PLC	signaling	affected	the	percentage	of	time	spent	on	the	
open	 arms	 (1st	 infusion:	 F(1,44)=1.75,	 p=0.19;	 2nd	 infusion:	 F(1,44)=4.72,	 p=0.036;	 interaction:	
F(1,44)=3.01,	p=0.09)	and	the	percentage	of	open	arm	entries	(1st	infusion:	F(1,44)=7.47,	p=0.009;	
2nd	 infusion:	 F(1,44)=3.42,	 p=0.072;	 interaction:	 F(1,44)=0.87,	 p=0.36)	 on	 the	 EPM.	 Post	 hoc	
analysis	 revealed	 that	 NPS-infused	 rats	 spent	 more	 percentaged	 time	 on	 the	 open	 arms	
(p=0.003	 vs.	 Veh1/Veh2	 rats)	 when	 pre-infused	 with	 Veh1.	 This	 anxiolytic	 effect	 of	 NPS	 was	
prevented	in	the	presence	of	U73122	(p=0.024	vs.	Veh1/NPS).	Likewise,	pre-infusion	of	U73122	
reduced	 the	 percentaged	 entries	 into	 the	 open	 arms	 compared	 to	 Veh1	 (p=0.009	 vs.	
Veh1/NPS).	 Also,	 U73122	 exerted	 a	 biologically	 slight,	 but	 significant	 stimulatory	 effect	 on	
locomotor	 activity	 (p=0.015	 vs.	 Veh1/NPS),	 as	 U73122/NPS	 animals	 showed	 an	 increased	
number	of	closed	arm	entries.		
Separate	inhibition	of	the	AC	signaling	by	pre-infusion	of	DDA	revealed	an	effect	for	the	second	
infusion	on	 the	percentage	of	 time	spent	on	 the	open	arms	 (1st	 infusion:	F(1,44)=0.09,	p=0.76;	
2nd	 infusion:	 F(1,44)=9.32,	 p=0.004;	 interaction:	 F(1,44)=0.68,	 p=0.42)	 and	 on	 the	 percentaged	
open	 arm	 entries	 (1st	 infusion:	 F(1,44)=0.76,	 p=0.39;	 2nd	 infusion:	 F(1,44)=8.78,	 p=0.005;	
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interaction:	 F(1,44)=0.16,	 p=0.69).	 Post	 hoc	 analysis	 indicated	 that	 NPS	 almost	 doubled	 the	
percentage	 of	 time	 the	 animals	 spent	 on	 the	 open	 arms	 (p=0.004)	 and	 increased	 the	
percentage	 of	 open	 arm	 entries	 (p=0.005)	 in	 comparison	 to	 Veh2-infused	 rats.	 More	
importantly,	 pre-infusion	 of	 DDA	 failed	 to	 block	 this	 anxiolytic	 effect	 of	 NPS	 (percentage	 of	
time	 spent	 on	 open	 arms:	 p=0.41	 vs.	 Veh1/NPS;	 percentaged	 open	 arm	 entries:	 p=0.73)	
suggesting	that	the	NPS-induced	anxiolysis	 is	 independent	of	AC	signaling.	None	of	 the	drug-
infused	rats	of	this	experiment	showed	any	signs	of	hyperlocomotion	as	the	number	of	closed	
arm	entries	was	not	altered	(F(1,45)=0.02,	p=0.90).	
	
Figure	17:	Effects	of	pre-infusion	of	either	U73122	(PLC	inhibitor,	0.5	nmol),	DDA	(AC	inhibitor,	12.5	nmol)	or	Veh1	
(0.5	µl	 of	Ringer’s	 solution	 supplemented	with	DMSO)	on	 the	anxiolytic	 effect	of	NPS	bilaterally	 infused	 into	 the	
MeA	(0.2	nmol/0.5	µl)	on	the	EPM	A/D)	Percentage	of	time	spent	on,	B/E)	percentage	of	entries	performed	into	the	
open	arms,	and	C/F)	closed	arm	entries.	As	Veh2,	0.5	µl	of	Ringer’s	solution	were	used.	Data	represent	mean	+	SEM,	
*p<0.05,	 **p<0.01	 as	 indicated,	 #p<0.05	 vs.	 Veh1/NPS,	 $p<0.05	 vs.	 Veh1/Veh2;	 group	 sizes:	 n=13-15,	 except	 Inh-
cock/Veh2:	n=6-8.	
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Chapter	III	–	Characterization	of	DREADD-induced	activation	of	
OXT	neurons	in	the	PVN	
1.	Monitoring	of	central	and	peripheral	OXT	release	following	chemogenetic	
OXT	neuron	activation	within	the	hypothalamus		
DREADDs	allow	selective	activation	(or	inhibition)	of	specific	neuronal	populations	in	order	to	
dissect	their	contribution	to	complex	behaviors	and	brain	circuitries	(Whissell	et	al.,	2016).	To	
examine	 the	 spatiotemporal	 dynamics	 of	 DREADD	 actions	with	 respect	 to	OXT	 neurons,	 the	
cell	 type-specific	 recombinant	AAV1/2	OXTpr-hM3Dq:mCherry	was	 infused	bilaterally	 into	 the	
PVN	or	PVN,	SON	and	AN	of	male	rats,	respectively.	Within	three	weeks,	an	excitatory	DREADD	
(hM3Dq)	was	selectively	expressed	under	the	control	of	an	OXT	promoter	fragment	indicated	
by	prominent	expression	of	the	reporter	protein	mCherry	in	OXT	neurons	(Fig.	18).		
Stimulated	 activity	 of	 OXT	 neurons	 is	 characterized	 by	 increased	 OXT	 release,	 for	 example	
within	 the	PVN	 in	 a	 somato-dendritic	 fashion	 (Neumann	&	 Landgraf,	 2012).	 Ca2+	 availability,	
specifically	an	increase	in	intracellular	Ca2+,	is	a	prerequisite	for	such	release	(Neumann	et	al.,	
1993b;	 Fisher	 &	 Bourque,	 1996;	 Ludwig	 et	 al.,	 2002).	 Since	 excitatory	 DREADDs	 have	 been	
described	 to	 increase	 intracellular	 Ca2+	 levels	 (Armbruster	 et	 al.,	 2007),	 I	 monitored	 the	
dynamics	 of	 OXT	 release	 within	 PVN,	 lateral	 septum,	 and	 peripheral	 blood	 following	
chemogenetic	 stimulation	of	OXT	neurons	 initiated	by	CNO	 (2	mg/kg,	 ip)	 using	microdialysis	
technique	and	via	jugular	vein	catheter,	respectively.	
3		 Results	 	
	
86
	
Figure	 18:	 Expression	 of	 excitatory	 DREADD	 (hM3Dq:mCherry,	 yellow)	 in	 OXT	 neurons	 (cyan)	 within	 the	 rat	
hypothalamic	PVN,	SON	and	AN	(scale	bar:	100	µm)	three	weeks	after	stereotaxic	rAAV	infusion.	
	
SON
Br: -1.4 mm
AN
Br: -1.8 mm
PVN
Br: -1.7 mm
Scale bar: 100 µmLegend to all figures hM3Dq OXT
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1.1	Chemogenetic	OXT	neuron	activation	evokes	OXT	release	within	the	PVN	
Herein,	I	monitored	the	dynamics	of	OXT	release	within	PVN	of	conscious	rats	in	response	to	ip	
administration	of	CNO	or	Veh,	respectively.	Microdialysis	was	performed	on	two	consecutive	
days	either	under	basal,	unstressed	conditions	(day	1)	or	before	and	after	exposure	to	forced	
swim	 (day	 2)	 in	 order	 to	 examine	 CNO-induced	 basal	 or	 stimulated	OXT	 release	 in	 hM3Dq-
transfected	PVN-OXT	neurons.	 In	 rats	bilaterally	expressing	an	excitatory	DREADD	under	 the	
control	 of	 the	 OXT	 promoter	 fragment,	 CNO	 induced	 a	 rise	 in	 the	 OXT	 content	 in	
microdialysates	indicative	for	intra-PVN	release	of	OXT	(Fig.	19).		
In	 detail,	 OXT	 baseline	 levels	 in	 microdialysates	 prior	 to	 ip	 injection	 of	 either	 CNO	 or	 Veh	
(samples	 b1+b2	 Fig	 19A	 and	 sample	 b	 Fig	 19B)	 did	 not	 differ	 between	 rats,	 which	 were	
previously	 infused	with	either	 intra-PVN	AAV1/2-OXTpr-hM3Dq-mCherry	 (AAV+)	or	Veh	 (AAV-)	
indicating	 that	expression	of	DREADD	without	 specific	CNO	stimulation	 in	OXT	neurons	does	
not	 change	 the	 activity	 of	 these	 cells.	 Specifically,	 comparison	 of	 the	 existing	 4	 groups	
(AAV+/Veh,	AAV+/CNO,	AAV-/Veh,	AAV-/CNO)	revealed	that	in	microdialysates	sampled	before	
any	 stimulation,	 OXT	 content	 in	microdialysates	 was	 not	 changed	 (two	way	 ANOVA;	 day	 1:	
basal	 1	 F1,17=2.32,	 p=0.15;	 basal	 2	 F1,17=0.15,	 p=0.71;	 day	 2:	 basal	 F1,18=0.14,	 p=0.71),	
demonstrating	 that	 basal	 OXT	 release	 is	 not	 influenced	 by	 the	 expression	 of	 DREADD.	
Moreover,	OXT	content	in	AAV+/Veh,	AAV-/Veh	and	AAV-/CNO	did	not	change	over	time	(two	
way	ANOVA	for	repeated	measures;	day	1:	F8,58=0.30,	p=0.96;	day	2:	F8,54=0.19,	p=0.99)	further	
revealing	 the	biologically	 inert	nature	of	CNO.	Therefore	 these	 three	groups	were	 combined	
and	below	defined	as	Veh-control.	
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Figure	19:	Chemogenetically	evoked	OXT	release	within	the	hypothalamic	PVN	in	male	Wistar	rats	expressing	an	
excitatory	DREADD	in	the	PVN-OXT	neurons.	A)	On	day	1,	30-min	dialysates	were	sampled	before	(b1	and	b2)	and	
after	 ip	 injection	 (Inj)	 of	 either	 vehicle	 (Veh;	 PBS,	 pH	 7.4)	 or	 CNO	 (2	mg/kg),	 n=8-11.	 B)	 On	 day	 2,	 one	 30-min	
dialysate	was	sampled	before	(basal	(b))	and	four	after	ip	CNO	(samples	30,	60,	90	and	120	min).	Samples	4	(90	min)	
and	5	(120	min)	were	collected	following	a	5	min	forced	swim	stress	(FS),	n=7-12.	Data	are	expressed	as	percentage	
of	baseline	 (=100%;	dotted	 line)	±	SEM;	*p<0.05,	**p<0.01	and	 (*)p=0.068	vs.	 respective	Veh-control,	 #p<0.05	vs.	
CNO	 basal	 (sample	 1),	 $p<0.05	 vs.	 Veh-control	 basal	 (sample	 1).	 Delta	 change	 in	 absolute	 OXT	 content	 in	
microdialysates	 in	 comparison	 to	mean	 baseline	 on	 C)	 day	 1	 and	D)	 day	 2.	 Data	 are	 expressed	 as	mean	 +	 SEM;	
*p<0.05.	
	
For	 day	 1,	 two-way	 ANOVA	 for	 repeated	 measures	 including	 AAV+/CNO	 and	 Veh-control	
revealed	a	 significant	 interaction	of	 treatment	 x	 time	 (F4,90=3.49,	p=0.012).	 Specifically,	post-
hoc	analysis	 revealed	a	more	pronounced	relative	elevation	 in	OXT	 release	 in	 the	AAV+/CNO	
group	at	both	60	min	(p=0.002)	and	90	min	(p=0.005)	vs.	respective	Veh-control	(Fig.	19A).	This	
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was	also	reflected	by	higher	delta	values	in	absolute	OXT	content	(sample	60	min	–	basalmean;	
t16=	-3.21,	p=0.005;	Fig.	19C).	
On	day	2,	 two	way	ANOVA	for	 repeated	measures	showed	a	significant	 interaction	of	 time	x	
treatment	 (F4,89=2.703,	 p=0.038).	 Post-hoc	 analysis	 revealed	 a	more	 pronounced	 rise	 in	OXT	
release	under	basal,	unstimulated	conditions	60	min	after	CNO	injection	in	comparison	to	both	
the	 respective	Veh-control	 (Fig.	 19B,	 p=0.002,	 between	 subjects)	 and	AAV+/CNO	basal	 levels	
(p=0.030,	within	 subjects).	 Likewise,	 as	 depicted	 in	 Fig.	 19D,	 the	 effect	 of	 an	 increased	OXT	
release	following	CNO	injection	in	AAV+	rats	is	reproduced	by	increased	delta	levels	in	absolute	
OXT	release	60	min	after	ip	injection	(t16=	-2.27,	p=0.037)	further	demonstrating	increased	OXT	
release	 following	 chemogenetic	 OXT	 neuron	 stimulation.	 In	 response	 to	 forced	 swimming	
following	 basal	 sampling,	 I	 found	 in	 CNO-injected	 Gq-DREADD-expressing	 rats,	 I	 found	 an	
increased	 OXT	 content	 in	 both	 groups.	 In	 detail,	 separate	 one-way	 ANOVA	 for	 repeated	
measures	 (within	 Veh-control:	 F4,55=6.12,	 p<0.001;	 within	 AAV+/CNO:	 F4,33=3.81,	 p=0.016)	
indicated	 reliably	 increased	 percentaged	OXT	 release	 in	 both	 groups.	More	 specifically,	 two	
way	ANOVA	for	repeated	measures	followed	by	post	hoc	corrections	showed	that	AAV+/CNO	
rats	 responded	with	a	distinct	 increased	percentaged	OXT	release	vs.	Veh-control	 (sample	4:	
Trend	 with	 p=0.068,	 sample	 5:	 p=0.006,	 Fig.	 19B)	 suggesting	 the	 hypothesis	 of	 a	 more	
sustained	OXT	release	once	the	system	is	activated.	
1.2	Chemogenetic	activation	of	hypothalamic	OXT	neurons	failed	to	increase	
measurable	OXT	release	within	lateral	septal	nuclei	
In	a	separate	cohort,	the	effect	of	chemogenetically	evoked	OXT	neuron	stimulation	within	the	
hypothalamic	PVN,	SON	and	AN	was	assessed	by	intracerebral	microdialysis	within	the	lateral	
septum	 in	 urethane-anesthetized	 rats.	 As	 the	 lateral	 septum	 is	 innervated	 by	 OXT	 fibers	
(Stoop,	 2012),	 I	 postulated	 increased	 OXT	 release	 within	 the	 lateral	 septal	 nuclei	 while	
chemogenetic	activation	of	hypothalamic	OXT	neurons.	In	contrast	to	my	hypothesis,	two-way	
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ANOVA	for	repeated	measures	revealed	neither	an	interaction	of	treatment	x	time	(F4,84=0.41,	
p=0.80,	Fig.	20A)	nor	main	effects	of	time	(F4,84=2.19,	p=0.08)	or	treatment	(F1,84=0.00,	p=0.99).	
This	result	was	also	reflected	by	unchanged	delta	values	 in	absolute	OXT	content	(sample	60	
min	–	basalmean;	t15=	-0.15,	p=0.88;	Fig.	20B).	
	
Figure	 20:	 Chemogenetic	 activation	 of	 hypothalamic	 OXT	 neurons	 failed	 to	 increase	 measurable	 OXT	 release	
within	the	lateral	septal	nuclei.	A)	30-min	dialysates	were	sampled	before	(b1	and	b2)	and	after	ip	injection	(Inj)	of	
either	vehicle	(Veh;	PBS,	pH	7.4)	or	CNO	(2	mg/kg),	n=8-9.	Data	are	expressed	as	percentage	of	baseline	(=100%)	±	
SEM.	 B)	 Delta	 change	 in	 absolute	 OXT	 content	 in	 microdialysates	 in	 comparison	 to	 mean	 baseline.	 Data	 are	
expressed	as	mean	+	SEM,	n=8-9.	
1.3	Chemogenetically	evoked	activation	of	hypothalamic	OXT	neurons	increases	
peripheral	OXT	release	
OXT	is	released	from	magnocellular	neurons	into	the	periphery	via	axons	forming	neurohemal	
contacts	 within	 the	 neurohypophysis	 (Gimpl	 &	 Fahrenholz,	 2001;	 Meyer-Lindenberg	 et	 al.,	
2011).	 Herein,	 the	 effect	 of	 chemogenetically	 evoked	 OXT	 neuron	 stimulation	 within	 the	
hypothalamic	PVN,	 SON	and	AN	on	peripheral	OXT	 release	was	 analyzed	 in	plasma	 sampled	
before	 and	 after	 stimulation.	 In	 rats	 bilaterally	 expressing	 an	 excitatory	 DREADD	 under	 the	
control	 of	 the	 OXT	 promoter	 fragment,	 CNO	 induced	 a	 rise	 in	 plasma	 OXT	 concentration	
indicative	for	peripheral	release	of	OXT	from	neurohypophysial	terminals	(Fig.	21).	
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In	 detail,	 two-way	 ANOVA	 for	 repeated	 measures	 revealed	 a	 significant	 interaction	 of	
treatment	x	time	(F1,29=11.60,	p=0.005;	Fig.	21A).	While	basal	plasma	OXT	levels	did	not	differ	
between	treatment	groups	(p=0.61),	post-hoc	analysis	revealed	reliably	increased	plasma	OXT	
concentration	 (CNO+45min	 vs.	 Veh+45	 min:	 p<0.001)	 when	 OXT	 neurons	 were	 chemogenetically	
activated.	 Within-group	 comparison	 demonstrated	 that	 chemogenetic	 activation	 of	 OXT	
neurons	 by	 CNO	 evokes	 peripheral	 OXT	 release	 as	 OXT	 content	 in	 plasma	 samples	 was	
increased	(within	CNO	group:	p<0.001).	In	contrast,	rats	receiving	an	ip	injection	of	sterile	PBS	
failed	 to	 alter	 OXT	 content	 in	 plasma	 (within	 Veh	 group:	 p=0.84).	 These	 findings	 are	 also	
reflected	by	higher	delta	values	in	absolute	OXT	content	(sample+45min	–	sample-45	min;	U=	81.0,	
p=0.002;	Fig.	21B).	
	
Figure	 21:	 Chemogenetic	 activation	 of	 hypothalamic	 OXT	 neurons	 evokes	 peripheral	 OXT	 release.	 A)	 Absolute	
plasma	OXT	concentration	sampled	before	(-45	min)	and	after	(+45	min)	ip	injection	(Inj)	of	either	vehicle	(Veh;	PBS,	
pH	 7.4)	 or	 CNO	 (2	mg/kg),	 n=8-9.	 Data	 are	 expressed	 as	mean	 ±	 SEM,	 n=7-9.	 B)	 Delta	 change	 in	 absolute	 OXT	
content	in	plasma	samples	(cOXT+45	min	–	cOXT-45min).	Data	are	expressed	as	mean	+	SEM,	n=7-9.	
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2.	Chemogenetically	activation	of	OXT	neurons	induces	anxiolysis	and	self-
grooming	behavior	
In	 order	 to	 test	 the	 hypothesis	 that	 chemogenetic	 activation	 of	 PVN-OXT	 neurons	 reduces	
anxiety-related	 behavior	 as	 a	 consequence	 of	 increased	 intracerebral	 OXT	 release,	 animals	
were	tested	in	the	LDB	55	min	after	ip	injection	of	CNO	or	Veh	(PBS).	Chemogenetic	activation	
of	 PVN-OXT	 neurons	 resulted	 in	 an	 anxiolytic	 effect,	 since	 CNO-treated	 animals	 spent	more	
time	 in	 the	 light	box	 (t13=	 -2.25,	p=0.042	Fig.	22A),	and	tended	to	perform	more	entries	 into	
the	 light	 box	 (t13=	 -1.29,	 p=0.22,	 Fig.	 20B).	 CNO	 did	 not	 alter	 the	 locomotor	 activity	 of	 the	
animals	(t13=	-1.50,	p=0.16,	Fig.	22C).		
	
Figure	22:	Behavioral	responses	following	chemogenetic	activation	of	PVN-OXT	neurons.	Anxiety-related	behavior	
was	 tested	 using	 the	 LDB.	 Data	 show	 A)	 time	 spent	 in	 light	 box,	 B)	 entries	 into	 the	 light	 compartment	 and	 C)	
locomotor	activity	of	rats	treated	with	CNO	(2	mg/kg,	ip)	or	Veh	(PBS,	1	ml/kg,	ip).	Data	are	represented	as	mean	+	
SEM;	 *p<0.05.	 D)	 During	 ongoing	 microdialysis	 within	 the	 hypothalamic	 PVN,	 behavioral	 assessment	 revealed	
increased	 self-grooming,	 when	 OXT	 neurons	 were	 activated	 chemogenetically.	 Data	 represent	 mean	 ±	 SEM,	
**p<0.01	vs.	respective	Veh.	Group	sizes:	n=7-8.	
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Behavioral	 analysis	 during	 ongoing	 intra-PVN	 microdialysis	 on	 day	 1	 revealed	 a	 significant	
interaction	 of	 time	 x	 treatment	with	 regard	 to	 self-grooming	 (F4,74=2.56,	 p=0.049;	 Fig.	 22D).	
Specifically,	 CNO	 treatment	 resulted	 in	 increased	 grooming	 behavior,	 which	 peaked	 60	min	
after	 ip	 injection	 in	comparison	 to	Veh-control	 (CNO+60	min	vs.	Veh+60	min:	p=0.002).	Moreover,	
within	 group	 analysis	 revealed	 that	 control	 rats	 spend	 significantly	more	 time	 on	 grooming	
behavior	during	the	first	30-min	period	after	ip	injection	of	Veh	compared	to	baseline	1	(Veh+30	
min	 vs.	 Vehb1:	 p=0.016).	 Other	 behaviors	 such	 as	 sleep	 (F4,74=0.74,	 p=0.57),	 exploration	
(F4,74=0.31,	 p=0.87)	 or	 food/water-intake	 (F4,74=0.06,	 p=0.99)	 did	 not	 differ	 between	 groups	
(data	not	shown).	
3.	Effect	of	chemogenetic	PVN-OXT	neuron	activation	on	EtOH-induced	
locomotor	impairments	
Icv	 infusion	 of	 synthetic	 OXT	 was	 found	 to	 selectively	 attenuate	 ethanol-induced	 motor	
impairments	in	rats	(Bowen	et	al.,	2015).	In	order	to	test	whether	DREADD-induced	excitation	
of	 OXT	 neurons	 in	 the	 PVN	 attenuates	 ethanol-induced	 locomotor	 impairments,	 PVN-OXT	
neurons	have	been	transfected	with	an	excitatory	DREADD	(Fig.	23).		
In	 contrast	 to	my	 hypothesis,	 I	 did	 not	 see	 any	 effect	 of	 PVN-OXT	 neuron	 activation	 on	 the	
wire-hanging	 test	 performance	 (+5	 min:	 U(67.0),	 p=0.383,	 +35	 min:	 U(78.0)	 p=0.758).	 The	
attenuation	of	acute	ethanol	effects	by	CNO-evoked	excitation	of	OXT	neurons	was	only	seen	
in	a	decreased	duration	of	 the	 rightning	 reflex	 test	during	 second	execution	of	 the	 test	 (+35	
min:	U(30.0),	p=0.009),	but	not	during	the	first	performance	(+5	min:	U(64.5),	p=0.479).	
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Figure	 21:	 Chemogenetic	 activation	 of	 PVN-OXT	 neurons	 partly	 attenuates	 ethanol-induced	 locomotor	
impairments.	A)	Experimental	timeline	of	rightning	reflex	test	(RRT)	and	wire-hanging	test	(WHT)	after	injection	of	
ethanol	(EtOH,	1.5	g/kg,	15%	wt/vol),	CNO	(2	mg/kg,	ip),	or	Veh	(sterile	PBS).	Effect	of	chemogenetic	activation	of	
PVN-OXT	neurons	on	ethanol-induced	locomotor	impairments	in	B)	the	rightning	reflex	test	and	C)	the	wire-hanging	
test	and.	Data	are	expressed	as	mean	+	SEM,	group	sizes:	n=8-13.	
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4	 General	discussion	
Brain	OXT	and	NPS	have	been	described	for	their	anxiolytic	profile	over	the	last	decades.	In	the	
present	study,	I	advanced	our	understanding	of	the	regulation	of	anxiety-like	behavior	by	brain	
NPS	and	OXT	in	male	Wistar	rats.	First,	I	described	a	novel	intra-hypothalamic	circuit	through	
which	NPS	activates	a	subpopulation	of	PVN-OXT	neurons	to	promote	anxiolysis.	Furthermore,	
I	found	that	intra-MeA	infusion	of	NPS	reduces	anxiety-related	behavior,	an	effect	that	strictly	
depends	on	NPSR-mediated	PLC	signaling.	Moreover,	I	examined	the	spatiotemporal	processes	
following	chemogenetic	activation	of	 the	endogenous	PVN-OXT	system.	These	 findings	come	
at	 a	 time	 of	 growing	 interest	 in	 the	 therapeutic	 potential	 of	 brain	 neuropeptides	 to	 treat	
psychopathologies,	 such	as	anxiety	disorders	 (Mathew	et	al.,	2008).	The	results	presented	 in	
this	thesis	reflect	the	 importance	of	brain	NPS	and	OXT	specifically	within	the	PVN	as	part	of	
the	 limbic	 system	 as	 a	 regulator	 of	 anxiety-related	 behavior,	 highlight	 these	 systems	 as	
potential	 targets	 to	 understand	 the	 development	 of	 anxiety	 disorders,	 and	 emphasize	 the	
importance	of	the	PVN	and	the	MeA	as	key	brain	regions	in	the	regulation	of	anxiety.	Below	I	
will	discuss	the	major	findings	revealed	in	each	of	the	three	chapters,	individually.	
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Chapter	I:	NPS-induced	anxiolysis	is	mediated	via	the	OXT	
system	within	the	hypothalamic	PVN	
Based	on	the	behavioral	similarities	of	the	NPS	and	OXT	system	(Neumann,	2008;	Pape	et	al.,	
2010),	and	the	overlap	in	NPS(R)	and	OXT(R)	expression	described	before,	I	hypothesized	that	
NPS	effects	are	mediated	via	 the	OXT	system	by	acting	on	OXT	neurons	within	the	PVN.	The	
present	 study	 describes	 a	 novel	 intra-hypothalamic	 circuit	 through	 which	 NPS	 activates	 a	
subpopulation	 of	 PVN-OXT	 neurons	 to	 promote	 anxiolysis.	 Herein,	 retrograde	 tracing	
demonstrated	 NPS	 afferents	 originating	 in	 the	 LC	 innervating	 the	 PVN.	 Moreover,	 FACS	
analysis	 revealed	 abundant	 NPSR	 expression	 in	 OXT	 neurons.	 Measuring	 Ca2+	 influx	 in	 OXT	
neurons	and	OXT	release	within	the	PVN	demonstrated	an	NPS-induced	activation	of	the	PVN-
OXT	 system.	 Both,	 chemogenetic	 silencing	 of	 PVN-OXT	 neurons	 and	 pharmacological	 OXTR	
antagonism	 blocked	 NPS-induced	 anxiolysis	 demonstrating	 that	 NPS	 promotes	 anxiolysis	 by	
acting	on	PVN-OXT	neurons.	
Antero-	and	 retrograde	 tracing	demonstrated	prominent	LC-neurons	 innervating	 limbic	brain	
regions	such	as	 the	PVN,	 the	amygdala,	 the	septum,	bed	nucleus	of	 the	stria	 terminalis,	and	
thalamus	 (Jones	 &	 Yang,	 1985).	 Besides	 arousal-promoting	 catecholamines	 such	 as	
noradrenaline	(Loughlin	et	al.,	1986),	the	LC	harbors	a	cluster	of	predominantly	glutamatergic	
neurons	synthetizing	NPS	(Xu	et	al.,	2007).	In	order	to	verify	neuroanatomical	target	structures	
receiving	input	from	NPS	neurons	located	in	the	LC,	I	performed	a	retrograde	tracing	study.	By	
intra-PVN	infusion	of	CTB-488,	a	powerful	retrograde	tracer,	 I	 identified	NPS-immunoreactive	
neurons	in	the	LC	projecting	towards	the	PVN.	The	correct	intra-PVN	infusion	of	CTB-488	was	
verified	 by	 co-staining	 of	 OXT	 in	 coronal	 brain	 slices	 containing	 the	 PVN.	 Prominent	 NPS-
immunopositive	afferents	innervating	the	PVN	have	also	been	described	in	C57Bl/6	mice	(Clark	
et	al.,	2011).	Altogether,	NPS	afferents	from	the	LC	innervate	the	PVN	in	both	rats	and	mice.	
In	 line,	 in	situ	hybridization	revealed	abundant	NPSR	expression	 in	the	PVN	of	rats	(Xu	et	al.,	
2007).	 In	order	 to	determine	whether	PVN-OXT	neurons	express	 the	NPSR,	 I	 applied	a	more	
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sensitive	 and	 highly	 specific	 technique	 –	 FACS	 analysis	 of	 Venus-labelled	 PVN	 and	 SON	OXT	
neurons	 -	 and	 demonstrated	 prominent	 NPSR	 expression	 in	 OXT	 neurons,	 whereas	 NPSR	
mRNA	 in	 Venus-negative	 cells,	 likely	 to	 be	 vasopressin	 or	 corticotrophin-releasing	 hormone	
(CRH)	 neurons,	 was	 almost	 negligible.	 Earlier	 experiments	 revealed	 selective	 expression	 of	
Venus	in	OXT	neurons	with	more	than	97	% colocalization	of	OXT	supporting	the	significance	
of	our	results	in	terms	of	cell-type	specific	Venus-labeling	(Knobloch	et	al.,	2012).	
My	attempt	 to	validate	 the	 finding	of	NPSR	mRNA	 in	OXT	neurons	at	protein	 level	 generally	
failed	due	to	 lack	of	a	specific	antibody	 for	NPSR.	My	 first	attempt	 to	 fluorescently	 label	 the	
NPSR	 using	 Ab2	 (Leonard	 &	 Ring,	 2011)	 in	 the	 PVN	 showed	mostly	 somatic	 and	 punctuate	
staining,	suggesting	vesicular	and	membrane	microdomain	localization	in	OXT-immunoreactive	
neurons.	The	antibody	Ab2	was	generated	in	rabbits	injected	with	keyhole	limpet	hemocyanin-
conjugated	 peptide	 encoding	 a	 portion	 of	 the	 second	 extracellular	 loop	
(GKRTLSNGEVQCWALWPD)	of	the	NPSR	(Leonard	&	Ring,	2011).	However,	 I	could	reveal	that	
Ab2	is	not	specific	to	reliably	detect	NPSR	protein.	Koller	and	colleagues	generated	the	NPSR-/-	
mouse	line	by	homologous	recombination	with	a	targeting	plasmid	and,	thus,	a	744-bp	region	
in	the	NPSR	gene	is	replaced,	which	includes	the	majority	of	exon	4	(Allen	et	al.,	2006b).	This	
deletion	 removes	 the	 third	 transmembrane	 domain	 and	 the	 second	 extracellular	 loop	
(predicted	 binding	 site	 of	 Ab2)	 of	 the	NPSR	 resulting	 in	 a	 non-functional	 GPCR	 (Allen	 et	 al.,	
2006b).	Thus,	Ab2	cannot	longer	bind	to	its	predicted	target	protein.	Specifically,	I	could	show	
that	 homozygous	 NPSR-/-	mice	 do	 not	 express	 NPSR	mRNA.	Moreover,	 PCR	 analysis	 of	 DNA	
from	NPSR+/+	 and	KO	mice	 revealed	 a	 PCR	product	 of	 418	bp	 from	 the	homozygous	NPSR+/+	
mice	and	a	599-bp	DNA	fragment	was	amplified	from	homozygous	NPSR-/-	mice	accordant	to	
the	 literature	 (Camarda	 et	 al.,	 2009).	 Having	 characterized	 tissue	micropunches	 at	 DNA	 and	
mRNA	 level,	 I	 performed	Western	 blot	 analysis	 using	 PVN	 tissue	micropunches	 from	NPSR-/-	
and	 NPSR+/+	 mice,	 which	 revealed	 a	 non-specific	 binding	 of	 Ab2.	 Thus,	 this	 antibody	 is	 not	
suitable	to	analyze	NPSR	localization.	
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Moreover,	 I	 verified	 the	 specificity	 of	 the	 commercially	 available	 NPSR1	 antibody	 (abcam,	
ab92425),	which	 targets	 residues	 350	 to	 the	 C-terminus	 of	 the	 human	NPSR1.	Western	 blot	
analysis	demonstrated	bands	in	both	NPSR+/+	and	NPSR-/-	mouse	samples	suggesting	aspecific	
binding	 of	 this	 antibody.	 Although	 this	 antibody	 targets	 the	 C-terminal	 domain,	 it	 is	 very	
unlikely	 that	 the	 NPSR	 is	 expressed	 in	 NPSR-/-	mice.	When	 the	 sequence	 of	 NPSR	 transcript	
from	NPSR-/-	mice	was	transfected	into	COS-1	cells,	a	fibroblast-like	cell	 line,	analysis	of	these	
transfected	 cells	 showed	 that	 the	 transcript	 failed	 to	 properly	 integrate	 into	 the	membrane	
(Allen	et	al.,	2006a).	Moreover,	Girolamo	Calo	and	colleagues	demonstrated	that	NPS	failed	to	
induce	any	behavioral	changes	following	NPS	infusion	in	NPSR-/-	mice	(Camarda	et	al.,	2009).	In	
conclusion,	although	I	could	find	NPSR	mRNA	in	PVN-OXT	neurons,	NPSR	localization	at	protein	
level	cannot	be	determined	due	to	non-specific	binding	of	currently	available	NPSR	antibodies.	
Having	evidenced	NPSR	mRNA	expression	 in	PVN-OXT	neurons	by	 FACS	analysis,	 I	 sought	 to	
determine	whether	NPS	activates	OXT	neurons.	Ultrasensitive	fluorescent	proteins	represent	a	
powerful	 tool	 to	 monitor	 changes	 in	 intracellular	 Ca2+	 levels,	 which	 is	 based	 on	 rapid	
deprotonation	 of	 green	 fluorescent	 protein	 following	 conformational	 change	 of	 calmodulin	
upon	Ca2+	binding	 (Chen	et	al.,	2013).	 In	hypothalamic	slice	preparations,	a	subpopulation	of	
constitutively	 silent	OXT	neurons	 expressing	 a	 genetically	 encoded	Ca2+	 indicator	 (GCaMP6s)	
responded	to	synthetic	NPS	with	transient	Ca2+	 influx,	which	reflects	neuronal	activation.	The	
recorded	 Ca2+	 response	was	 heterogeneous,	 but	massive,	with	 a	 slow	 rise	 time	 and	 relative	
long-lasting	responses	of	several	seconds.	This	observation	is	compatible	with	a	previous	study	
in	hippocampal	mouse	neurons	 (Erdmann	 et	 al.,	 2015).	 The	NPS	effects	on	 intracellular	Ca2+	
also	studied	 in	NPSR1-transfected	HEK293T	and	CHO	cells	are	most	 likely	mediated	by	NPSR-
induced	Gq-signaling	(Reinscheid	et	al.,	2005;	Liao	et	al.,	2016;	Clark	et	al.,	2017).	
It	is	important	to	note	that	repeated	NPS	application	failed	to	induce	a	repeated	Ca2+	response	
in	the	same	OXT	neurons,	as	already	reported	by	previous	studies	(Jungling	et	al.,	2008;	Meis	
et	al.,	 2008).	While	 the	mechanism	 involved	 is	 yet	 to	be	determined,	one	can	hypothesize	a	
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high	 desensitization	 of	 NPSR.	 However,	 the	 specific	 involvement	 of	 NPSR	 on	 NPS-induced	
activation	 of	 OXT	 neurons	 was	 successfully	 demonstrated,	 since	 NPS	 failed	 to	 increase	
intracellular	Ca2+	 levels	 in	the	presence	of	the	selective	NPSR	antagonist	SHA-68	(Okamura	et	
al.,	2008;	Ruzza	et	al.,	2010).	
Thus,	from	these	experiments	I	concluded	that	NPS	originating	from	the	LC	acts	at	NPSR	in	the	
PVN,	 specifically	 in	 OXT	 neurons	 causing	 their	 activation.	 This	 conclusion	 has	 further	 been	
substantiated	 by	 the	 finding	 of	 increased	 OXT	 release.	 Ca2+	 influx	 in	 OXT	 neurons	 is	 a	
prerequisite	 for	 OXT	 release	 (Ludwig	 et	 al.,	 2002;	 Ludwig	 &	 Leng,	 2006).	 Central	 OXT	 is	
released	 from	OXT	 neurons	 of	 the	 PVN	 and	 SON	 (Ludwig,	 1998;	 Bergquist	&	 Ludwig,	 2008).	
Like	 the	 release	 of	 OXT	 from	 axonal	 terminals	 in	 the	 neurohypophysis	 (Fisher	 &	 Bourque,	
1996),	 dendritic	 release	of	OXT	depends	on	 local	 increase	 in	 intracellular	 Ca2+	 concentration	
(Neumann	 et	 al.,	 1993b;	 de	 Kock	 et	 al.,	 2003).	 Herein,	 microdialysis	 in	 combination	 with	 a	
highly	 sensitive	 radioimmunoassay	 demonstrated	 NPS-evoked	 OXT	 release	 within	 the	 PVN,	
dose-dependently.	When	NPS	was	infused	at	1	nmol	while	ongoing	microdialysis,	a	moderate,	
but	 long	 lasting	 increase	 in	 OXT	 content	 in	 microdialysates	 was	 monitored.	 This	 might	 be	
explained	 by	 an	 autocrine	mechanism	 through	which	 dendritic	 OXT	 release,	 once	 triggered,	
can	become	self-sustaining	and	thus	 long-lasting	 (Ludwig	et	al.,	2002).	 In	contrast,	5	nmol	of	
NPS	 induced	a	prominent	 increase	 in	relative	OXT	content	 in	microdialysates,	which	declined	
to	 baseline	 in	 the	 next	 sample.	 Since	 the	 rise	 in	 intracellular	 Ca2+	 levels	 induced	 by	 NPS	 is	
reported	to	have	different	sources	(Erdmann	et	al.,	2015),	it	is	unclear	which	mechanism(s)	of	
NPS-induced	 intracellular	 Ca2+	 rise	 predominates	 in	 PVN-OXT	 neurons	 and	 whether	 these	
mechanisms	are	dose-dependent.	
The	stimulatory	effects	of	NPS	on	the	activity	of	OXT	neurons	within	the	PVN,	which	are	NPSR-
mediated,	highlight	an	 intra-hypothalamic	mechanism	at	cellular	 level.	Moreover,	 I	can	show	
that	NPS	exerts	a	behavioral	effect	directly	within	the	PVN,	and	this	anxiolytic	effect	required	
the	activation	of	local	OXT	neurons.	Based	on	pharmacological	and	chemogenetic	inhibition	of	
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the	OXT	system,	my	results	indicate	an	important	role	for	OXT	to	mediate	the	anxiolytic	effect	
of	NPS	in	the	hypothalamic	PVN.	
Specifically,	 pre-infusion	 of	 a	 selective	 OXTR-A	 (Manning	 et	 al.,	 2012)	 into	 the	 cerebral	
ventricular	system	was	able	to	prevent	the	NPS-induced	reduction	in	anxiety	levels	as	seen	in	
two	separate	and	well	established	tests	for	anxiety-related	behavior,	namely	the	LDB	and	the	
OF.	The	OXTR-A	alone	did	not	alter	general	anxiety	in	comparison	to	control;	an	effect	that	has	
been	observed	earlier	 in	male	rats	(Waldherr	&	Neumann,	2007).	 Importantly,	also	 local	pre-
infusion	of	OXTR-A	bilaterally	into	the	PVN	reduced	the	robust	NPS-induced	anxiolysis	seen	in	
rats	pre-infused	with	vehicle,	although	to	a	lower	degree.	Thus,	I	hypothesize	that	NPS	infused	
into	the	PVN	activates	local	OXT	neurons	and	local	somato-dendritic	OXT	release;	endogenous	
as	well	synthetic	OXT	within	the	PVN	have	been	repeatedly	shown	to	exert	anxiolytic	effects	
(Neumann	 et	 al.,	 2000;	 Blume	 et	 al.,	 2008;	 Jurek	 et	 al.,	 2012;	 van	 den	 Burg	 et	 al.,	 2015).	
Moreover,	local	NPS	may	activate	those	OXT	neurons	in	the	PVN,	which	project	to	other	limbic	
brain	regions,	such	as	the	amygdala	(Knobloch	et	al.,	2012),	where	OXT	was	also	found	to	exert	
anxiolytic	effects	(Neumann	et	al.,	2000;	Bale	et	al.,	2001).	
In	order	to	specifically	prove	for	the	involvement	of	PVN-OXT	neurons	in	the	behavioral	effects	
of	 NPS,	 I	 chemogenetically	 silenced	 OXT	 neurons	 of	 the	 PVN	 using	 a	 Gi-coupled	 designer	
receptor	 selectively	 expressed	 under	 the	 control	 of	 the	 OXT	 promoter	 fragment.	 DREADD-
evoked	 silencing	 of	 OXT	 neurons	 by	 ip	 CNO	 reliably	 prevented	 the	 anxiolytic	 effect	 of	 a	
subsequent	 central	 NPS	 infusion	 as	 seen	 on	 the	 EPM.	 At	 cellular	 level,	 CNO-induced	 hM4Di	
stimulation	 has	 been	 shown	 to	 result	 in	 reduced	 mean	 frequency	 of	 spikes	 induced	 by	
application	 of	 currents,	 increased	 inward	 currents,	 and	 decreased	 input	 resistance	 of	 OXT	
neurons	 (Eliava	 et	al.,	2016).	Thus,	 chemogenetically	 silenced	OXT	neurons	can	no	 longer	be	
activated	by	NPS.	 In	my	experiment,	 I	 found	a	 loss	of	 the	anxiolytic	profile	of	NPS	after	CNO	
injection,	which	provides	final	evidence	for	the	essential	role	of	stimulated	PVN-OXT	neurons	
in	mediating	this	behavioral	effect	of	NPS.	 Importantly,	 injection	of	CNO	alone,	which	should	
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result	 in	 a	 general	 inhibition	 of	 OXT	 neurons	 of	 the	 PVN,	 slightly	 increased	 anxiety-related	
behavior.	Although	this	has	only	be	seen	from	a	reduced	percentage	of	entries	performed	into	
the	open	arms	of	the	EPM,	chemogenetic	silencing	of	OXT	neurons	might	abolish	intracerebral	
OXT	 release	under	basal	 conditions	within	 the	PVN	or	 in	other	 relevant	 limbic	brain	 regions,	
important	for	the	individual	level	of	state	anxiety.	Also,	dysregulation/disinhibition	of	the	CRH	
system	 after	 silencing	 of	 OXT	 neurons,	 especially	 during	 exposure	 to	 an	 emotional	 stressor	
such	 as	 the	 EPM,	 cannot	be	 ruled	out,	 the	more	 as	OXT	was	 found	 to	 attenuate	 the	 stress-
induced	expression	of	CRH	in	a	CREB-dependent	manner	(Jurek	et	al.,	2015).		
Based	 on	 my	 results	 I	 postulate	 the	 following	 scenario	 under	 physiological	 conditions:	 In	
response	 to	 a	 challenging	 and	 stressful	 situation,	 pericoerulear	 CRH-sensitive	 NPS	 neurons	
become	activated	(Jungling	et	al.,	2012),	resulting	in	NPS	release	from	NPS	axonal	projections	
as	shown	in	the	basolateral	amygdala	during	forced	swimming	(Ebner	et	al.,	2011).	However,	
NPS	neurons	also	project	to	the	PVN	as	described	in	mice	(Clark	et	al.,	2011),	and	in	rats	using	
a	powerful	 retrograde	 tracer	 infused	 into	 the	PVN.	 Thus,	NPS	 released	within	 the	PVN	 from	
terminals	 of	 pericoerulear	 NPS	 neurons	 activate	 OXT	 neurons,	 as	 indicated	 by	 increased	
intracellular	Ca2+	levels,	which	results	in	local	OXT	release	or	stimulation	of	centrally	projecting	
OXT	 neurons	 as	 described	 above.	 Finally,	 the	 rise	 in	 OXT	 availability	 in	 the	 regional	
extracellular	fluid	results	in	the	modulation	of	an	appropriate	anxiety	response	of	an	individual	
to	cope	with	the	environmental	challenge.		
In	 summary,	 my	 findings	 demonstrate	 a	 novel	 intra-hypothalamic	 neurophysiological	
mechanism	 involving	NPSR-expressing	OXT	 neurons	 of	 the	 PVN,	which	 are	 activated	 by	NPS	
and	 respond	 with	 transient	 increase	 in	 intracellular	 Ca2+	 and	 local	 somato-dendritic	 OXT	
release.	 The	 stimulation	 of	 local	OXT	neurons	 is	 essential	 for	NPS-induced	 anxiolysis,	 as	 this	
effect	 was	 blocked	 by	 specific	 pharmacological	 and	 chemogenetic	 inhibition	 of	 the	 OXT	
system.	 These	 findings	 provide	 important	 evidence	 for	 interactions	 of	 NPS	 with	 another	
neuropeptidergic	 system,	 but	 obviously	 warrant	 further	 research	 into	 how	 these	 circuits	
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orchestrate	 specific	 physiological	 effects	 resulting	 in	 distinct	 behavioral	 outputs,	 i.e.	 such	 as	
the	 regulation	 of	 stress	 or	 anxiety-related	 behavior.	 Based	 on	 a	 growing	 interest	 in	 the	
development	of	therapeutic	strategies	for	anxiety-	and	stress-related	disorders,	a	wide-ranging	
knowledge	about	the	neuronal	and	behavioral	consequences	of	brain	neuropeptide	signaling	
modulating	 emotional	 responses	 is	 required	 for	 efficient	 development	 of	 new	 therapeutic	
strategies.	 	
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Chapter	II:	NPS	induces	acute	anxiolysis	by	PLC-dependent	
signaling	within	the	MeA	
The	 present	 study	 describes	 the	 MeA	 as	 an	 important	 brain	 target	 of	 NPS	 to	 induce	 an	
anxiolytic	effect	in	male	rats	and	the	Gq	pathway	as	the	essential	intracellular	signaling	cascade	
underlying	 this	 local	 anxiolytic	 effect.	More	 specifically,	 the	 PLC	 inhibitor	U73122	 prevented	
NPS-induced	anxiolysis	in	NPS-sensitive	amygdalar	neurons.		
The	 MeA	 pointed	 out	 as	 an	 important	 relay	 station	 and	 regulator	 of	 emotional	 responses	
including	 anxiety-related	 behaviors	 (LeDoux,	 2007;	 Keshavarzi	 et	 al.,	 2014).	 It	 receives	 input	
from	 various	 brain	 regions	 involved	 in	 sensory	 processing,	 neuroendocrine	 and	 autonomic	
regulation	 including	 the	pericoerulear	 region	and	 the	parabrachial	nucleus	 (Moore	&	Bloom,	
1979;	 Saper	 &	 Loewy,	 1980).	 In	 the	 latter	 brain	 regions,	 a	 cluster	 of	 predominantly	
glutamatergic	 NPS-immunoreactive	 neurons	 has	 been	 identified	 (Xu	 et	 al.,	 2007).	 This	
suggested	 that	 NPS	 neurons	 project	 towards	 the	 MeA	 thereby	 regulating	 behavioral	
responses.	In	rats,	in-situ	hybridization	revealed	that	the	MeA	and	the	intercalated	nucleus	of	
the	amygdala	prominently	express	NPSR,	whereas	NPSR	expression	in	other	amygdala	nuclei	is	
almost	 negligible	 (Xu	 et	 al.,	 2007).	 This	 was	 recently	 confirmed	 by	 immunohistochemical	
localization	 of	 NPSR	 at	 protein	 level	 (Leonard	&	 Ring,	 2011),	 although	 the	 specificity	 of	 the	
available	NPSR	antibodies	has	been	questioned	(Slattery	et	al.,	2015).		
Our	data	demonstrating	that	NPS	infusion	into	the	MeA	reduced	the	anxiety-related	behavior	
both	 on	 the	 EPM	 and	 in	 the	 OF	 of	 male	 rats,	 confirm	 the	 robust	 anxiolytic	 profile	 of	 NPS	
described	following	icv	infusion	(Xu	et	al.,	2004;	Leonard	et	al.,	2008;	Rizzi	et	al.,	2008;	Vitale	et	
al.,	 2008;	 Wegener	 et	 al.,	 2011;	 Slattery	 et	 al.,	 2015;	 Zoicas	 et	 al.,	 2016)	 and	 intranasal	
application	(Ionescu	et	al.,	2012;	Lukas	&	Neumann,	2012;	Dine	et	al.,	2015)	 in	both	rats	and	
mice,	 and	 infusion	 into	 the	 lateral	 and	 basolateral	 amygdala	 in	mice	 (Jungling	 et	 al.,	 2008).	
Specifically,	intra-MeA	infusion	of	NPS	increased	the	percentage	of	time	the	animals	spent	on	
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the	open	arms	of	the	EPM	and	in	the	exposed	center	zone	of	the	OF	indicating	reduced	anxiety	
levels.	
In-vitro	activation	of	 the	NPSR	has	been	described	to	 increase	 intracellular	Ca2+	 levels	and	to	
phosphorylate	 ERK1/2	 in	 NPSR-transfected	 HEK293T	 cells	 (Reinscheid	 et	 al.,	 2005).	 Further,	
NPS-induced	 mobilization	 of	 intracellular	 Ca2+	 has	 been	 reported	 in	 NPSR-transfected	
hippocampal	 mouse	 neurons	 in	 vitro,	 an	 effect	 that	 was	 strictly	 dependent	 on	 PLC	 activity	
(Erdmann	et	al.,	2015).	As	activation	of	intracellular	signaling	cascades	is	cell-type	specific	and	
depends	 on	 the	 cellular	 micro-environment,	 the	 NPS-induced	 increase	 in	 intracellular	 Ca2+	
levels	and	activation	of	ERK1/2	found	in	vitro	may	not	necessarily	reflect	intracellular	signaling	
upon	 NPS	 binding	 to	 its	 receptor	 within	 the	 brain.	My	 in-vivo	 results	 are	 the	 first	 to	 show	
NPSR-induced	 activation	 of	 intracellular	 signaling	 cascades	 within	 the	 brain.	 Specifically,	
quantification	of	pCaMKIIɑ	as	a	biological	marker	of	NPSR-mediated	Ca2+	 influx	after	 icv	NPS	
revealed	 increased	relative	quantities	of	pCaMKIIɑ	reflecting	NPS-induced	rise	 in	 intracellular	
Ca2+	 levels.	 My	 results	 also	 demonstrate	 NPS-induced	 activation	 of	 the	 MAPK	 pathway	 in	
amygdala	punches	as	 reflected	by	 increased	pERK1/2	 levels	 in	 relation	 to	both,	 total	ERK1/2	
and	 beta-tubulin.	 Thus,	 NPSR-evoked	 phosphorylation	 and	 synthesis	 of	 CaMKIIɑ	 and	 the	
phosphorylation	 of	 ERK1/2	 provide	 important	 confirmation	 of	 intracellular	 actions	 of	NPS	 in	
the	 amygdala.	 However,	 my	 results	 are	 based	 on	 amygdala	 micropunches.	 Therefore,	 it	
remains	 elusive,	 whether	 the	 described	 NPSR-mediated	 pathway	 activation	 is	 restricted	 to	
NPSR-positive	neurons.	Thus,	future	studies	should	address	signal	amplification	at	cellular	level	
by	fluorescent	labeling	of	neurons	using	NPSR	promoter-based	expression	of	reporter	proteins.		
As	 in-vitro	 studies	 demonstrated	 that	NPSR	 can	 couple	 to	 intracellular	 Ca2+	 as	well	 as	 cAMP	
pathways,	 indicating	 interaction	with	 both	 Gq	 and	 Gs	 types	 of	 G	 proteins	 (Reinscheid	 et	 al.,	
2005),	 I	 aimed	 to	 reveal	 the	 specific	 involvement	of	PLC	and/or	AC	 signaling	 in	NPS-induced	
anxiolysis.	As	an	initial	approach,	I	infused	a	cocktail	composed	of	both,	the	aminosteroidic	PLC	
inhibitor	 U73122	 and	 the	 non-competitive	 AC	 inhibitor	 DDA	 prior	 to	 NPS	 infusion	 into	 the	
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MeA.	NPS	failed	to	induce	anxiolysis	in	rats	pre-treated	with	an	inhibitor	cocktail	composed	of	
U73122	and	DDA	indicating	that	either	both	or	one	of	these	intracellular	pathways	in	the	MeA	
are	 critically	 involved	 in	 NPS-induced	 behavioral	 changes.	 Next,	 each	 of	 the	 inhibitors	 was	
separately	applied	prior	 to	 local	 infusion	of	NPS.	Separate	pre-infusion	of	U73122	prevented	
the	 anxiolytic	 effect	 of	 locally	 infused	NPS	 both	 on	 the	 EPM	 and	 in	 the	OF,	 suggesting	 that	
activation	of	PLC	 is	 crucial	 to	orchestrate	acute	NPS-induced	anxiolysis.	 In	 contrast,	 separate	
pre-infusion	of	DDA	failed	to	block	NPS-induced	anxiolysis	suggesting	that	the	behavioral	effect	
is	 independent	 of	 AC	 activation.	 Although	 NPS	 was	 already	 found	 to	 induce	 cAMP	
accumulation	 in	 HEK293T	 cells	 in	 vitro	 (Reinscheid	 et	 al.,	 2005),	 a	 cAMP-independent	
mechanism	seems	to	be	 involved	 in	 the	anxiolytic	effect	of	NPS	 in	 the	MeA.	My	observation	
that	 U73122	 and	 DDA,	 when	 infused	 alone,	 did	 not	 significantly	 alter	 anxiety-like	 behavior	
compared	to	control,	excluded	the	possibility	that	the	inhibitors	changed	baseline	anxiety.	
Based	 on	 their	 chemical	 structure	 both,	 U73122	 and	 DDA,	 are	 cell	 membrane-permeable.	
Thus,	 inhibitor	 infusion	20	min	prior	 local	NPS	treatment	should	be	sufficient	to	 locally	block	
the	 respective	 effector	 proteins.	 The	 different	 doses	 of	 U73122	 and	 DDA	 used	 need	 some	
considerations:	U73122	is	reported	to	reliably	inhibit	PLC	(MacMillan	&	McCarron,	2010),	and	
usually	used	at	a	concentration	of	10	µM	in	vitro	(Erdmann	et	al.,	2015).	As	the	binding	domain	
of	 PLC	 isoforms	 is	 highly	 conserved	 (Rhee	 et	 al.,	 1989;	 Rhee	 &	 Bae,	 1997),	 U73122	 should	
inhibit	all	isoforms	of	PLC	(Carvou	et	al.,	2007).	Moreover,	U73122	reduces	Ca2+	release,	when	
evoked	 by	 direct	 activation	 of	 inositol-1,4,5-triphosphate	 receptors	 or	 ryanodine	 receptors	
independent	of	Gq	or	PLC	activity	(MacMillan	&	McCarron,	2010).	Here,	we	used	a	dose	of	0.5	
nmol	of	U73122	for	local	infusion	into	each	MeA.		
In	 mammals,	 nine	 isoforms	 of	 AC	 are	 expressed	 catalyzing	 the	 production	 of	 the	 second	
messenger	 cAMP	 (Hanoune	 &	 Defer,	 2001).	 A	 Ca2+/Calmodulin-dependent	 mechanism	 was	
demonstrated	 to	 activate	 the	AC	 isoforms	 1,	 3	 and	 8	 (MacNeil	 et	 al.,	 1985;	Halls	&	Cooper,	
2011).	Hence,	this	demonstrates	that	 intracellular	pathways	do	not	necessarily	act	 in	a	 linear	
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fashion,	 but	 can	 be	 integrated	 to	 bring	 about	 the	 appropriate	 physiological	 and	 behavioral	
responses.	 However,	 whether	 NPS-evoked	 cAMP	 accumulation	 depends	 on	 local	 rise	 in	
intracellular	 Ca2+	 levels	 needs	 further	 investigation.	 For	 example,	 the	 analysis	 of	 NPSR	 /	 G	
protein	 interactions	 using	 fluorescence	 resonance	 energy	 transfer	 might	 demonstrate,	
whether	NPSR	stimulation	recruits	both	Gq	and	Gs	proteins	or	whether	cAMP	accumulation	is	
maintained	by	a	Ca2+-dependent	activation	of	AC.	Herein,	I	used	DDA	to	block	the	membrane-
bound	AC.	The	half-maximal	inhibitory	concentration	of	DDA	is	described	with	250	µM	in	vitro	
(Holgate	 et	 al.,	 1980;	 Ogawa	 et	 al.,	 1995).	 Therefore,	 I	 infused	 DDA	 at	 a	 25-fold	 higher	
concentration	in	order	to	exert	a	potentially	similar	effective	inhibition	compared	to	U73122.	
The	 total	amount	of	U73122	 (0.5	nmol)	and	DDA	(12.5	nmol)	applied	was	selected	 following	
diffusion-based	calculations	in	order	to	maintain	at	least	half-maximal	inhibition	of	the	effector	
proteins	within	the	MeA.		
In	 summary,	 the	 in	 vivo	 data	 identified	 another	 brain	 region	 in	 rats,	 the	 MeA,	 where	 NPS	
reliably	 exerts	 anxiolytic	 properties,	 and	 demonstrated	 that	 this	 behavioral	 effect	 is	 strictly	
dependent	 upon	 local	 NPSR-mediated	 PLC	 activation.	 I	 could	 further	 show	 that	 icv	 NPS	
infusion	 induced	 phosphorylation	 and	 synthesis	 of	 CaMKIIɑ	 in	 amygdala	 punches,	 thereby	
promoting	 the	 activation	 of	 the	 MAPK	 pathway	 as	 another	 NPSR-mediated	 intracellular	
signaling	 cascade.	 These	 findings	 contribute	 to	 a	 broader	 knowledge	 about	 the	 molecular,	
cellular,	 and	 behavioral	 consequences	 of	 NPSR	 activation	 in	 the	 context	 of	 its	 profound	
anxiolytic	profile.			
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Chapter	III:	Efficiency	of	DREADD	system	in	PVN-OXT	neurons	
Chemogenetics	 is	 based	 on	 genetically	 engineered	 GPCRs	 that	 are	 activated	 by	 biologically	
inert	 drugs	 (Boyden	 et	 al.,	 2005;	Armbruster	 et	 al.,	 2007).	During	 the	 last	 decade,	DREADDs	
have	evolved	as	a	new	technique	to	regulate	the	activity	of	a	particular	neuronal	population.	
As	 the	hypothalamic	PVN	consists	of	a	heterogeneous	group	of	neurons	expressing	amongst	
others	OXT,	vasopressin	and	CRH,	pharmacological	approaches	are	 limited	in	a	way,	since	icv	
or	even	local	infusions	to	inhibit	or	activate	neurons	act	more	generally	rather	than	specifically	
on	a	subpopulation	of	PVN-OXT	neurons.	 In	a	myriad	of	neurophysiological	and	 translational	
settings,	DREADD	 technology	has	been	used	 in	different	 species	 to	 specifically	modulate	 the	
activity	 of	 various	 cell	 types,	 for	 example	 serotonergic	 neurons	 demonstrating	 that	 acute	
enhancement	 of	 serotonergic	 activity	 in	 the	 hindbrain,	 but	 not	 inhibition,	 is	 anxiogenic	
(Teissier	 et	 al.,	 2015).	 Other	 DREADD	 studies	 have	 revealed	 an	 important	 contribution	 of	
inhibitory	 circuitry	 in	 the	medial	 prefrontal	 cortex	 to	mood	 regulation	 (Perova	 et	 al.,	 2015;	
Whissell	 et	 al.,	 2016).	With	 respect	 to	OXT	 neurons,	 there	 is	 still	 a	 lack	 of	 precise	 temporal	
control	 that	 causes	 complications	when	attempting	 to	dissect	 complex	circuitries	 involved	 in	
anxiety-,	 depressive-	 and	 aggressive-like	 behavior,	 fear	 responses,	 or	 empathy.	 Thus,	 it	 is	
essential	 to	 validate	 DREADD	 as	 a	 specific	 tool	 to	 modulate	 OXT	 neuronal	 activity.	 In	 this	
context	it	was	also	the	aim	to	characterize	the	specific	temporal	dynamics	of	DREADD-evoked	
OXT	neuron	activation.	OXT	is	released	within	the	brain,	both	from	soma	and	dendrites	within	
the	 PVN	 and	 SON,	 as	 well	 as	 from	 axon	 terminals	 in	 distant	 brain	 and	 spinal	 cord	 areas	
(Landgraf	&	Neumann,	2004;	Ludwig	&	Leng,	2006;	Knobloch	et	al.,	2012;	Eliava	et	al.,	2016)	
and,	moreover,	OXT	can	be	released	from	the	neurohypophysis	into	the	circulation	in	response	
to	 various	 stimuli	 (Neumann	 &	 Landgraf,	 2012).	 For	 instance	 forced	 swim	 stress	 has	 been	
demonstrated	 to	 result	 in	both,	 increased	central	 and	peripheral	OXT	 release	 (Wotjak	 et	al.,	
1998).	However,	 it	has	repeatedly	been	shown	that	central	OXT	release	does	not	necessarily	
coincide	with	peripheral	OXT	secretion	(Engelmann	et	al.,	2004;	Torner	et	al.,	2017).	Herein,	I	
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demonstrated	that	chemogenetic	activation	of	OXT	neurons	resulted	in	increased	OXT	content	
in	plasma	samples	and	PVN	microdialysates	indicative	for	evoked	axonal	and	somato-dendritic	
OXT	release	in	the	periphery	and	the	PVN,	respectively,	whereas	local	OXT	release	within	the	
lateral	septum	was	not	altered.	Moreover,	chemogenetic	stimulation	of	OXT	neurons	reduced	
anxiety-related	 behavior,	 increased	 self-grooming,	 and	 partly	 attenuated	 ethanol-induced	
locomotor	impairments.	
In	order	to	monitor	local	OXT	release	within	the	PVN	as	a	consequence	of	chemogenetic	OXT	
neuron	 activation,	 I	 infused	 AAV1/2OXTpr-hM3Dq-mCherry	 bilaterally	 into	 the	 PVN.	 Here,	
hM3Dq	was	expressed	selectively	under	the	control	of	an	OXT	promoter	fragment	in	PVN-OXT	
neurons	 and,	 hence,	DREADD	expression	was	 confined	 to	 PVN-OXT	neurons	 as	 illustrated	 in	
Fig.	 18.	 In	human	pulmonary	 artery	 smooth	muscle	 cells,	 stimulation	of	hM3Dq	by	CNO	has	
been	shown	to	activate	PLC	and	thereby	increases	intracellular	Ca2+	levels	in	an	IP3-dependent	
manner	(Armbruster	et	al.,	2007).	A	rise	in	intracellular	Ca2+	concentration	is	a	prerequisite	for	
neuronal	 OXT	 release	 (Ludwig	 et	 al.,	 2002;	 Ludwig	 &	 Leng,	 2006;	 Ludwig	 et	 al.,	 2016).	 On	
experimental	day	1,	OXT	content	in	microdialysates	sampled	under	otherwise	basal	conditions	
from	conscious	rats	was	not	increased	during	the	1st	(0-30	min),	but	peaked	within	the	2nd	30-
min	dialysate	(30-60	min)	after	CNO	administration	indicative	for	increased	local	OXT	release	in	
comparison	to	Veh-control	 injected	with	sterile	PBS.	This	effect	was	reliably	recapitulated	on	
experimental	 day	 2,	 as	 OXT	 content	 in	 microdialysates	 was	 doubled	 within	 the	 2nd	 30-min	
sampling	 period	 following	 CNO	 administration,	 further	 demonstrating	 maximal	 OXT	 release	
between	30-60	min	after	chemogenetic	activation	of	OXT	neurons.	 In	accordance	with	 these	
findings,	 analysis	 of	 plasma	 concentrations	 of	 CNO	 demonstrated	 a	 prominent	 peak	 30	min	
following	ip	injection	of	CNO	(Guettier	et	al.,	2009).	Thus,	bioavailable	CNO	binds	to	designer	
receptors	at	around	30	min	following	ip	injection,	which	explains	the	increased	OXT	content	in	
the	2nd	30-min	dialysate	following	CNO	administration.	Various	reports	controversially	describe	
the	 intensity	 and	 duration	 of	 CNO-induced	 activation	 of	 DREADD-expressing	 cell	 types	
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(Alexander	et	al.,	2009).	Here,	OXT	content	in	microdialysates	was	still	increased	within	the	3rd	
30-min	 dialysate	 following	 CNO	 injection	 compared	 to	 ip	 Veh-control	 suggesting	 a	 longer-
lasting	stimulation	of	the	OXT	neurons	within	the	PVN.		
Forced	swim	stress	has	been	demonstrated	to	trigger	OXT	release	within	the	PVN	(Wigger	&	
Neumann,	 2002).	 In	 line	 with	 this,	 5-min	 forced	 swim	 stress	 at	 the	 beginning	 of	 the	 3rd	
sampling	 period	 reliably	 increased	 OXT	 content	 in	 microdialysates	 in	 the	 control	 group	
compared	 to	 baseline	 levels.	 In	 rats,	 transfected	with	 hM3Dq	 under	 the	 control	 of	 the	OXT	
promoter	 fragment,	 forced	 swim	 stress	 failed	 to	 further	 enhance	OXT	 release	 in	AAV+/CNO+	
group	 suggesting	 the	 incidence	 of	 a	 ceiling	 effect.	 As	 the	 release	 of	 Ca2+	 from	 intracellular	
stores	 triggers	dendritic	OXT	 release,	which	can	become	self-sustaining	and	 thus	 long-lasting	
due	to	autocrine	mechanisms	(Lambert	et	al.,	1994;	Ludwig	et	al.,	2002),	 it	might	explain	the	
increased	 OXT	 content	 in	 microdialysates	 indicative	 for	 increased	 brain	 OXT	 release	 over	 a	
larger	 timescale.	 In	 conclusion,	 the	monitoring	 of	 local	 somato-dendritic	 OXT	 release	within	
the	 PVN	 as	 a	 consequence	 of	 chemogenetic	 activation	 of	 PVN-OXT	 neurons	 demonstrates	 a	
reliable	 chemogenetic	 activation	 of	 PVN-OXT	 neurons	 and	 describes	 the	 spatiotemporal	
release	patterns	of	OXT.		
Moreover,	 I	 postulated	 an	 increase	 in	 local	 OXT	 release	 within	 the	 lateral	 septum	 as	 a	
consequence	 of	 chemogenetic	 activation	 of	 OXT	 neurons	 located	 in	 the	 PVN,	 SON	 and	 AN.	
Although	OXT	neurons	were	successfully	transfected	with	an	OXTpr-hM3Dq-mCherry	construct	
bilaterally	in	all	three	hypothalamic	nuclei	expressing	OXT,	monitoring	of	septal	OXT	revealed	
no	 measurable	 differences	 in	 local	 OXT	 release	 during	 the	 30-min	 sampling	 periods.	 This	
finding	is	in	contrast	to	my	hypothesis	and	need	some	elucidation	with	respect	to	microdialysis	
procedure:	First,	the	microdialysis	procedure	is	 limited	to	a	30-min	dialysis	period,	as	shorter	
sampling	periods	result	in	lower	sampling	volumes	and	OXT	concentrations	near	the	detection	
limit,	 thus	making	 it	difficult	 to	monitor	 short	bursts	of	OXT	 release.	Second,	due	 to	 the	 low	
number	 of	 septal	 OXT	 fibers,	 it	 is	 problematic	 to	 adequately	 place	 the	 microdialysis	 probe	
4	 General	discussion	 	
	
110
resulting	in	inter-individual	differences	in	OXT	content	in	dialysates	that	might	explain	the	high	
standard	error	of	the	mean	when	delta	OXT	levels	were	analyzed.		
In	order	to	analyze	the	consequence	of	chemogenetic	OXT	neuron	activation	in	PVN,	SON	and	
AN	on	peripheral	OXT	release,	I	examined	OXT	content	in	plasma	samples	collected	via	jugular	
vein	catheter	45	min	before	and	after	chemogenetic	stimulation,	respectively.	Here,	my	results	
indicate	 that	 basal	 OXT	 concentration	 in	 plasma	 did	 not	 differ	 between	 treatment	 groups,	
demonstrating	that	rAAV	infusion	and	expression	of	an	excitatory	DREADD	does	not	alter	basal	
OXT	release	into	the	periphery.	Following	chemogenetic	activation	of	OXT	neurons	within	the	
hypothalamic	 PVN,	 SON	 and	 AN,	 plasma	 OXT	 concentration	 was	 more	 than	 doubled	 when	
animals	were	 treated	with	 CNO,	whereas	 plasma	OXT	 in	 the	 control	 group	was	 not	 altered.	
This	 result	 is	 indicative	 for	 increased	 axonal	 OXT	 release	 via	 the	 neurohypophysis	 into	 the	
blood	stream	after	chemogenetic	activation	of	hypothalamic	OXT	neurons.	My	findings	are	in	
line	with	 increased	 local	OXT	 release	within	 the	 PVN	during	 the	 2nd	 30-min	 sampling	 period	
post	treatment,	demonstrating	DREADD	technique	as	a	powerful	tool	to	reliably	 increase	the	
activity	of	hypothalamic	OXT	neurons.	
In	order	to	analyze	behavioral	consequences	of	CNO-evoked	activation	of	OXT	neurons	within	
the	 PVN,	 I	 focused	 on	 three	 independent	 behavioral	 readout	 parameters	 described	 to	 be	
reliably	influenced	by	OXT.	OXT	applied	icv	is	known	to	increase	self-grooming	in	rats	(Drago	et	
al.,	1986),	a	behavior	blocked	by	pre-infusion	of	an	OXTR-A	into	the	nucleus	accumbens	(Drago	
et	 al.,	 1991).	 Here,	 I	 monitored	 grooming	 behavior	 during	 ongoing	 microdialysis	 on	
experimental	 day	 1	 and	 found	 that	 self-grooming	 behavior	 peaked	 during	 the	 2nd	 30-min	
sampling	period	(+60	min)	of	microdialysis	after	CNO	administration,	at	a	time	of	highest	OXT	
release	 following	 chemogenetic	 activation	 of	 PVN-OXT	 neurons.	 However,	 self-grooming	
behavior	was	restored	to	control	level	during	the	3rd	30-min	sampling	period	(+90	min)	even	in	
the	 presence	 of	 increased	 OXT-release,	 which	 might	 be	 an	 effect	 of	 OXTR	 desensitization	
following	stimulation	within	a	20-min	period	(Conti	et	al.,	2009).	This	 limits	the	time	window	
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when	behaviors	are	analyzed	that	depend	on	intracellular	OXTR	signaling.	As	self-grooming	is	
unlikely	 due	 to	 local	 OXT	 release	 within	 the	 PVN,	 it	 is	 quite	 plausible	 that	 chemogenetic	
activation	of	PVN-OXT	neurons	evokes	OXT	release	in	other	brain	regions,	too,	i.e.	the	nucleus	
accumbens.	 Since	 I	 monitored	 central	 OXT	 release	 exclusively	 within	 the	 PVN	 and	 lateral	
septum,	 I	 cannot	 rule	 out	 intracerebral	 OXT	 release	 as	 a	 consequence	 of	 chemogenetic	
stimulation	 of	 OXT	 neurons	 in	 other	 brain	 regions.	 To	 draw	 a	 clear	 picture	 with	 respect	 to	
locally	increased	OXT	release	in	various	brain	regions,	a	receptor-autoradiography	is	needed	in	
order	 to	 quantify	 relative	 amount	 of	 OXT	 binding	 to	 its	 GPCR	 following	 chemogenetic	
activation	of	hypothalamic	OXT	neurons.	
Besides	 OXT-evoked	 increase	 in	 self-grooming,	 intra-PVN	 infusion	 of	 synthetic	 OXT	 has	
repeatedly	been	shown	to	reliably	reduce	general	anxiety-related	behavior	in	male	rats	(Blume	
et	 al.,	 2008;	 Neumann,	 2008;	 van	 den	 Burg	 &	 Neumann,	 2011;	 van	 den	 Burg	 et	 al.,	 2015).	
Moreover,	mating-induced	 release	of	OXT	within	 the	PVN	has	been	associated	with	 reduced	
anxiety-related	behavior	 in	male	rats	 (Waldherr	&	Neumann,	2007).	Therefore,	 in	a	separate	
cohort	of	hM3Dq-expressing	rats,	I	assessed	anxiety-like	behavior	in	the	LDB	55	min	after	CNO	
injection.	 Rats	 bilaterally	 expressing	 hM3Dq	 in	 PVN-OXT	 neurons	 spent	more	 time	 in	 the	 lit	
compartment	and	tended	to	increase	the	number	of	entries	into	the	light	box	in	the	presence	
of	CNO,	indicative	for	being	less	anxious.		
The	third	behavioral	effect	of	OXT	I	have	tested	in	the	context	of	chemogenetic	stimulation	of	
OXT	neurons	in	the	PVN	was	the	prevention	of	ethanol-induced	locomotor	impairment	shown	
in	 rats	 (Pucilowski	 et	 al.,	 1985;	 Bowen	 et	 al.,	 2015).	 Specifically,	 McGregor	 and	 colleagues	
demonstrated	 that	 OXT	 prevents	 the	 potentiating	 actions	 of	 ethanol	 on	 GABAA	 receptor	
signaling.	 Although	 these	 OXT	 effects	 were	 found	 to	 be	 independent	 of	 OXTR	 signaling,	 I	
examined	 the	 consequence	 of	 chemogenetic	 activation	 of	 PVN-OXT	 neurons	 on	 ethanol-
induced	locomotor	impairments	in	two	locomotor	tests.	CNO	administration	in	rats	expressing	
an	excitatory	DREADD	 in	PVN-OXT	neurons	 failed	to	attenuate	the	ataxic	effects	 in	 the	wire-
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hanging	test,	but	improved	the	performance	in	the	rightning	reflex	65	min	after	ip	CNO	or	35	
min	after	ip	ethanol	injection,	respectively.	In	detail,	CNO	administration	reduced	the	duration	
of	 the	 rightning	 reflex	 in	 ethanol-pretreated	 rats	 suggesting	 that	 activation	 of	 brain	 OXT	
neurons	 beneficially	 counteracts	 ethanol-induced	 prolongation	 of	 the	 rightning	 reflex.	 The	
differences	in	the	behavioral	outcome	of	these	two	studies	need	further	critical	discussion:	In	
the	experiments	of	McGregor	and	colleagues,	a	relatively	high	dose	of	1	µg	of	OXT	was	applied	
icv	(Bowen	et	al.,	2015)	thus	reaching	all	relevant	brain	regions.	After	CNO	administration,	only	
a	specific	population	of	OXT	neurons	in	the	PVN	was	targeted	and	activated,	and	it	is	unknown	
where	these	neurons	project	to	and	to	which	extent	they	also	release	OXT.		
Altogether,	 DREADD	 represents	 a	 powerful	 tool	 to	 manipulate	 the	 activity	 of	 hypothalamic	
OXT	neurons.	Herein,	 I	 demonstrated	 a	 reliable	 increase	 in	 both	 central	 and	peripheral	OXT	
release	as	a	 consequence	of	 chemogenetic	activation	of	OXT	neurons.	Moreover,	my	 results	
indicate	 that	 stimulation	 of	 an	 excitatory	 DREADD	 selectively	 expressed	 in	 OXT	 neurons	
increases	 self-grooming,	 reduces	 anxiety-related	 behavior,	 and	 partly	 attenuates	 ethanol-
induced	 locomotor	 impairments.	 Although	 experiments	 in	 the	 presence	 of	 an	 OXTR-A	 are	
necessary	 to	 provide	 a	 final	 causal	 link,	 my	 results	 validate	 DREADD	 as	 a	 specific	 tool	 to	
modulate	 OXT	 neuronal	 activity.	 In	 this	 context,	 my	 data	 also	 characterize	 the	 specific	
temporal	dynamics	of	DREADD-evoked	OXT	neuron	activation	and,	 thus,	proves	 the	DREADD	
technology	 as	 a	 reliable	 tool	 in	 order	 to	 dissect	 complex	 circuitries	 involved	 in	 emotional	
behaviors,	such	as	anxiety	and	fear.	
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Perspectives	and	future	directions	
The	findings	described	in	this	thesis	open	up	a	number	of	additional	research	questions,	which	
will	 lead	to	a	better	understanding	of	the	etiology	of	anxiety	disorders	and	of	the	underlying	
mechanisms	responsible	for	the	anxiolytic	profile	of	NPS.	These	future	studies	can	be	divided	
into	the	following	sections:		
	
OXTR	expression	in	NPS	neurons	and	OXT	projections	to	the	locus	coeruleus	
My	 findings	 demonstrate	 a	 novel	 intra-hypothalamic	 mechanism	 involving	 NPSR-expressing	
OXT	 neurons	 of	 the	 PVN	 that	 are	 activated	 by	 NPS.	 Here,	 OXT	 neurons	 treated	 with	 NPS	
respond	with	transient	 increase	in	 intracellular	Ca2+	and	local	somato-dendritic	OXT	release.	I	
demonstrated	that	stimulation	of	local	OXT	neurons	is	essential	for	NPS-induced	anxiolysis,	as	
this	 effect	was	 blocked	 by	 specific	 pharmacological	 and	 chemogenetic	 inhibition	 of	 the	OXT	
system.	 These	 findings	 provide	 important	 evidence	 for	 interactions	 of	 NPS	 with	 another	
neuropeptidergic	 system,	 but	 obviously	 warrant	 further	 research	 into	 how	 these	 circuits	
orchestrate	 specific	 physiological	 effects	 resulting	 in	 distinct	 behavioral	 outputs,	 i.e.	 such	 as	
the	 regulation	 of	 stress	 or	 anxiety-related	 behavior.	 Based	 on	 a	 growing	 interest	 in	 the	
development	of	therapeutic	strategies	for	anxiety-	and	stress-related	disorders,	a	wide-ranging	
knowledge	about	the	neuronal	and	behavioral	consequences	of	brain	neuropeptide	signaling	
modulating	 emotional	 responses	 is	 required	 for	 efficient	 development	 of	 new	 therapeutic	
strategies.		
It	 has	 been	 demonstrated	 that	 NPS-synthesizing	 neurons	 originating	 in	 the	 pericoerulear	
region	 innervate	the	PVN	(Xu	et	al.,	2004;	Xu	et	al.,	2007).	 Interestingly,	 in	situ	hybridization	
revealed	OXTR	expression	in	the	pericoerulear	region	and	parabrachial	nucleus	(Vaccari	et	al.,	
1998;	Yoshida	et	al.,	2009).	Thus,	an	interesting	hypothesis	is	that	NPS	and	OXT	neurons	form	a	
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bilateral	 functional	 circuitry	 to	modulate	 behavioral	 and	 physiological	 parameters.	However,	
whether	NPS-synthesizing	neurons	express	the	OXTR	or	whether	these	neurons	are	innervated	
by	OXT	fibers	remains	elusive.	To	answer	these	questions,	NPS-immunoreactive	neurons	have	
to	 be	 labeled	 in	 transgenic	 rats	 expressing	 Venus	 selectively	 under	 the	 control	 of	 the	OXTR	
promoter	 fragment.	 Future	 antero-	 and	 retrograde	 tracing	 studies	 in	 combination	 with	 an	
immunofluorescent	staining	of	both,	OXT	and	NPS,	will	unravel	potential	OXT	afferents	within	
the	NPS-synthesizing	brain	clusters.		
Examination	of	the	intracellular	signaling	mechanisms	of	NPSR-positive	neurons		
I	 demonstrated	 that	 pharmacological	 blockade	 of	 the	 membrane-bound	 PLC	 inhibited	 NPS-
induced	anxiolysis	suggesting	Gq	protein	activation,	whereas	infusion	of	an	AC	inhibitor	failed	
to	block	NPS-induced	anxiolysis.	Whether	NPS	activates	AC	by	a	Gs-dependent	mechanism	 is	
currently	 not	 known,	 as	 increased	 Ca2+	 levels	 have	 been	 demonstrated	 to	 activate	
Ca2+/calmodulin-dependent	 AC	 isoforms	 1,	 3	 and	 8	 (MacNeil	 et	 al.,	 1985;	 Halls	 &	 Cooper,	
2011).	Thus,	fluorescence	resonance	energy	transfer	approach	is	necessary	to	analyze	possible	
NPSR	 interaction	 with	 Gs	 protein.	 Moreover,	 the	 route	 of	 extracellular	 Ca2+	 entry	 in	 NPSR-
positive	 cells	 needs	 to	 be	 investigated.	 In	 most	 cells,	 Ca2+	 release	 from	 the	 endoplasmic	
reticulum	(ER)	and	the	according	 fall	 in	ER-luminal	Ca2+	concentration	subsequently	activates	
Ca2+	channels	in	the	cell	membrane	in	a	process	called	store-operated	Ca2+	entry	(SOCE).	Pape	
and	colleagues	demonstrated	a	reduced	amplitude	and	duration	of	the	slow	Ca2+	entry	in	the	
presence	 of	 two	 SOCE	 inhibitors	 called	 ML-9	 and	 SKF96365	 (Erdmann	 et	 al.,	 2015).	 Both	
blockers	inhibit	the	stromal	interaction	molecule	1	(which	activates	Ca2+	release-activated	Ca2+	
channel	1	upon	Ca2+	decrease	 to	a	 critical	 level	 in	 the	ER),	but	 they	also	block	voltage-gated	
Ca2+	channels	and	transient	receptor	potential	cation	channels	(Merritt	et	al.,	1990;	Varnai	et	
al.,	 2009;	 Singh	 et	 al.,	 2010).	 Therefore,	 further	 studies	 should	 address	 the	 underlying	
mechanism	of	extracellular	Ca2+	entry	and	the	related	cellular	activation.		
NPSR-transfected	 cell	 cultures	 represent	 a	 limited	 model	 to	 study	 intracellular	 signaling	
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pathways	 as	 intracellular	 signaling	 depends	 on	 the	 cellular	 microenvironment.	 Therefore,	
evaluation	of	a	microarray	or	next	generation	sequencing	in	RNA	samples	extracted	from	brain	
tissue	 micropunches	 are	 necessary	 to	 reveal	 NPS-induced	 gene	 expression.	 Analysis	 of	 the	
target	 genes	 and	 the	 knowledge	 about	 the	 putative	 transcription	 factor	 binding	 sites	 to	 the	
respective	 promoter	 will	 confine	 the	 number	 of	 signaling	 pathways	 activated	 upon	 NPSR	
activation.	
Projections	of	NPS(R)-positive	neurons	and	their	involvement	in	stress-	and	fear	circuitries	
I	 have	 found	 that	 NPS	 stimulates	 the	 activity	 of	 OXT	 neurons	 within	 the	 PVN,	 which,	 as	 a	
consequence	of	activation,	exert	anxiolytic	activity.	Besides	anxiolysis,	OXT	is	well	described	for	
its	stress-coping	actions	(Neumann	&	Landgraf,	2012).	In	this	context,	it	would	be	of	interest	to	
evaluate	 possible	 stress-protective	 effects	 of	 NPS.	 Stress	 is	 a	 critical	 factor	 that	 induces	 an	
anxiogenic	phenotype	(Roozendaal	et	al.,	2009).	Following	acute	stress	exposure,	an	increased	
number	 of	 cFos-positive	 NPS	 neurons	 indicative	 of	 an	 activation	 of	 the	 endogenous	 NPS	
system	 due	 to	 CRH-R1	 stimulation	 on	 NPS-immunoreactive	 neurons	 in	 mice	 have	 been	
demonstrated	(Jungling	et	al.,	2012).	In	addition,	Singewald	and	colleagues	showed	increased	
NPS	 release	 in	 the	 amygdala	 following	 forced	 swim	 stress	 (Ebner	 et	 al.,	 2011).	 These	 data	
clearly	 identify	 the	 NPS	 system	 to	 play	 a	major	 role	 in	 stress	 responsiveness.	Whether	 NPS	
exerts	stress-protective	effects	is	currently	not	known.	Thus,	it	is	suitable	to	analyze	the	effect	
of	 a	 chemogenetic	 as	 well	 as	 pharmacological	 stimulation	 or	 inhibition,	 respectively,	 of	 the	
NPS/NPSR	 system	 and	 its	 effect	 on	 hypothalamo-pituitary	 adrenal	 axis	 activity,	 plasma	
adrenocorticotropic	 hormone	 and	 corticosterone	 levels	 in	 rodents	 in	 response	 to	 a	 stressor.	
Specifically,	 this	 could	 be	 achieved	 by	 infusion	 of	 AAV1/2NPSpr-hM3Dq-mCherry	 or	 AAV1/2-
NPSpr-hM4Di-mCherry	or	by	 icv	 infusion	of	either	NPS	or	SHA-68	prior	 to	5-min	exposure	 to	
stressors	such	as	forced	swimming	or	a	novel	environment.	
In	 rats	 selectively	 bred	 for	 high	 anxiety-related	 behavior,	 icv	 NPS	 reliably	 reduced	 freezing	
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during	 cued	 fear	 extinction	 in	 the	 cued	 fear-conditioning	 model	 (Slattery	 et	 al.,	 2015).	
However,	within	the	central	nucleus	of	the	amygdala,	NPSR	expression	is	almost	negligible	(Xu	
et	 al.,	 2007).	Whether	 fear-on/off	 neurons	 are	 innervated	 by	 afferents	 deriving	 from	NPSR-
positive	 neurons	 located	 in	 the	 MeA	 remains	 elusive.	 At	 cellular	 and	 tissue-wide	 levels,	
fluorescent	 labeling	 of	 NPSR-positive	 neurons	 using	 adenoviral	 promoter-based	 reporter	
protein	 expression	 provides	 the	 basis	 to	 successfully	 trace	 projections	 of	 NPSR-positive	
neurons	and	their	potential	effects	on	other	neuronal	populations	such	as	fear-on/off	neurons	
in	the	central	nucleus	of	the	amygdala.	
Spatiotemporal	activation	patterns	of	OXT	neurons	expressing	an	excitatory	DREADD	
The	 DREADD	 technique	 represents	 a	 powerful	 tool	 to	 unravel	 neuronal	 circuits,	 and	
contributes	to	the	experimental	regulation	of	the	behavioral	phenotype	of	an	individual.	Here,	
my	findings	demonstrate	increased	OXT	release	locally	within	the	PVN	and	in	the	periphery	as	
a	 consequence	of	DREADD-evoked	activation	of	OXT	neurons.	 Sampling	of	microdialysates	 is	
limited	to	a	30-min	dialysis	period,	as	shorter	sampling	periods	may	result	 in	 lower	sampling	
volumes	and	OXT	concentrations	near	 the	detection	 limit,	 thus	making	 it	difficult	 to	monitor	
short	bursts	of	OXT	release	especially	in	brain	regions	innervated	by	few	OXT	fibers.	Therefore,	
my	 findings	 would	 benefit	 from	 three	 experimental	 approaches	 in	 order	 to	 draw	 a	 clear	
conclusion	regarding	the	spatiotemporal	resolution	of	DREADD-induced	neuronal	activation	of	
OXT	neurons:	First,	a	receptor-autoradiography	will	give	rise	to	increased	relative	OXT	release	
and	 binding	 to	 its	 receptor	 once	 the	 hypothalamic	 OXT	 neurons	 are	 activated	 by	 DREADD	
technique.	Second,	in	vivo	electrophysiological	recordings	of	OXT	neurons	in	anesthetized	rats	
before	 and	 after	 administration	 of	 CNO	 ip	will	 illuminate	 the	 exact	 time	 points	 for	 first	 and	
maximal	stimulatory	effects	of	chemogenetic	activation	of	OXT	neurons.	Finally,	Ca2+	 imaging	
using	 genetically	 encoded	 Ca2+	 sensors	 (e.g.	 GCaMP6s)	 selectively	 co-expressed	 with	 an	
excitatory	DREADD	in	OXT	neurons	will	demonstrate	the	intensity	of	CNO-evoked	Ca2+	influx	as	
a	consequence	of	neuronal	activation.	Moreover,	in	the	presence	of	Ca2+	channel	blockers,	the	
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source	of	Ca2+	can	be	identified,	which	might	be	indicative	for	the	type	of	OXT	release	since	the	
source	of	Ca2+	impacts	on	somato-dendritic	as	well	as	axonal	release	and	even	priming	effects	
as	previously	described	(Ludwig	et	al.,	2016).	
With	the	help	of	 these	approaches	 it	 should	be	possible	 to	expand	the	 findings	presented	 in	
this	thesis	and	to	understand	the	neuronal	circuits	underlying	the	potent	anxiolytic	and	fear-
attenuating	 effects	 of	NPS	 and	OXT.	 These	 factors	 could	 potentially	 serve	 as	 a	 basis	 for	 the	
development	of	novel	pharmacological	treatments	of	anxiety	disorders.		
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